1
Status: Approved ,  Date: 16 November 2017Janssen Scientific Affairs, LLC
Clinical Protocol
A Phase 3, Single- arm, Open -label Study to Evaluate the Efficacy and Safety of 
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily 
Fixed -dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment -
naïve Human Immunodeficiency Virus Type 1 (HIV -1) Infected Subjects Receiving Care in 
a Test and Treat Model of Care
Protocol TMC114FD2HTX3002; Phase 3
Amendment 1
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200mg/tenofovir 
alafenamide 10 mg)
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
Status: Approved   
Date: 16 November 2017
Prepared by: [CONTACT_48824], LLC
EDMS number: EDMS -ERI-137602439, 2.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidenti al and 
may not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
2
Approved , Date: [ADDRESS_1047526] OF IN -TEXT T ABLES.......................................................................................................................... 4
PROTOCOL A MENDMENTS ....................................................................................................................... 5
SYNOPSIS .................................................................................................................................................... 7
TIME AND EVENTS SCHE DULE .............................................................................................................. 18
ABBREVIA TIONS ...................................................................................................................................... 21
1. INTRODUCTION ................................................................................................................................ 24
1.1. Study Drug ..................................................................................................................................... 24
1.2. Background .................................................................................................................................... 24
1.2.1. Darunavir (PREZISTA®)............................................................................................................. 28
1.2.2. Cobicistat (T ybost®).................................................................................................................... 28
1.2.3. Emtricitabine (Emtriva®).............................................................................................................. [ADDRESS_1047527] POPUL ATION.................................................................................................................. 38
4.1. Inclusion Criteria ............................................................................................................................ 38
4.2. Exclusion Criteria ........................................................................................................................... 40
4.3. Prohibitions and Restrictions ......................................................................................................... 41
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 41
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 41
7. TREA TMENT COMPLIA NCE ............................................................................................................ 42
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 42
9. STUDY EVA LUATIONS .................................................................................................................... 44
9.1. Study Procedures ........................................................................................................................... 44
9.1.1. Overview ..................................................................................................................................... 44
9.1.2. Screening Phase ........................................................................................................................ 45
9.1.3. Open -Label Treatment Phase .................................................................................................... 45
[IP_ADDRESS]. Main Study Period ................................................................................................................... 45
[IP_ADDRESS]. Extension Period ..................................................................................................................... 46
9.2. Efficacy  Evaluations ....................................................................................................................... 46
9.2.1. Antiviral Efficacy  and Immunologic Change ............................................................................... 46
9.2.2. Resistance Determinations ......................................................................................................... 47
9.3. Pharmacokinetics ........................................................................................................................... 47
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
3
Approved , Date: 16 November [ZIP_CODE].4. Medical Resource Utilization and Health Economics .................................................................... 47
9.5. Adherence ...................................................................................................................................... 48
9.6. Retention in Care ........................................................................................................................... 48
9.7. Safety Evaluations ......................................................................................................................... 48
9.8. Toxicity Management ..................................................................................................................... 52
9.8.1. General Guidance for the Management of Clinical Events and Laboratory Abnormalities ........ 52
9.8.2. Cutaneous Events/Rash ............................................................................................................. 53
9.8.3. Acute Sy stemic Allergic Reaction ............................................................................................... 55
9.8.4. Potential Renal Toxicity .............................................................................................................. 56
9.8.5. Potential Posterior Uveitis Cases ............................................................................................... 57
9.8.6. Hyperglycemia ............................................................................................................................ 57
9.8.7. Hypertriglyceridemia and Hypercholesterolemia ........................................................................ 58
9.8.8. Lipody strophy /Fat Redistribution/Body Changes ....................................................................... [ADDRESS_1047528] COMPLETION/D ISCONTINUA TION OF ST UDY TREA TMENT/ WITHD RAWAL 
FROM THE STUDY ........................................................................................................................... [ADDRESS_1047529] Quality ............................................................................ 72
14. STUDY DRUG INFORM ATION......................................................................................................... 72
14.1. Physical Description of Study Drug(s) ........................................................................................... 72
14.2. Packaging ...................................................................................................................................... 72
14.3. Labeling .......................................................................................................................................... 72
14.4. Preparation, Handling, and Storage ............................................................................................... 72
14.5. Drug Accountability ........................................................................................................................ 72
15. STUDY -SPECIFIC M ATERIA LS....................................................................................................... 73
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
4
Approved , Date: [ADDRESS_1047530] ................................................... 74
16.2.3. Informed Consent ....................................................................................................................... 75
16.2.4. Privacy of Personal Data ............................................................................................................ 76
16.2.5. Long- Term Retention of Samples for Additional Future Research ............................................ 77
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 77
17.1. Protocol Amendments .................................................................................................................... 77
17.2. Regulatory Documentation ............................................................................................................ 77
17.2.1. Regulatory Approval/Notification ................................................................................................ [ADDRESS_1047531] Identification, Enrollment, and Screening Logs ................................................................ 78
17.4. Source Documentation ................................................................................................................... 79
17.5. Case Report Form Completion ...................................................................................................... 79
17.6. Data Quality Assurance/Quality Control ........................................................................................ [ADDRESS_1047532] Retention ........................................................................................................................... 80
17.8. Monitoring ...................................................................................................................................... 81
17.9. Study Com pletion/Termination ....................................................................................................... 81
17.9.1. Study Com pletion/End of Study .................................................................................................. [ADDRESS_1047533] OF A TTACHMENTS
Attachment 1: Schema for Follow -up of Subjects who Meet the Criteria for Protocol -Defined 
Virologic Failur e........................................................................................................................ 88
Attachment 2: DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events ............. 90
Attachment 3: WHO Clinical Staging of HIV/AIDS .............................................................................. 111
Attachment 4: Management of Clinically Significant Laborator y Toxicities* ....................................... 113
Attachment 5: Management of Dyslipi[INVESTIGATOR_035] ...................................................................................... 114
Attachment 6: Cardiovascular Safety : Definitions of Abnormalities .................................................... 117
Attachment 7: HIV-Treatment Satisfaction Questionnaire (HIVTSQs) ............................................... 118
Attachment 8: Anticipated Events ....................................................................................................... [ADDRESS_1047534] OF IN -TEXT TA BLES 
Table 1: Summary  of Cutaneous Reaction/Rash Follow -up................................................................... 55
Table 2: Summary  of Allergic Reaction Follow -up.................................................................................. 56
Table 3: LDL and non -HDL Cholesterol Goals and Thresholds for Therapeutic Lifestyle 
Changes and Drug Therapy in Different Risk Categories ...................................................... 116
Table 4: Choice of Drug Therapy for Dyslipi[INVESTIGATOR_83315]- infected Individuals Receiving 
HAART .................................................................................................................................... 116
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
5
Approved , Date: [ADDRESS_1047535] recent amendment .
Amendment 1 (this document )
The overall reason for the amendment: Following FDA feed back on the clinical protocol TMC114FD2HTX3002, 
3-May-2017, the requested changes have been implemented. In addition, an extension period has been added to give 
subjects who have completed the Week 48 visit an opportunity to continue D/C/F/TAF treatment until the
D/C/F/TAF FDC tablet becomes commercially available and is reimbursed, or can be accessed through another 
source, or until the sponsor terminates clinical development. Further changes have been made to the protocol for 
clarification or correction.
Applicable Section(s) Description of Change(s)
Rationale: To m aintain continuity of treatment, subjects who have completed 48 -weeks of treatment with 
D/C/F/TAF will be given the opportunity to continue D/C/F/TAF treatment during an extension period until the 
D/C/F/TAF FDC tablet becomes commercially available and is reimbursed, or can be accessed through another 
source, or until the sponsor terminates clinical development.
SYNOPSIS
TimeandEvents Schedule
2.1Objectives and Endpoints
3.1Overview of Study Design
3.2Study Design Rationale
[ADDRESS_1047536] Completion /Discontinuation ofStudy Treatment / Withdraw al FromtheStudy
11Statistical Methods
Rationale: In order to minimize the chance of resistance development, HIV -1 RNA retesting in subjects with
HIV-1 RNA ≥50 copi[INVESTIGATOR_014]/mL will occur 2 -4 weeks after the date of confirmation of viral load ≥50 copi[INVESTIGATOR_014]/ mL rather
than after 3 -6 weeks. 
SYNOPSIS
TimeandEvents Schedule
3.1Overview of Study Design
Attachment 1
Rationale: To ensure patient safety and allow for an early analy sis of this new Test and Treat model of care 
paradigm , the timing of the interim analysis has been advanced from when the last subject reaches Week [ADDRESS_1047537] has been assessed for safety at Day 3 ,and for resistance stoppi[INVESTIGATOR_764532] 4 .
SYNOPSIS
3.1Overview of Study Design
11Statistical Methods
Rationale: In order to m ake inclusion criteri on #7consistent w ith footnote win the TimeandEvents Schedule and 
with the text in Section 9.7, Clinical Laboratory Tests . 
SYNOPSIS
4.1Inclusion Criteria
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
6
Approved , Date: 16 November 2017Applicable Section(s) Description of Change(s)
Rationale: In order to incorporate the footnote associated with Attachment 4 into Section 9.8.1 , and to specify that 
the attachment footnote and the new text in Section 9.8.1 do not apply to the retesting of abnormal screening/
baseline laboratory values .
9.7Safety Evaluations
9.8.1 General Guidance for the Management of Clinical Events and Laboratory Abnormalities
Attachment 4
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
7
Approved , Date: 16 November 2017SYNOPSIS
A Phase 3, Single -arm, Open -label Study to Evaluate the Efficacy and Safety of 
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed -dose 
Combination (FDC) Regi men in Newly Diagnosed, Antiretroviral Treatment -naïve Human 
Immunodeficiency Virus Type 1 (HIV -1) Infected Subjects Receiving Care in a Test and Treat Model of 
Care
STUDY DRUGS
The darunavir/cobicistat/emtricitabi ne/tenofovir alafenamide (D/C/F/TAF) fixed -dose combination (FDC) 
tablet is a 4-agent FDC tablet in development for oral once -daily use for the treatment of human 
immunodeficiency virus (HIV) -1 infection. This tablet contains the protease inhibitor (PI) darunavir 
(DRV or D) (800 mg), the pharmacokinetic enhancer cobicistat (COBI or C) (150 mg), the nucleoside 
reverse transcriptase inhibitor (NRTI) emtricitabine (FTC or F) (200 mg), and the tenofovir (TFV) 
prodrug tenofovir alafenamide (TAF) (10 mg).
Darunav ir (PREZISTA®) used with a pharmacokinetic booster is approved for treatment of HIV-1 
infection in subjects aged 3 years and above, either as a 600-mg twice-daily treatment for antiretroviral 
therapy (ART) -experienced subjects or as an 800-mg once -daily treatment for ART -naïve subjects and 
ART -experienced subjects without DRV resistance -associated mutations (RAMs) . 
Cobicistat (Tybost®) 150mgis approved as a pharmacokinetic enhancer of select antiretroviral (ARV )
agents requiring the effects of a pharmaco kinetic enhancer . 
The DRV/COBI 800/150- mg FDC tablet (PREZCOBIX®) is a once -daily treatment approved for use in 
combination with other ARV agents for treatment of HIV-1 infected treatment -naïve and treatment -
experienced adults without DRV RAMs . 
Emtricita bine is approved for use in combination with other agents for the treatment of HIV -1 infection in 
adults and children (4 months of age or older) and is available as a single agent (Emtriva®) or as part of 
FDCs, including Descovy®(F/TAF).
Tenofovir alafenamide is approved as part of FDCs, including Descovy®(FTC/TAF), Genvoya®
(elvitegravir [EVG]/COBI/FTC/TAF or E/C/F/TAF), and Odefsey®(rilpi[INVESTIGATOR_12979] [RPV]/FTC/TAF). 
Descovy®is a once -daily treatment approved for use in combination with other ARV agents (including 
DRV/COBI) for treatment of HIV -1 infected adults and adolescents (aged 12 years and older).
The D/C/F/TAF FDC tablet is intended as a complete regimen for the treatment of HIV-1 infection in 
adults and adolescents (aged 12 years and older) with no mutations known to be associated with 
resistance to any of the active components. The D/C/F/TAF FDC is currently being studied in 2 ongoing 
Phase 3 clinical studies ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]).
OBJECTIVES, ENDPOINTS, AND HYPOTHESIS
Objectives
The primary objective of this study is to assess the efficacy of D/C/F/TAF FDC in a Test and Treat model 
of care in newly diagnosed HIV-1-infected, treatment -naive subjects as determined by [CONTACT_184865]-1 ribonucleic acid (RNA) <50copi[INVESTIGATOR_014] /mL at Week 48 (Food 
and Drug Administration [FDA] -defined intent to treat [ITT] snapshot analysis). 
The secondary objectives of this study are:
 To assess virologic and immunologic changes in the study population through 12, 24, and 48weeks 
of treatment 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
8
Approved , Date: 16 November 2017 To evaluate the incidence of grade 3 and 4 adverse events, serious adverse events, and premature 
discontinuations due to adverse events through 24 and 48 weeks of treatment ,and during the 
extension phase
 To evaluate the frequency of discontinuation of D/C/F/TAF FDC due to protocol -specific stoppi[INVESTIGATOR_764533] (refer to the section Overview of Study Design below)
 To assess baseline viral resistance in t he study population 
 To assess the development of viral resistance in the study population through 24 and 48weeks of 
treatment ,and during the extension phase
 To assess the proportion of subjects retained in care after discontinuation of study drug before
Week 48
 To evaluate the influence of various intrinsic and extrinsic factors on retention in care
 To assess the proportion of subjects lost to follow -up through 24 and 48 weeks of treatment
 To evaluate adherence by [CONTACT_21173][INVESTIGATOR_764534] D/C/F/TAF FDC in the study population through 24and 
48weeks of treatment 
 To evaluate adherence by [CONTACT_35704] -report, using a 4 -day recall period through Weeks 24 and 48
 To describe predictors of suboptimal adherence (<95% adherence by [CONTACT_21173][INVESTIGATOR_692]) in the study 
population 
 To assess the HIV Treatment Satisfaction Questionnaire -status version (HIVTSQs )at Week s 4, 24, 
and 48
 To evaluate healthcare resource utilization (HRU) and cost and their temporal trends in the study 
population through [ADDRESS_1047538] HIV-1 RNA <50copi[INVESTIGATOR_014] /mL at 
Week 48 as defined by [CONTACT_90706] (ITT). 
The secondary endpoints of this study are:
Efficacy
 Change from baseline in log 10HIV-1 RNA viral load at Weeks 2, 4, 8, 12, 24, 36, and 48 
 Proportion of subjects who have HIV -1 RNA <50 copi[INVESTIGATOR_014] /mL at Week 24 
 The change from baseline in CD4+cell count at Weeks 12, 24, and 48 
Safety
 Proportion of subjects that required discontinuation after enrollment based on safety stoppi[INVESTIGATOR_004] 
(refer to the section Overview of Study Design below)
 Proportion of subjects discontinuing therapy due to adverse events
 Proportion of subjects experiencing grade 3 and 4 adverse events
 Proportion of subjects experiencing grade 3 and4 laboratory abnormalities 
Resistance
 Proportion of subjects meeting resistance stoppi[INVESTIGATOR_004](refer to the section Overview of Study 
Design below) requiring discontinuation of study drug due to baseline resistance findings
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
9
Approved , Date: 16 November 2017 Proportion of subjects with baseline protease (PR), reverse transcriptase (RT), and integrase (INI)
RAMs 
 Proportion of subjects developi[INVESTIGATOR_764535], when available, upon 
meeting protocol -defined virologic failure
 Proportion of subjects with protocol- defined virologic failure at Week 24 and Week 48, and during 
the extension phase
Retention in Care
 Proportion of subjects lost -to-follow -upthroughout the 48 weeks of treatment 
 Proportion of subjects discontinuing study drug for any reason other than withdrawal of consent 
prior to Week [ADDRESS_1047539] a documented clinic visit with a healthcare provider within 90 days of 
discontinuing study drug
Adherence
 Adherence rates by [CONTACT_21173][INVESTIGATOR_764536] 4, 8, 12, 24, 36, and 48 
 Adhe rence rates by [CONTACT_35704] -report, using a 4 -day recall at Weeks 4, 8, 12, 24, 36, and 48 
Tolerability/Patient -reported Outcomes 
 Mean total scores for the HIVTSQ s at Week s4, 24, and 48
Healthcare Resource Utilization/Pharmacoeconomics
 The number and duration of hospi[INVESTIGATOR_602], number and type of outpatient visits, number of 
emergency room visits, and number and type of medications used (both HIV -related and All-c ause as 
assessed by [CONTACT_093] ) throughout the main study period
 Direct medical costs will be calculated in [LOCATION_002] ([LOCATION_003])dollars based on HRU noted above 
Hypothesis
No formal hypothesis will be tested. The findings from this study will be used to generate data on the 
efficacy and safety profile of D/C/F/TAF FDC in newly diagnosed HIV-[ADDRESS_1047540] and Treat model of care.
OVERVIEW OF STUDY DESIGN
This is asingle -arm, open -label, prospective, multicenter Phase 3 study to assess the efficacy and safety 
of D/C/F/TAF FDC in newly diagnosed (ie, within 2 weeks of the screening/baseline visit [Day 1] ) HIV-[ADDRESS_1047541] and Treat model of care in the 
[LOCATION_003].
After obtaining informed consent, a blood sample will be collected for central laboratory testing. 
Study drug will be dispensed before the results from the screening/baseline safety and resistance 
laboratory tests are available. Subjects must start treatment with D/C/F/TAF FDC within 24 hours of the 
screening/baseline v isit. 
Following initiation of treatment, a safety assessment will be performed by [CONTACT_232133] 3 
+1week, or as soon as the final screening/baseline laboratory report becomes available. Subjects meeting  
any of the below safety stoppi[INVESTIGATOR_004] (based on the receipt of the screening /baseline laboratory findings) 
will be contact[CONTACT_764575] (ESTD) and 
for additional follow -up.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
10
Approved , Date: 16 November 2017 Estimated glomerular filtration rate (eGFR ) according to the Modification of Diet in Renal Disease 
(MDRD) formula <50 mL/min. 
 Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5×upper limit of normal 
(ULN) 
 Serum lipase ≥1.5×ULN 
 Positive serum human chorionic gonadotropin pregnancy test (β-hCG) for women of childbearing 
potential
 Laboratory results that the investigator believes should result in discontinuation of study medication 
(Note: It is recommended that the investigator contacts the sponsor’s medical monitor to discuss the 
disconti nuation)
 Subjects identified with active hepatitis C virus (HCV )infection that in the opi[INVESTIGATOR_764537] D/C/F/TAF FDC.
Retesting of abnormal screening/baseline safety laboratory values noted abov e will be allowed once. 
Retesting will take place during an unscheduled visit.
The investigator will review the ARV screening/baseline resistance data at Week 4 ±7 days or sooner, 
depending on the availability of the screening/baseline HIV genotypic drug resistance testing results from  
the central laboratory. Subjects who do not show full sensitivity to all drugs in the FDC study regimen 
according to the susceptibility assessment in the GenoSure Prime®report will be contact[CONTACT_764576]. Subjects with identified resistance to lamivudine/ FTC, attributed to the presence of 
the M184I/ V mutation alone will be permitted to remain in the study.
Subjects will be treated for 48 weeks in the main study period and will return to the site for visits at 
Weeks 2, 4, 8, 12, 24, 36, and 48. Assessment of drug accountability and reasons for non-adherence, and 
recording of concomitant therapi[INVESTIGATOR_014], adverse events, vital signs (including the subject’s body weight), and 
physical examinations (complete or symptom -directed) will be performed at each visit from baseline 
onwards. Laboratory evaluations for efficacy and safety (HIV -1 viral load, biochemistry, hematology, and 
urinalysis) will be performed at all study visits. CD4+/CD8+cell count will be assessed at Weeks 4, 8, 12, 
24, 36, and 48. Patient -reported outcome (PRO )measures will be assessed at Weeks 4, 24, and 48using 
the validated 10-item HIVTSQs (Version 2006). Medical resource utilization data will be collected from  
all subjects throughout the main study period. 
Subjects who are on study drug and who experience a protocol- defined virologic failure (see below) will 
undergo genotypic and phenotypic resistance testing, preferably at the time of the confirmed virologic 
failure visit if the HIV-1 RNA is ≥ 400 copi[INVESTIGATOR_014]/mL . If resistance testing is not able to be performed at the 
time of confirmed virologic failure, resistance testing may be perfo rmed at the point of unconfirmed 
virologic failure or a later time point if HIV-1 RNA is ≥400 copi[INVESTIGATOR_014]/mL. Subjects who have persistent 
HIV-1 RNA ≥ 400 copi[INVESTIGATOR_014]/mL past Week [ADDRESS_1047542] may be discontinued from the study at 
the investigator's discretion. If the investigator makes the decision that the subject can continue in the 
study , additional resistance testing may be performed asdeemed necessary. Protocol -defined virologic 
failure is not considered a stoppi[INVESTIGATOR_1877]. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
11
Approved , Date: 16 November 2017Virologic failure will be defined in this study as follows:
Virologic Nonresponse: 
HIV-1 RNA <1 log 10reduction from baseline, AND
HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL at the Week 12 visit, subsequently confirmed at anunscheduled visit
conducted within 2 to 4 weeks after Week 12
Virologic Rebound: 
At any visit, after achieving confirmed consecutive HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL, a rebound in 
HIV-1 RNA to ≥50 copi[INVESTIGATOR_014]/mL, which is subsequently confirmed at ascheduled or unscheduled
visit conducted within 2 to 4 weeks of the HIV-1 RNA result ; OR
At any visit, a >[ADDRESS_1047543] who has an ongoing adverse event or serious
adverse event at the time of his/her last study visit. These subjects are required to return to the site 
30days (±7 days) after completion of the last study -related visit (unless consent is withdrawn) .
Subjects who have completed the Week 48 visit will be given the opportunity to continue D/C/F/TAF 
treatment during an extension period until the D/C/F/TAF FDC tablet becomes commercially available 
and is reimbursed, or can be accessed through another source, or until the sponsor terminates clinical 
development. At Week 48 the investigat or should dispense a sufficient supply of D/C/F/TAF to maintain 
continuity of care for the subject, however no more than [ADDRESS_1047544] a study visit at the site once every 6 months , if applicable, 
and complete the procedures indicated in the TimeandEvents Schedule , and additionally at the time of 
transition to commercial D/C/F/TAF, for final data collection.
At the end of the study (or at ESTD ),subjects will resume routine clinical care with their care provider 
who will determine the future care of that subject. In anticipation of transitioning the subject to routine 
clinical care at the end of the study (or early discontinuation), the investiga tor should take steps to ensure 
a smooth transition (ie, secure insurance etc.) well in advance of the final study visit, so that the subjects’ 
ARTis not interrupted.
For those subjects discontinuing therapy before Week 48, the investigator will be asked to monitor the 
subject’s retention in care defined as having one documented clinic visit within 90days of discontinuing 
the study treatment (unless consent is withdrawn). 
The end of the study is defined as completion of the last data collection visit for the last subject 
participating in the study. For the purpose of the primary analysis, asubject will be considered to have 
completed the study if data collection as require d per protocol through the complete course of [ADDRESS_1047545] enrolled has been assessed for safety at Day 3 ,
and for resistance stoppi[INVESTIGATOR_764532] 4 . 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
12
Approved , Date: [ADDRESS_1047546] completed the Week 48 visit 
and the 30- day follow -up visit (if applicable) or discontinued earlier.
SUBJECT POPULATION
Inclusion Criteria
Sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required 
for, the study and is willing to participate in the study.
Man or w oman at least 18 years of age.
Newly diagnosed with HIV -1 evidenced by [CONTACT_764577] 2 w eeks of the screening/baseline visit:
HIV Rapid Antibody positive*; OR
HIV Immunoassay positive; OR
Positive p24 antigen and a HIV -1 RNA viral load ≥5,000 copi[INVESTIGATOR_014] /mL; OR
Non-reactive HIV-1 antibody/antigen assays and HIV-1 RNA viral load ≥5,000 copi[INVESTIGATOR_014] /mL. HIV-[ADDRESS_1047547].
*For those subjects testing initially positive on a 4thgeneration HIV Rapid Antibody Assay, results should be 
confirmed on a 3rdgeneration HIV Rapid Antibody Assay at a minimum , or an HIV Immunoassay, unless the 
investigator suspects acute or recent infection.
Antiretroviral treatment -naïve, except forthe use of TRUVADA®for pre- exposure prophylaxis (PrEP).
Contraceptive use by [CONTACT_764578]. A w oman must be either:
Postmenopausal for at least 2 years (medical documentation of cessation of menses for at least 2 years and of 
horm onal ovar ian failure [follicle -stimulating hormone (FSH) level ≥40mIU/mL ]is required) ; OR
Surgically sterile (had total hysterectomy or bilateral oophorectomy, tubal ligation/bilateral tubal clips without 
reversal operation, or otherw ise incapable of becoming pregnant); OR
Not heterosexually active for the duration of the study; OR
Have a vasectomized partner; OR
If of childbearing potential and heterosexually active, practicing a highly effective method of birth control (as 
specified below ) before entry, and agree to continue to use a highly effective method of contraception 
throughout the study, and for at least [ADDRESS_1047548] dose of study drug. Wom en with tubal 
ligation are required to use one additional contraceptive method.
Estrogen -based horm onal contraception may not be reliable when taking the study drug. Therefore, to be 
eligible for this study, women of childbearing potential should either use:
a double -barrier method (male condom + either diaphragm or cervical cap); OR
non-estrogen horm onal based contraceptives in combination with a barrier contraceptive (male condom, 
diaphragm or cervical cap, or female condom); OR
intrauterine device in combination with a barrier contraceptive (male condom, diaphra gm or cervical cap, or 
female condom).
Note : A male condom and female condom should not be used together due to risk of breakage or damage caused 
by [CONTACT_648221].
A wo man must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study 
and for [ADDRESS_1047549] agree to use ade quate reliable contraceptive methods (see 
above) during the study until [ADDRESS_1047550] dose of study drug 
Men who have had a vasectomy without reversal operation minimally 2 months prior to screening are not 
required to use birth control methods.
For all male subjects, it is the responsibility of the subject to ensure that his partner(s) do(es) not becom e 
pregnant during treatment with the study drug and for up to [ADDRESS_1047551] dose of study drug (or 
longer, if dictated by [CONTACT_427]).
Must be able to swallow whole tablets.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
13
Approved , Date: 16 November 2017Exclusion Criteria
Known active cryptococcal infection, active toxoplasmic encephalitis, Mycobacterium tuberculosis infection, or 
another acquired immunodeficiency syndrome (AIDS)- defining condition that in the judgem ent of the investigator 
would increase the risk of morbidi ty or mortality.
Known history of clinically relevant hepatic disease or hepatitis that in the investigator’s judgement is not 
compatible with D/C/F/TAF FDC.
Known history of cirrhosis as diagnosed based on local practices. 
Known history of chronic (≥3 months) renal insufficiency, defined as having an eGFR <50mL/min according to 
the MDRD formula. 
Pregnant, or breast -feeding, or planning to become pregnant while enrolled in this study or w ithin [ADDRESS_1047552] 5 years or ongoing malignancy other than cutaneous Kaposi’s 
sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma.
Known active, severe infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy 
within [ADDRESS_1047553] (eg, compromise the well-being) or that could prevent, limit, or confound the protocol -
specified assessments.
Subject unlikely to comply with the protocol requirements, based on clinical judgment.
Received an investigational drug (including investigational vaccines) or used an invasive investigational medic al 
device within [ADDRESS_1047554] dose of study treatment or is currently enrolled in an investigational 
study without prior approval from the sponsor.
Subjects receiving ongoing therapy with contraindicated, not recommended, drugs that cannot be adequately dose-
adjusted, or subjects w ith any known allergies to the excipi[INVESTIGATOR_364971] D/C/F/TAF FDC.
Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the 
direction of that investigator or study site, as well as family members of the employ ees or the investigator, or 
employees of [COMPANY_012] or [COMPANY_009].
DOSAGE AND ADMINISTRATION
All subjects will receive treatment with D/C/F/TAF FDC (DRV 800mg + COBI 150mg + FTC 200 mg 
+ TAF 10 mg)in an open -label fashion.
Initiation of study treatment can only start after all screening/baseline tests and procedures have been 
completed and must take place within 24 hours after the baseline visit. D/C/F/TAF FDC must be taken
orally with food. All subjects will be counseled to swallow D/C/F/TAF whole once daily at 
approximately the same time each day, according to their preference. 
If subjects notice that they have missed a medication intake and it is still within [ADDRESS_1047555] longer than 4 consecutive weeks. The sponsor should be notified when 
such temporary interruption occurs. 
In order to maintain continuity of care, subjects will be given the opportunity to continue the D/C/F/TAF 
treatment after Week 48 during an ext ension period until the D/C/F/TAF FDC tablet becomes 
commercially available and is reimbursed, or can be accessed through another source, or until the sponsor 
terminates clinical development.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
14
Approved , Date: 16 November 2017EFFICACY EVALUATIONS 
Antiviral Efficacy and Immunologic Change
Blood samples for determination of plasma HIV-1 RNA viral load and immunologic parameters will be 
taken at the time points specified in the TimeandEvents Schedule . 
Plasma viral load will be measured using a validated assay at acentral laboratory. 
Immunologic change will be determined by [CONTACT_184913]4+cell count (absolute and %). 
Changes in viral load, changes in CD4+cell counts (either decreases or increases), or detected resistance 
will be part of the efficacy analysis and should not be reported as adverse events or serious adverse 
events. 
Resistance Determinations
HIV-1 genotype/phenotype resistance testing will be performed at the time points specified in the Time
andEvents Schedule . 
Resistance testing at the screening/baseline visit (Day 1) will be performe d utilizing the GenoSure Prime®
assay. Resistance -associated mutations present at baseline will be reported and include mutations in the 
domain of PR, RT ,and INI.
To investigate the emergence of resistance, the following subjects will be eligible for 
geno typic/phenotypic resistance testing (PhenoSense GT®): 
 Any subject who experiences a protocol -defined virologic failure (see above) ; 
 Any subject who discontinues study treatment after Week 12 for any reason and has an HIV-1 RNA 
value ≥400 copi[INVESTIGATOR_014] /mL at the last viral load measurement ;
 Any subject who haspersistent HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL past Week 24 but does not meet the 
definition of virologic failure . 
Baseline phenotypi[INVESTIGATOR_764538] -defined 
virologic failure if after virologic failure they showed evidence of reduced phenotypi [INVESTIGATOR_764539]. Evaluations may be performed at o ther time points at the sponsor’s discretion.
PHARMACOKINETIC EVALUATIONS
Plasma concentrations of DRV and COBI may be determined in subjects experiencing protocol -defined 
virologic failure , or subjects who have persistent HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL past Week 24 but do not 
meet the definition of virologic failure ,using stored blood samples collected throughout the study, if 
deemed necessary.
MEDICAL RESOURCE UTILIZATION AND HEALTH ECONOMICS
Medical resource utilization data will be collected in the electronic case report form (eCRF) by [CONTACT_154915] -site personnel . The following will be evaluated throughout the study as noted in 
the TimeandEvents Schedule : 
 Number and duration of hospi[INVESTIGATOR_602].
 Number of outpatient visits, including type of visit (eg, general practitioner, specialist)
 Number of emergency room visits.
 Number and type of medications used (from the Concomitant Medication page of the eCRF) . 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
15
Approved , Date: [ADDRESS_1047556] self -report, using a 4 -day recall period .
Subjects should be counseled regarding the importance of adherence, and be instructed to bring unused 
medication and empty packaging to the unit at each visit.
RETENTION IN CARE
Retention in care will be described as the proportion of subjects who discontinue study treatment prior to 
Week 48 and remain in care after discontinuation (defined as having a documented office visit within 
90days of discontinuing the study drug). Subjects who withdraw consent will not be followed to assess 
retention in care. 
SAFETY EVALUATIONS
Safety and tolerability will be evaluated throughout the study from the time a signed and dated ICF is 
obtained until completion of the subject’s last study -related activity.
The study will include the following evaluations of safety and tolerability as indicated in the Timeand
Events Schedule :
 Adverse events ;
 Clinical laboratory tests (including biochemistry, hematology, urinalysis, urine chemistry);
 Vital signs;
 Physical examination (complete or symptom -directed);
 Follow -up on specific toxicities.
PATIENT -REPORTED OUTCOMES
Patient- reported outcomes will be assessed at the time points indicated in the TimeandEvents Schedule
utilizing the HIVTSQs.
STATISTICAL METHODS
The following analyses will be performed:
 The interim analysis: once all subjects have been assessed for safety at Day 3,and for resistance 
stoppi[INVESTIGATOR_764532] 4.
 The primary analysis: once all subjects have completed the Week 48 assessments and the 30-day 
follow -up visit (if applicable), or discontinued earlier.
Sample Size Determination 
The primary efficacy endpoint is the proportion of subjects who have HIV-1 RNA<50 copi[INVESTIGATOR_014]/m L at 
Week 48 as defined by [CONTACT_90706] (ITT). As this is an exploratory study with no formal 
hypothesis testing on the primary endpoint, no formal sample size calculation was performed. With a 
sample size of 100 subjects and an expected virol ogic response rate ranging from 60-80%, the exact 
corresponding 95% confidence intervals (CIs) are: 60% (49.7%, 69.7%), 70% (60.0%, 78.8%), and 80% 
(70.8%, 87.3%). The half-width of the exact corresponding 2-sided 95% CI is10.0%, 9.4%, and 8.3%, 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
16
Approved , Date: 16 November 2017respectively ,and is therefore less than 10% across the range of expected outcomes which is the desired 
precision . Additionally, with a sample size of 100 subjects, the probability to observe an adverse event 
with a true incidence of 1% or 4% is 63% and 98 % respectively .
Efficacy Analyses
Antiviral Efficacy and Immunologic Change
The primary efficacy endpoint is the proportion of subjects who have HIV-1 RNA<50 copi[INVESTIGATOR_014] /mL at 
Week 48 as defined by [CONTACT_90706] (ITT). 
Virologic suppression (HIV -1RNA<50 copi[INVESTIGATOR_014]/mL) will also be analyzed as secondary endpoints at 
Week 24 and Week 48 according to the below analyses:
 FDA Snapshot algorithm in the ITT and Per -Protocol population
 Time to loss of virological response (TLOVR) algorithm in the ITT populati on
Virologic decay will be reported as the mean log 10change in HIV-1 viral load from baseline to Weeks 2, 
4, 8, 12, and 24 as part of the interim analysis as a secondary endpoint.
The proportion of subjects experiencing protocol defined virologic failure at Week 24 and Week 48 will 
be tabulated using descriptive statistics along with the 95% CIs. The Wilson (Score) method for the CI 
will be used. 
The changes from baseline in CD4+cell count at Weeks 12, 24, and 48 will be summarized using 
descriptive stat istics. 
Resistance Determinations
The number of PR mutations (including International AIDS Society -[LOCATION_002] of America [IAS -[LOCATION_003]] 
primary and secondary PI [INVESTIGATOR_764540]), RT mutations (including IAS-[LOCATION_003] nucleoside/nucleotide RT inhibitor 
[N(t)RTI] RAMs and IAS-[LOCATION_003] non-nucleoside RT inhibitor [NN(t)RTI] RAMs), and INI mutations 
(including IAS-[LOCATION_003] primary and secondary INI-RAM s)present will be tabulated based on resistance 
tests performed at the screening/baseline visit. 
The proportion of subjects meeting resistance stoppi[INVESTIGATOR_004], requiring discontinuation of study drug, 
based on the findings of screening /baseline resistance testing will be tabulated as part of the interim  
analysis. 
HIV-1 genotype/phenotype will be analyzed from samples of subjects with protocol -defined virologic 
failure and with HIV -1 RNA ≥400 copi[INVESTIGATOR_014] /mL. 
The number of treatment -emergent PR mutations (including IAS-[LOCATION_003] primary and secondary PI [INVESTIGATOR_764540])
and RT m utations (including IAS-[LOCATION_003] N(t)RTI RAMs andIAS-[LOCATION_003] NNRTI RAMs), as well as specific 
mutations associated with resistance to DRV, FTC, and TAF will be tabulated based on the observed 
protocol- defined virologic failures through the study period . 
Fold change (FC) in 50% effective concentration (EC 50)of ARVs will betabulated .Loss of phenotypic 
susceptibility may be analyzed dependent on the number of virologic failures and phenotypes available 
through the study period.
Medical Resource Utilization Analyses 
All-cause and HIV-specific HRU during the study period will be summarized overall and by [CONTACT_764579] (PPPM) . Monthly average counts per subject will also be calculated to 
show the temporal trend for each cate gory. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
17
Approved , Date: 16 November 2017Costs of care will be calculated by [CONTACT_764580] & Medicaid Services 
(CMS) fee schedule to assessed HRU on a per subject per month basis. Descriptive statistics will be 
calculated to compare the costs of care from baseline to Weeks 12, 24, and 48. 
Adherence Analyses
Treatment adherence based on pi[INVESTIGATOR_764541]-report will be summarized by [CONTACT_764581].
Adherence rates will be reported according to the propor tion of subjects taking >95%, 80 -95% and <80% 
of study drug as assessed by [CONTACT_21173][INVESTIGATOR_764542] 4, 12, 24, and 48.
Retention in Care Analyses
Number of subject with retention of care by [CONTACT_654], gender, race, sexual orientation, time from diagnosis to 
baseline visit, baseline CD4+ cell count, baseline HIV-1 RNA, patient satisfaction as assessed by 
[CONTACT_764582], and socioeconomic factors will be tabulated .
Safety Analyses
The verbatim terms used by [CONTACT_764583] s will becoded using the Medical 
Dictionary forRegulatory Activities (MedDRA). All reported adverse event s with onset during the study 
will be included in theanalysis. For each adverse event , the percentage of subjects who experience 
≥1occurrence of the given e vent will be summarized.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those subjects 
who die, who discontinue treatment due to an adv erse event, or who experience a severe or life-
threatening (grade 3 or 4) or a serious adverse event .
Additionally, a summary and listing of those subjects meeting predefined stoppi[INVESTIGATOR_764543].
Laboratory data will be summarized by [CONTACT_58696]. Descriptive statistics will becalculated for each 
laboratory analyte for observed values and changes from baseline at each scheduled time point. Graphical 
presentation of changes in laboratory parameters can be made as applicable.
Abnormalities will be determined according to the Division of AIDS (DAIDS) grading table and in
accordance with the normal ranges of the clinical laboratory. Maximum toxicity grade after baseline will 
be tabulated and special attention will be given to the subjects who developed grade 3 or 4 toxicities.
Descriptiv e statistics of vital signs (pulse rate, systolic and diastolic blood pressure ,and body weight ) 
values and changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinically important limits wil l be tabulated.
Physical examination findings and changes from baseline at each scheduled time point will be listed.
Patient -reported Outcomes 
Descriptive statistics for absolutes values and changes in HIVTSQ sscores will be calculated at each time
point, where applicable. 
Extension Period
For the extension period, descriptive statistics or patient data listing swill be provided for adverse events, 
virologic failure, or resistance.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
18
Approved , Date: 16 November 2017TIMEAND EVENTS SCHEDULE
PhaseOpen -label Treatment PhaseESTD 
(Early 
Study 
Treatm ent 
Discont -
inuation) 
Visite30-day 
Follow -
upf90-day 
Follow -
upDay 1
Screening/
BaselinebMain Study 
PeriodExtension 
Periodd
Weeka
Day 3 
Safety 
Assessmentc2 4 8 12 24 36 48
Study Procedures
Screening/Administrative
Informed consent processgX
Dem ographic information X
Medical historyhX
HIV history X
Inclusion/exclusion criteria X
Determine Continued Eligibility (by [CONTACT_10670]) 
Form al review of central screening/baseline 
safety laboratory test s by [CONTACT_1697] (no 
scheduled clinic visit)X
Form al review of screening/baseline HIV 
genotypic drug resistance testing by 
[CONTACT_764584] X X X X X XkXk
Drug accountability (pi[INVESTIGATOR_692])lX X X X X X X X
Adherence (subject self -report)mX X X X X X X X
Efficacy Assessments
HIV-1 RNAnX X X X X X X X X X X
CD4+/CD8+X X X X X X X X X
Com bined Genotype/PhenotypeoXpX X X X X X X X X
Safety Assessments
Vital signs, body weight and heightqX X X X X X X X X X X
Full physical examinationrX X X X
Symptom -directed physical examinationrX X X X X X X X
Revie w concom itant medications X X X X X X X X X X X
Adverse events assessmentsX X X X X X X X X X X
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
19
Approved , Date: 16 November 2017Note: R etesting of abnormal screening/baseline safety laboratory values that may lead to exclusion will be allow ed once.
Unscheduled visit(s) may be required for safety reasons, for technical issues with the samples, or for confirmation of virologic failure in case of unconfirmed virologic 
failure (virologic nonresponse or virologic rebound [see Attachment 1]). When human immunodeficiency virus ( HIV)-1 ribonucleic acid ( RNA )repeat testing is 
required at an unscheduled visit, an HIV -1 genotype/phenotype plasma sample and a plasma storage sample should also be drawn at the same unscheduled visit. 
a.All study visits are to be scheduled relative to the screening/ baseline visit date and are to occur at the end of Weeks 2, 4, 8, 12, 24, 36, and 48 . A window of ±2 days 
is allowed for Visit 2. All other study visits through Week 48 are to be completed within ±7 days of the protocol -specified visit date .
b.Screening /baseline visit should be w ithin 2 weeks of diagnosis. The screening and baseline assessments should preferably be completed the same day (Day 1), but if 
necessary, can be performed on different days, but must be completed with in2 business days of signing the ICF. Study drug s hould not be dispensed until all 
screening procedures have been completed and the investigator has determined that the subject meets the inclusion/exclusion c riteria.
c.A safety assessment will be performed by [CONTACT_232133] 3 +1 w eek, or as soon as the final screening/baseline laboratory report becomes available. Subjects 
meeting any of the safety stoppi[INVESTIGATOR_764544] w-up.
d.Subjects will have a study visit at the site once every 6 months, if applicable, and additionally at the time of transition to commercial D/C/F/TAF .
e.Subjects who prematurely discontinue study treatment during the open -label treatment period (ie, including the extension period) will be required to complete ESTD 
assessments as soon as possible but no later than 1 w eek of discontinuing study treatment.PhaseOpen -label Treatment PhaseESTD 
(Early 
Study 
Treatm ent 
Discont -
inuation) 
Visite30-day 
Follow -
upf90-day 
Follow -
upDay 1
Screening/
BaselinebMain Study 
PeriodExtension 
Periodd
Weeka
Day 3 
Safety 
Assessmentc2 4 8 12 24 36 48
Study Procedures
Health Outcome Assessments
Medical resource utilization X X X X X X X XuX
HIV Treatment Satisfaction Questionnaire 
(HIVTSQ s)tX X X Xu
Clinical Laboratory Assessments
Hepatitis B/C serology X
Estimated glomerular filtration rate (eGFR) X X X X X X X X X X X
GenotypevX
Pregnancy testwX X X X X X X X X X X
Hem atology XxXxXxX XxX X XxX X X
Chemistry X X X X X X X X X X X
Serum amylase/lipaseyX
UrinalysiszX X X X X X X X X X X
Other
Retention in care assessment Xbb
Blood samples storedaa
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
20
Approved , Date: [ADDRESS_1047557] w ho has an ongoing adverse event or serious adverse event at the time of his/her last study visit (unless consent is withdrawn); a ±7 days 
window  may be used.
g.Signing of the inform ed consent form ( ICF)needs to be done before the first study -related activity .
h.Including family history of premature cardiovascular disease, diabetes, hypertension, low  high-density lipopr otein ( HDL )cholesterol, and prior history of 
cardiovascular disease.
i.The investigator will review the antiretroviral ( ARV )screening/baseline resistance data at Week 4 ±7 days or sooner, depending on the availability of the 
screening/baseline HIV genotypic drug resistance testing results from the central laboratory .
j.Subjects must start treatment within 24 hours of the screening/baseline visit (Day 1).
k. At Week 48 the investigator should dispense a sufficient supply of D/C/F/TAF to maintain continuit y of care for the subject, how ever no more than [ADDRESS_1047558] self -report, using a 4 -day recall .
n.Leftover blood samples from the HIV-1 RNA determinations could be used for protocol -related testing (virology, safety, pharmacokinetic anal ysis) at additional 
time points.
o.Com bined genotype/phenotype ( PhenoSense GT®) will be assessed at the central laborat ory for subjects who experience a protocol -defined virologic failure, for 
subjects who discontinue study treatment after Week [ADDRESS_1047559] HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL , or for subjects who have persistent HIV -1 RNA ≥400 copi[INVESTIGATOR_014]/mL 
past Week [ADDRESS_1047560] of the sponsor’s virologist .
p.Baseline phenotypi[INVESTIGATOR_764545] w ith confirmed protocol -defined virologic failure if after virologic failure they showed evidence 
of reduced phenotypic susceptibility to any of the study drugs. Evaluations may be performed at other time points at the sponsor’s discretion .
q.Vital signs include systolic and diastolic blood pressure, pulse rate (supi[INVESTIGATOR_184819] [ADDRESS_1047561]), and weight. Hei ght will be measured at screening.
r.A complete physical examination will be conducted at screening , Week 48, at the time of transition to commercial D/C/F/TAF , or at the ESTD visit . Sym ptom  
directed physical exam ination s may be conducted at all other scheduled and unscheduled study visits based on reported safety or tolerability issues.
s.In the setting of a sus pected renal adverse event, urine chemistry (quantitative measurement) w ill be assessed: creatinine, sodium, phosphate, gluco se, protein, 
albumin.
t.The HIVTSQs assessment should be completed before all other study -related procedures planned during these vis its to prevent influencing subject perceptions .
u.MRU and the HIVTSQ w ill not be collected as part of ESTD during the extension period .
v.Genotype ( GenoSure Prime®) will be assessed at the time of screening .
w.At screening ,pregnancy will be determined by [CONTACT_764585]. A serum human chorionic gon adotropin 
(β-hCG )pregnancy test will be assessed at a central lab oratory , but the results are not required for enrollment. Subsequently pregnancy will be assessed by [CONTACT_764586].
x.Peripheral blood mononuclear cells ( PBMCs )will be isolated from whole blood at the central laboratory , and stored for future analysis if needed.
y.Serum amylase and serum lipase will be asses sed at screening. If a subject is suspected of having pancreatitis during the study period serum amylase and serum 
lipase may be reassessed at scheduled or unscheduled visits .
z.Urinalysis (dipstick) . If dipstick results are abnormal, the sediment will be examined microscopi[INVESTIGATOR_897] .
aa.Plasma concentrations of darunavir ( DRV )and cobicistat (COBI )may be assessed from stored blood samples in those subjects who experience protocol -defined 
virologic failure , or subjects who have persistent HIV -1 RNA ≥400 copi[INVESTIGATOR_014]/mL past Week 24 but do not meet the definition of virologic failure .
bb.Subjects who discontinue study drug for any reason before Week 48 w ill be assessed for completion of a documented clinic visit within 90 days of discontinuing 
study drug (providing consent is not withdrawn).
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
21
Approved , Date: [ADDRESS_1047562] cancer resistance protein
BMD bone mineral density 
BMI body mass index
BPAP bilevel positive airw ay pressure
bpm beats per minute
BUN blood urea nitrogen
C cobicistat
CAD coronary artery disease
CFR Code of Federal Regulations 
CHD coronary heart disease
CI confidence interval
CKD -EPI [INVESTIGATOR_764546] & Medicaid services
CNS central nervous system
COBI cobicistat
CPAP continuous positive airway pressure
CYP cytochrome P450
D darunavir
D/C/F/TAF darunavir/cobicistat/emtricitabine/tenofovir alafenamide
DAIDS Division of AIDS
DBP diastolic blood pressure 
DHHS Department of Health and Human Services
DRESS drug rash with eosinophilia and systemic symptoms
DRV darunavir (formerly known as TMC114)
DTG dolutegravir (formerly known as S/[COMPANY_004]1349572)
E elvitegravir
E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
EC 50 50% effective concentration
ECG electrocardiogram
eCRF electronic case report form 
eDC electronic data capture
eGFR estimated glomerular filtration rate 
eGFRcreatinine eGFR for creatinine clearance 
ESTD early study treatment discontinuation
EU European Union
EVG elvitegravir
F emtricitabine
FC fold change
FDA Food and Drug Administration 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
22
Approved , Date: 16 November 2017FDC fixed -dose combination
FTC emtricitabine
GCP Good Clinical Practice
GSI [COMPANY_009] Sciences, Inc
HAART highly -active antiretroviral therapy
HBc hepatitis B core
HBs hepatitis B surface
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCO 3 bicarbonate
HCV hepatitis C virus
HDL high-density lipoprotein
HDPE high-density polyethylene
HIV human immunodeficiency virus
HIV-1 human immunodeficiency virus type 1
HIVTSQs HIV Treatment Satisfaction Questionnaire -status version
HRU healthcare resource utilization
IAS-[LOCATION_003] International AIDS Society -[LOCATION_002] of America
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
ID identification
IEC Independent Ethics Committee
IND Investigational New Drug
INI integrase
INR international normalized ratio
IRB Institutional Review Board
ITT intent to treat
IV intravenous
LDL low-density lipoprotein
LLN lower limit of normal range
MATE multi -antimicrobial extrusion protein
MDR1 multidrug resistance protein [ADDRESS_1047563] Modification of Diet in Renal Disease
MedDRA Medical Dictionary for Regulatory Activities
N(t)RTI nucleoside/nucleotide reverse transcriptase inhibitor
N[t]RTI nucleoside/nucleotide reverse transcriptase inhibitor
NA not applicable
NCEP National Cholesterol Education Program 
NN(t)RTI non-nucleoside/nucleotide reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
OATP organic anion -transporting polypeptide
PBMCs peripheral blood mononucleated cells
P-gp P-glycoprotein
PI [INVESTIGATOR_764547]-exposure prophylaxis
PRO patient -reported outcome(s) (paper or electronic as appropriate for this study)
PT prothrombin time
PTT partial thromboplastin time
RAM resistance -associated mutation
RAPID Rapid ART Program for Individuals with an HIV Diagnosis 
RBC red blood cell
RNA ribonucleic acid
RPV rilpi[INVESTIGATOR_764548]
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
23
Approved , Date: 16 November 2017rtv ritonavir when used as pharmacokinetic booster
RTV ritonavir
SBP systolic blood pressure 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic -pyruvic transaminase
SJS Stevens -Johnson syndrome
START Strategic Timing of Antiretroviral Therapy
S[LOCATION_003]R suspected unexpected serious adverse reaction
TAF tenofovir alafenamide
TDF tenofovir disoproxil fumarate
TEN toxic epi[INVESTIGATOR_764549]114 Tibotec Medicinal Compound 114 (darunavir)
UGT1A1 uridine diphosphate glucuronosyltransferase 1A1
ULN upper limit of normal range
[LOCATION_003] [LOCATION_002] of America
WBC white blood cell
WHO World Health Organization
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
24
Approved , Date: 16 November [ZIP_CODE]. INTRODUCTION
1.1. Study Drug
The darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed -dose 
combination (FDC) tablet is a 4-agent FDC tablet in development for oral once -daily use for the 
treatment of human immunodeficiency  virus (HIV)-1 infection. This tablet contains the protease 
inhibitor (PI ) darunavir (DRV or D) (800 mg), the pharmacokinetic enhancer cobicistat (COBI or 
C) (150 mg), the nucleoside reverse transcriptase inhibitor (NRTI ) emtricitabine (FTC or F) 
(200 mg), and the tenofovir (TFV) prodrug tenofovir alafenamide (TAF) (10 mg).
Darunavir (PREZI STA®) used with a pharmacokinetic booster is approved for treatment of 
HIV-[ADDRESS_1047564] s aged 3 years and above, either as a 600-mg twice -daily treatment for 
antiretroviral therapy  (ART)-experienced subjects or as an 800-mg once -daily treatment for 
ART -naïve subjects and ART -experienced subjects without DRV resistance -associated 
mutations (RAMs).28
Cobicistat (Tybost®) 150mgis approved as apharmacokinetic enhancer of select antiretroviral 
(ARV) agents requiring the effects of a pharmacokinetic enhancer .39
The DRV/COBI 800/150 -mg FDC tablet (PREZCOBIX®) is a once -daily  treatment approved for 
use in combination with other ARV agents for treatment of HIV-1 infected treatment -naïve and 
treatment -experienced adults without DRV RAMs.27
Emtricitabine is approved for use in combination with other agents for the treatment of HIV-1 
infection in adults and children (4 months of age or older) and is available as a single agent 
(Emtriva®) oras part of FDCs, including Descovy®(F/TAF).8,10
Tenofovir alafenamide is approved as part of FDCs, including Descovy®(FTC/TAF ), Genvoy a®
(elvitegravir [EVG]/COBI/FTC/TAF or E/C/F/TAF) , and Odefsey®(rilpi[INVESTIGATOR_12979] 
[RPV]/FTC/TAF) . Descovy®is a once -daily  treatment approved for use in combination with 
other ARV agents (including DRV/COBI) for treatment of HIV- 1 infected adults and a dolescents 
(aged 12 years and older).8,11,23
The D/C/F/TAF FDC tablet is intended as a complete regimen for the treatment of HIV-1 
infection in adults and adolescents (aged 12 years and older) with no mutations known to be 
associated with resistance to any of the active components. The D/C/F/TAF FDC is currently 
being studied in 2 ongoing Phase 3 clinical studies ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]).[ADDRESS_1047565] comprehensive nonclinical and clinical information regarding the study  drug, refer
to the I nvestigator’s Brochure (IB) for D/C/F/TAF and its addendum.14,[ADDRESS_1047566] around the world. In 2015, approximately  36.7 million people were 
living with HIV-1 worldwide, an estimated 2.1million people became newly infected with 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
25
Approved , Date: 16 November 2017HIV-1 and 1.1 million died from acquired immunodeficiency  syndrome ( AIDS)-related causes.[ADDRESS_1047567] been significa ntly advanced by 
[CONTACT_184881] -active antiretroviral therap y (HAART); the introduction of HAART 
was associated with a dramatic decrease in AIDS -related morbidity  and mortality .9,21,[ADDRESS_1047568] 
accomplished by [CONTACT_764587]-1 ribonucleic acid (RNA) (viral load) below limits of quantification. Durable viral 
suppression improves immune function and overall quality  oflife, lowers the risk of both AIDS-
defining and non-AIDS-defining complications, and prolongs life.9Furthermore, high plasma 
HIV-1 RNA is a major risk factor for HIV transmission, and effective ART can reduce viremia 
and transmission of HIV to sexual partners b y more than 96%.7,29Thus, a secondary  goal of ART 
is to reduce the risk of HIV transmission.
Since 2012, the [LOCATION_002] ([LOCATION_003]) Department of Health and Human Services (DHHS) Panel 
on Antiretroviral Guidelines for Adults and Adolescents (the Panel) has recommended initiating 
ART in all HIV-infected subjects , regardless of CD4+cell count .9More recentl y, based on 
findings from 2large, randomized controlled studies that addressed the optimal time to initiate 
ART (ie,START [Strategic Timing of Antiretroviral Therap y]13and TEMPRANO37),the Panel 
increased the strength and evidence rating of this recommendation. 
While increased HIV screening efforts have helped identify  nearly 85% of 1.2 million people 
living with HIV in the [LOCATION_003], a significant gap exists in the percentage of subjects who are 
activel y engaged in care (40%), prescribed ART (37%), and those who achieve virologic 
suppression (30%) .3Many  factors may influence a subject ’s ability  or desire to be engaged in 
care, and efforts to improve engagement in care are currently  being explored as part of the 
National HIV/AIDS Strategy . One potential intervention to improve engagement in care and 
potentially  the receipt of suppressive ART is the initiation of ART through a Test and Treat 
model of care. 
In traditional care models, before starting ART, it is recommended that healthcare providers 
assess various patient specific factors, including but not limited to pretreatment HIV RNA level, 
CD4+cell count, results of baseline HIV genot ypic drug resistance testing, baseline renal and 
hepatic function, pre-existing medical conditions that could affect or be affected by [CONTACT_309231], and 
regimen-specific considerations such as potential adverse effect profile, a regimen’s genetic 
barrier to resistance, and dosing requirements. While some of these assessments can be made 
relativel y quickl y, several require advanced laboratory  testin g, which can take 2to 3weeks for 
results to become available (particularl y HIV genoty pic drug resistance testing). Traditional care 
models often require multiple clinic visits to identify  a feasible regimen for subject s, potentiall y 
increasing the percen tage of subject s who do not return to initiate ART after diagnosis.9
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
26
Approved , Date: [ADDRESS_1047569] detected a 76% increase in rates of virologic suppression and a 65% decrease 
in the risk of mortality  in the group who started ART immediately  compared those who delay ed 
ART initation.17A similar study  (RapIT) is currently  ongoing in South Africa.30Test and Treat 
models have also been explored in the developed world, but in smaller patient populations. 
Pi[INVESTIGATOR_764550], recentl y compared outcomes of subject s who initiated ART between [ADDRESS_1047570] and Treat model (n=39), or a traditional model of care (n=47). In this cohort, 
the median time to suppression was reduced from 4.[ADDRESS_1047571] s managed according to the “Rapid ART Program for 
Individuals with an HIV Diagnosis ( RAPID )” care initiation protocol .[ADDRESS_1047572] and Treat
model of care, it is important to consider a regimen’s ability  to work in the setting of possible
resistance, the safet y of that regimen, and the subject ’s ability  to adhere to such a regimen. 
Currently ,the DHHS treatment guidelines recommend baseline genoty pic resistance testing for 
all newly  diagnosed subject s before starting ART as 10% to 17% ofART -naïve subject s may 
have evidence of transmitted drug-resistant HIV strains.9,46However, recognizing a potential 
benefit in initiating treatment sooner in certain populations such as those with acute HIV 
infection, pregnancy , and opportunistic infections, the DHHS treatment guidelines have provided 
guidance on ART initiation while awaiting the results of HIV genot ypic drug resistance testing, 
or when resistance testing is not available. In those individuals in whom treatment needs to begin 
before resistance testing result s are available, boosted -DRV may have an important role given 
the low rate of transmitted PI [CONTACT_41634], its high genetic barrier to resistance, and low rate of 
treatment -emergent resistance during many ye ars of clinical experience.9While genotypic 
resistance testing is recommended for all newly  diagnosed subject s before starting ART, once -
daily  boosted- DRV may be used in treatment -naïve subjects without conducting baseline 
genot ypic and or phenoty pic resistance testing due to its unique resistance profile and due to the 
very low prevalence of DRV RAMs in treatment- naïve subjects .27,28Eleven HIV -1 protease (PR) 
mutations associated with DRV resistance were previously  identified ,based on analysis of a 
pooled dataset of studies in highl y treatment -experienced subjects (ie,V11I , V32I, L33F, I47V, 
I50V, I54L/M, T74P, L76V, I84V, and L89V); the virologic efficacy  of DRV (with ritonavir 
used as pharmacokinetic booster [rtv]) is compromised in the presence of ≥3DRV RAMs and 
each of the 11 DRV RAMs is found in association with amedian number of 13 to 
15International AIDS Society -[LOCATION_002] of America (IAS-[LOCATION_003] )PI [INVESTIGATOR_764540] .28In a  recent 
analysis of nearl y 78,000 isolates obtained and submitted in the [LOCATION_003]for routine genot ypic 
resistance testing, the prevalence of isolates without DRV RAM sincreased consistently  from 
77.7% in 2006 to 92.8% in 2012, indicating a low prevalence of DRV RAMs.18In the same 
analysis a very low proportion of isolates (2.6%) were identified as having ≥[ADDRESS_1047573] s 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
27
Approved , Date: 16 November 2017experiencing virologic failure, boosted- darunavir (either with rtv or COBI ) demonstrated a high 
genetic barrier to resistance, with almost no treatment -emergent pr imary  or DRV RAMs and no 
loss of DRV susceptibility detected.24,[ADDRESS_1047574] ’s ability  to 
adhere to a regimen. Currently , there are only [ADDRESS_1047575] s: Genvo ya®(or E/C/F/TAF); Stribild®(EVG/COBI/FTC/ tenofovir 
disoproxil fumarate (TDF )or E/C/F/TDF); and Triumeq®(abacavir [ABC] /lamivudine 
[3TC]/dolutegravir [DTG]).9These single -tablet regimens have characteristics that limit their 
ability  to be used in a Test and Treat model of care. Elvitegravir has been noted to have a low 
genetic barrier to resistance, evidenced by [CONTACT_3148]- emergent primary  integrase (INI) mutations 
developi[INVESTIGATOR_764551] -naïve subject s who experience virologic failure.11Triumeq®contains 
ABC, which requires human leukocy te antigen (HLA )-B*[ADDRESS_1047576] adherence 
levels. Once -daily boosted- darunavir has been extensively  studied in Phase 3 clinical studie s. 
ARTEMI S (AntiRetroviral Therap y with Tibotec Medicinal Compound 114 (TMC114 )
Examined In naïve Subjects; [STUDY_ID_REMOVED]), a randomized, open -label, Phase 3, 192 -week 
study evaluating the safet y and efficacy  of once daily DRV/ ritonavir (RTV ), showed a 
discontinuation rate due to adverse drug reactions (ADRs) of only 2.3% at 192weeks. The most 
common clinical ADRs to DRV/RTV greater than or equal to grade 2 were diarrhea, nausea, 
rash, headache, abdominal pain, and vomiting.24Additionally , in Study  0130, a Phase 3b open -
label, single -arm study designed to evaluate the safet y, tolerability , efficacy ,and 
pharmacokinetics of COBI -boosted DRV in HIV-1 infected adults (as single agents) in 
combination with 2fully active, investigator -selected nucleoside/nucleotide reverse transcriptase 
inhibitors ( N[t]RTI s), ADRs associated with DRV + COBI evaluated through Week 24 or 48 did 
not differ substantially  from those reporte d in clinical studies with DRV/RTV.36Ongoing 
Phase 3 studies are evaluating the efficacy  and safety  profile of D/C/F/TAF.2The combination of 
D/C/F/TAF is not anticipated to exacerbate known toxicities or lead to new toxicities compared 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
28
Approved , Date: 16 November 2017with DRV/COBI  FDC coadministered with FTC/TDF FDC. TAF and FTC have established 
clinical safet y profiles with no significant toxicities observed.
Given these factors, the single -tablet regimen of D/C/F/TAF may serve as an ideal regimen for a 
Test and Treat model of care, combining potency , sustained efficacy ,a high genetic barrier to 
resistance, with a well described safet y profile of the individual components, and practical, 
convenient dosing.
1.2.1. Darunavir (PREZISTA®)
Darunavir (formerl y known as TMC114) is an inhibitor of the cataly tic activity  of HIV-[ADDRESS_1047577] registered in the [LOCATION_003](June 2006) and has obtained marketing authorization 
in the European Union (EU) in February 2007. As of 23 December 2014, DRV was registered in 
more than 99 countries around the world. Adverse drug reactions identified during postmarking 
experience were: drug hypersensitivity , angioedema, urticaria, osteonecrosis, toxic epi[INVESTIGATOR_184793] (TEN), acute generalized exanthematous pustulosis (AGEP), and drug rash with 
eosinophilia and sy stemic sy mptoms (DRESS). 
In treatment -naïve and treatm ent-experienced patients with no DRV RAMs, the recommended 
dose of DRV is 800mg taken with a booster once daily  and with food. This dose 
recommendation is generally  safe and well tolerated. The majorit y of the DRV ADRs reported 
inthePhase 3 studies during treatment with DRV/rtv and NRTIs were mild in severit y. In 
ART-naïve HIV-1 infected adult subjects (343 subjects, total exposure of 1,072 patient years), 
the most frequent (≥5%) ADRs of moderate to severe (grade 2 to 4) intensity  with DRV/rtv 
800/10 0mgonce daily were diarrhea, headache and abdominal pain. Only 2.3% of the subjects 
discontinued DRV treatment due to ADRs. Frequency , type and severit y of ADRs in pediatric 
patients were comparable to those observed in adults.
1.2.2. Cobicistat ( Tybost®)
Cobic istat (formerl y known as GS- 9350) is a structural analog of rtv that has been shown to be a 
potent inhibitor of cy tochrome P450 ( CYP) 3A enzy mes. Cobicistat has been shown to be a more 
specific, mechanism -based CYP3A inhibitor than rtv. Cobicistat display s weak to minimal 
inhibition of other CYP enzy mes; it is a less potent inducer of other metabolizing enzy mes in 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
29
Approved , Date: [ADDRESS_1047578] fewer 
adverse biochemical effects (eg, effect on adipocy te functions such as lipid accumulation) than 
rtv.
Cobicistat , as a single 150-mg tablet, has been developed by [CONTACT_10869], Inc (GSI)and is 
approved for once daily use in adults as apharmacokinetic enhancer to increase systemic 
exposure levels of coadministered drugs metabolized by  [CONTACT_097]3A , including PI s such as DRV and 
atazanavir (ATV) for the treatment of HIV-1 infection. Cobicistat has also been coformulated 
with other HIV-1 ARV drugs in several FDCs such as DRV/COBI (codeveloped by [CONTACT_764588]), ATV/COBI (codeveloped by [CONTACT_184887] -Myers Squibb), a combination tablet 
containing EVG boosted with COBI, and FTC + TDF (or E/C/F/TDF, by  [CONTACT_184883]) for use in HIV-1-
infected, ART-naïve patients. As part of these FDCs, COBI  has shown to inhibit CYP3A -
mediated metabolism of EVG, ATV, and DRV similar to rtv. The FDC DRV/COBI 
(PREZCOBIXTM/REZOLSTA®) has recentl y been approved in Canada, Europe and the United 
States, and is indicated in combination with other ARV medicinal products for the treatment of 
HIV-[ADDRESS_1047579] been established in the pi[INVESTIGATOR_9205] 3 Study  
GS-US-216-0114 and the supportive P hase 2 Study  GS- US-216-0105. Both of these studies were 
double -blind and active -controlled studies with combination ARV regimens in ART-naïve 
subjects with HIV-1 infection, and both studies were designed to compare COBI -boosted ATV 
with rtv-boosted ATV in combination with FTC and TDF. In addition, study  GS-US-216-0130 
demonstrated the safet y and efficacy  of COBI with DRV dosed in a once daily  regimen 
combined with a backbone therap y of 2 NRTIs in HIV-1 infected, ART-naïve and treatment -
experienced adults with no DRV RAMs.
In the clinical studies to date, COBI 150-mg tablets, dosed daily for up to 60 weeks, were 
generall y well tolerated, did not cause clinically significant toxicities in humans that were 
identified in nonclinical testing (heart, liver, thyroid abnormalities, and decreased 
immunoglobulin Glevels), and did not potentiate the side effects of the coadministered ARV 
medications. In Phase 2 clinical studies (GS-US-216-0105 and GS-US-236-0104), small 
(approximately  12% to 15%) decreases in estimated glomerular filtration rate (eGFR) calculated 
using the Cockcroft -Gault calculation occurred within the first few weeks of COBI  initiation (in 
GS-US-216-0105, the decreases were comparable to those associated with rtv in the comparator 
group). 
A Phase [ADDRESS_1047580] that COBI blocks secretion of serum creatinine, resulting in a 
difference between eGFR and actual GFR, as seen with several other drugs that are currently 
approved, including trimethoprim and cimetidine. The increase in serum creatinine with COBI 
occurs within days of drug initiation and is reversible with values returning to baseline within 
days of cessation of COBI. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
30
Approved , Date: 16 November [ZIP_CODE].2.3. Emtricitabine (Emtriva®)
Emtricitabine is an NRTI for the treatment of HIV -1 infection, in com bination with other ARVs, 
in adults and pediatrics patients aged 3 months and older. Emtricitabine has been developed by 
[CONTACT_764589] a once -daily capsule (200 mg) and as an oral solution (10 mg/mL). It is a 
synthetic analogue of the naturally  occurring py rimidine 2 ′-deox ycytidine. I ntracellularl y, FTC is 
phosphory lated by  [CONTACT_184889], emtricitabine triphosphate.
Since first marketing authorization in the [LOCATION_002] (July  2003), FTC obtained marketing 
authoriz ation in the EU, and also Argentina, Israel, Switzerland, Mexico, Australia, Japan, New 
Zealand, and Canada. The registration of FTC for the treatment of HIV-1 infection in adults and 
pediatric patients less than 18 years of age was supported by [CONTACT_764590] -infected subjects, which provided detailed assessments of its 
pharmacokinetics, pharmacod ynamics, potential drug-drug interactions, and clinical efficacy  and 
safet y. Emtricitabine has also been coformulated with other HIV-1 ARV drugs in several FDCs
such as EVG/FTC/TDF, E/C/F/TDF, and FTC/TDF (see below). 
1.2.4. Tenofovir Alafenamide 
Tenofovir alafenamide (also known as GS-7340) is a second generation oral prodrug of TFV, a 
nucleotide analog that inhibit s HIV-1 reverse transcription, developed by [CONTACT_184883]. TAF has been 
coformulated with other ARVs, such as E/C/F/TAF and F/TAF (developed by [CONTACT_184883]) and 
D/C/F/TAF (codeveloped by [CONTACT_184891]), for the treatment of HIV-1 infection because 
of its potential forenhanced distribution of TFV into peripheral blood mononucleated cells 
(PBMCs) and to l ymphatic organs following oral administration. This provides the possibility  for 
using a low dose and to reduce systemic TFV concentrations, resulting in lower potentia l for 
adverse effects (including renal and bone toxicity ) without compromising antiviral activit y. 
Based on nonclinical data, the clinical safet y and resistance profile for TAF is expected to be 
similar to that characterized for TDF. 
Following its release from the TAF prodrug, TFV is metabolized intracellularly  to the active 
metabolite, TFV -diphosphate, a competitive inhibitor of HIV-1 reverse transcriptase (RT), 
thereb y effectivel y blocking the replication and spread of infectious HIV-1. The in vitro activity 
of TAF against HIV-1 in various human immune cell types is 100-to 600-fold greater than that 
of TFV and 4- to 6-fold greater than that of TDF.
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.3. Overall Rationale for the Study
The goals of this study  are to assess the efficacy and safet y of D/C/F/TAF in newly  diagnosed 
HIV-[ADDRESS_1047581] been completed or are ongoing are limited to the developi[INVESTIGATOR_19744], and conducted with 
regimens that are not recommended by [CONTACT_764591].9Differences in 
screening, healthcare system administration, treatment guidelines, and treatment regimens may 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
31
Approved , Date: [ADDRESS_1047582] the applicability  of these studies to new ly diagnosed HIV -1 infected subjects in the United 
States and other developed nations. As the D/C/F/TAF FDC is still being examined in Phase 3 
clinical studies, no evidence currently  exists using D/C/F/TAF FDC in a Test and Treat model. 
Given these factors , findings from this study  will be used to generate data on the efficacy  and 
safet y profile of D/C/F/TAF FDC in newl y diagnosed HIV-[ADDRESS_1047583] and Treat model of care.
2. OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
2.1. Objectives and Endpoints
2.1.1. Objectives
Primary Objective
The primary  objective of this study  is to assess the efficacy  of D/C/F/TAF FDC in a Test and 
Treat model of care in newly  diagnosed HIV-1- infected, treatment -naive subjects as determined 
by [CONTACT_184866]-1 RNA <50 copi[INVESTIGATOR_014]/mL  at 
Week 48 (Food and Drug Administration [ FDA ]-defined intent to treat [ ITT]snapshot analy sis).
Secondary Objectives
The secondary  objectives of this study  are:
To assess virologic and immunologic changes in the study  population through 12, 24, and 
48weeks of treatment 
To evaluate the incidence of grade 3 and 4 adverse events, serious adverse events, and 
premature discontinuations due to adverse events through 24 and 48 weeks of treatment, and 
during the extension phase
To evaluate the frequency  of discontinuation of D/C/F/TAF FDC due to protocol -specific 
stoppi[INVESTIGATOR_004] (refer to Section 3.1)
To assess baseline viral resistance in the stud y population 
To assess the development of viral resistance in the study  population through 24 and 
48weeks of treatment , and during the extension phase
To assess the proportion of subjects retained in care after discontinuation of study  drug 
before Week 48
To evaluate the influence of various intrinsic and extrinsic factors on retention in care
To assess the propor tion of subjects lost to follo w-up through 24 and 48 weeks of treatment
To evaluate adherence by [CONTACT_21173][INVESTIGATOR_764534] D/C/F/TAF FDC in the study  population through 
24 and 48 weeks of treatment 
To evaluate adherence by [CONTACT_35704]-report, using a 4-day recall period through Weeks 24 
and 48
To describe predictors of suboptimal adherence (<95% adherence by [CONTACT_21173][INVESTIGATOR_692]) in the study  
population 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
32
Approved , Date: 16 November 2017To assess the HIVTreatment Satisfaction Questionnaire -status version (HIVTSQ s)at 
Weeks 4, 24, and 48
To evaluate healthcare resource utilization (HRU) and cost and their temporal trends in the 
study  population through [ADDRESS_1047584] HIV-1 RNA 
<50copi[INVESTIGATOR_014]/mL at Week 48 as defined b y the FDA sna pshot anal ysis (ITT).
Secondary Endpoints
The secondary  endpoints of this study  are:
Efficacy
Change from baseline in log 10 HIV-1 RNA viral load at Weeks 2, 4, 8, 12, 24, 36, and 48
Proportion of subjects who have HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL  at Week 24
The change from baseline in CD4+cell count at W eeks 12, 24, and 48 
Safety
Proportion of subjects that required discontinuation after enrollment based on safety  
stoppi[INVESTIGATOR_004] (refer to Section 3.1)
Proportion of subjects discontinuing therap y due to adverse events
Proportion of subjects experiencing grade 3 and 4 adverse events
Proportion of subjects experiencing grade 3 and4 laborat ory abnormalities 
Resistance
Proportion of subjects meeting resistance stoppi[INVESTIGATOR_004] (refer to Section 3.1), requiring 
discontinuation of study  drug due to baseline resistance findings
Proportion of subjects with baseline PR, RT, and INI RAMs
Proportion of subjects developi[INVESTIGATOR_764552] , when 
available, upon meeting protocol -defined virologic failure
Proportion of subjects with protocol -defined virologic failure at Week 24 and Week 48, and 
during the extension phase
Retention in Care
Proportion of subjects lost- to-follow -upthroughout the 48 weeks of treatment
Proportion of subjects discontinuing study  drug for any reason other than withdrawal of 
consent prior to Week [ADDRESS_1047585] a documented clinic visit with a healthcare provider 
within 90 day s of discontinuing study  drug
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
33
Approved , Date: 16 November 2017Adherence
Adherence rates b y pi[INVESTIGATOR_764553] s4, 8, 12, 24, 36, and 48
Adherence rates b y subject self -report, using a 4- day recall at Weeks 4, 8, 12, 24, 36, and 48
Tolerability /Patient -reported Outcomes 
Mean total scores for the HIVTSQ s at Weeks 4, 24, and 4812
Healthcare Resource Utilization/Pharmacoeconomics
The number and duration of hospi[INVESTIGATOR_602], number and type of outpatient visits, number 
of emergency  room visits, and number and type of medications used (both HIV-related and
All-c ause as assessed b y the investigator ) throughout the main study period
Direct medical costs will be calculated in [LOCATION_003] dollars based on HRU noted above 
Refer to Section 9, Study Evaluation, for evaluations related to endpoints.
2.2. Hypothesis
No formal hypothesis will be tested. The findings from this study  will be used to generate data 
on the efficacy  and safety  profile of D/C/F/TAF FDC in newl y diagnosed HIV-[ADDRESS_1047586] and Treat model of care .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview of Study  Design
This is a single -arm, open -label, prospective, multicenter Phase 3study  to assess the efficacy  and 
safet y of D/C/F/TAF FDC in newly  diagnosed (ie, within 2 weeks of the screening/baseline visit
[Day 1]) HIV-[ADDRESS_1047587]’s eligibility . The 
screening /baseline visit (Day 1)should take place no later than 2 weeks following evidence of 
newly  documented HIV -1 infection.
Study  drug will be dispensed before the results from the screening/baseline safety  and resistance 
laboratory  tests are available. Subjects will receive treatment in a single -arm open -label fashion 
as follows:
D/C/F/TAF: DRV 800 mg+ COBI 150 mg+ FTC 200mg+ TAF [ADDRESS_1047588] start treatment within 24 hours of the screening/baseline visit. 
Following initiation of treatment, a safet y assessment will be performed by [CONTACT_764592] 3 +1 week ,or as soon as the final screening/baseline laboratory  report beco mes available .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
34
Approved , Date: 16 November 2017Subjects meeting any of the below safet y stoppi[INVESTIGATOR_004] (based on the receipt of the 
screening /baseline laboratory  findings) will be contact[CONTACT_764593] y treatment discontinuation (ESTD) and for additional follow -up.
Estimated glomerular filtration rate (eGFR ) according to the Modification of Diet in Renal 
Disease (MDRD19,22,33) formula <50mL/min.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5×upper limit of 
normal ( ULN )
Serum lipase ≥1.5×ULN 
Positive serum human chorionic gonadotropin pregnancy  test(β-hCG) for women of 
childbearing potential
Laboratory  results that the investigator believes should result in discontinuation of study  
medication (Note: It is recommended that the investigator contacts the sponsor’s medical 
monitor to discuss the discontinuation)
Subject s identified with active hepatitis C virus ( HCV )infection that in the opi[INVESTIGATOR_764554] y with agents not compatible with D/C/F/TAF FDC.
Retesting of abnormal screening/baseline safet y laboratory values noted above will be allowed 
once. Retesting will take place during an unscheduled visit.
The investigator will review the ARVscreening/baseline resistance data at Week4±7 days or 
sooner , depending on the availabilit y of the screening/ baseline HIV genoty pic drug resistance 
testing results from the central laboratory . Subjects who do not show full sensitivity  to all drugs 
in the FDC study  regimen according to the susceptibility  assessment inthe Geno Sure Prime®
report will be contact[CONTACT_764594]. Subjects with identified resistance 
to lamivudine/ FTC, attributed to the presence of the M184 I/V mutation alone will be permitted 
to remain in the study .
Subjects will be treated for 48 weeks in the main study  period and will retu rn to the site for visits 
at Weeks 2, 4, 8, 12, 24, 36, and 48. Assessment of drug accountability  and reasons for non-
adherence, and recording of concomitant therapi[INVESTIGATOR_014], adverse events, vital signs (including the 
subject’ s body  weight), and physical examina tions (complete or symptom -directed) will be 
performed at each visit from baseline onwards . Laboratory  evaluations for efficac y and safet y 
(HIV -1 viral load, biochemistry , hematology , and urinaly sis) will be performed at all study visits. 
CD4+/CD8+cell count will be assessed at Weeks4, 8, 12, 24, 36, and 48. Patient- reported 
outcome (PRO )measures will be assessed at Weeks 4, 24 , and 48 using the validated 10-item 
HIVTSQ s (Version 2006)12(Attachment 7). Medical resource utilization data will be collected 
from all subjects throughout the main study period .
Subjects who are on study  drug and who experience a protocol -defined virologic failure (see 
below) will undergo genoty pic and phenot ypic resistance testing , preferably  at the time of the 
confirmed virologic failure visit if the HIV-1 RNA  is ≥400 copi[INVESTIGATOR_014]/mL . If resistance testing is not 
able to be performed at the time of confirmed virologic failure, resistance testing may be 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
35
Approved , Date: 16 November 2017performed at the point of unconfirmed virologic failure or a later time point if HIV-1 RNA  is 
≥400 copi[INVESTIGATOR_014]/mL . Subjects who have persistent HIV -1 RNA  ≥400 copi[INVESTIGATOR_014]/mL  past Week24 but do 
not meet the definition of virologic failure, should have their viral load monitored closely , and if 
appropriate undergo genoty pic and phenot ypic resistance testing. In case resistance to study  
drugs is observed, the subject may  be discontinued from the study  at the investigator's discretion.
If the investigator makes the decision that the subject can continue in the study , additional 
resistance testing may be performed asdeemed necessary .Protocol defined virologic failure is 
not considered a stoppi[INVESTIGATOR_1877].
Virologic failure will be defined in this study  as follows:
Virologic Nonresponse: 
HIV-1 RNA <1 log 10reduction from baseline, AND
HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL  at the Week 12 visit, subsequently  confirmed at an
unscheduled visit conducted within 2 to 4 weeks after Week 12
Virologic Rebound: 
At any visit, after achieving confirmed consecutive HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL , a 
rebound in HIV-1 RNA to ≥50 copi[INVESTIGATOR_014]/mL , which is subsequently  confirmed at a
scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result ; 
OR
At any visit, a >1 log 10increase in HIV-1 RNA from the nadir, which is subsequently 
confirmed at the following scheduled or unscheduled visitconducted within 2 to 
4weeks of the HIV-1 RNA result . 
Subjects who meet the criteria for protocol -defined virologic failure will be managed according 
to the schema provided in Attachment 1.
Unscheduled visits can be conducted as needed based on individual tolerability  issues , or 
virologic reasons (ie, suspected virologic failure) that occur between scheduled visits.
Subjects who prematurely  discontinue study  treatment during the open -label treatment period 
will be required to complete ESTD assessments as soon as possible but no later than [ADDRESS_1047589] who has an ongoing adverse event or 
serious adverse event at the time of his/her last study  visit.These subjects are required to return 
to the site 30 days (±7 days) after completion of the last study -related visit (unless consent is 
withdrawn) .
Subjects who have completed the Week 48 visit will be given the opportunity  to continue 
D/C/F/TAF treatment during an extension period until the D/C/F/TAF FDC tablet becomes 
commerciall y available and is reimbursed, or can be accessed through another source, or until the 
sponsor terminates clinical development. At Week [ADDRESS_1047590] y of D/C/F/TAF to maintain continuity  of care for the subject, however no more 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
36
Approved , Date: [ADDRESS_1047591] a study  visit atthe site once every  6 m onths, if 
applicable, and complete the procedures indicated in the Time and Events Schedule , and 
additionally  at the time of transition to commercial D/C/F/TAF, for final data collection.
At the end of the study  (or at ESTD ),subjects will resume routine clinical care with their care 
provider who will determine the future care of that subject. In anticipation of transitioning the 
subject to routine clinical care at the end of the study  (or early discontinuation), the investigator 
should take steps to ensure a smooth transition (ie, secure insurance etc.) well in advance of the 
final stu dy visit, so that the subjects’ AR Tis not interrupted.
For those subjects discontinuing therap y before Week 48, the investigator will be asked to 
monitor the subject ’s retention in care defined as having one documented clinic visit within 
90days of discontinuing the study  treatment (unless consent is withdrawn).
The end of the study  is defined as completion of the last data collection visit for the last subject 
participating in the study . For the purpose of the primary  analysis, a subject will be considered to 
have completed the study  if data collection as required per protocol through the complete course 
of [ADDRESS_1047592] completed the 
Week 48 visit and the 30- day follow -up visit (if applicable), or discontinued earlier.
3.2. Study Design Rationale
Study Period
A treatment duration of 48 weeks is chosen toalign with the traditional efficacy  endpoint of 
previous clinical studies in treatment -naïve subjects. This is the minimal duration of time 
required to provide clinically  relevant results regarding the efficacy  and safety  of this regimen in 
this patient population. To assure continued follow -up of the study  participants and gain further 
safet y information, subjects who prematurel y discontinue study  treatment will be asked to attend 
the ESTD (and an additional follow -up visit, if applicable). In order to maintain continuity  of 
care, subjects will be given the opportunit y to continue D/C/F/TAF treatment after Week 48 
during an extension period , until the D/C/F/TAF FDC tablet becomes commercially  available 
and is reimbursed, or can be accessed through another source, or until the sponsor terminates 
clinical development.
Dose Selection
Darunavir 800mgboosted by [CONTACT_10843] 150mg, and FTC 200mgin the D/C/F/TAF FDC tablet 
represent the mark eted doses. The dose of TAF 10 mgin the D/C/F/TAF FDC tablet is the study 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
37
Approved , Date: 16 November 2017selected dose expected to attain TAF plasma concentrations in range of those demonstrated to 
show potent antiviral activity  with TAF as a stand -alone agent, and TFV plasma concentra tions 
that are considerabl y lower than those obtained with TDF. A TAF 10 mgdose is also being used 
for other TAF regimens including a pharmacoenhancer (rtv or COBI), currently  in development.
The proof -of-concept study  GS-US-120- 0104 evaluated 3 doses of TAF monotherapy  (8, 25, and 
40mgonce dail y) and demonstrated potent antiviral activity  in HI V-1 patients, with mean ( ±SD) 
change from baseline in HIV-1 RNA of -0.95±0.45, -1.53±0.40, -1.7±0.22 log 10copi[INVESTIGATOR_014]/mL  at 
TAF 8, 25, 40 mgonce daily , respectivel y (data unblinded only at dose level; TAF dosed for 
10days).15Administration of TAF 25mg in the presence of DRV/COBI  resulted in 
approximately  3-fold higher than historical TFV exposures following administration of TAF 
25mgalone (GS-US-120-0104, GS-US-292-0101, and GS-US-292-0103).15GS-US-299-0101 
was a Phase 1, healthy -volunteer, adaptive -design, multiple -dose study  that evaluated the 
bioavailability  of 3 formulations of a D/C/F/TAF FDC tablet. The results indicated that the 
D/C/F/TA F 25mgtablet formulations provided TAF exposures in a range associated with 
antiviral activity  (GS-US-120-0104) and consistent with the findings from study  GS-US-311-
0101 (Cohorts 2 and 3), where DRV/COBI was coadministered with FTC/TAF 25mg. The 
pharma cokinetic data also demonstrated achievement of TAF exposures that were associated 
with potent antiviral activity  with the D/C/F/TAF 10mg(monolay er formulation) tablet, and 
moreover TFV exposures with this formulation were in the range of historical data with TAF 
25mgdosed alone or with the E/C/F/TAF 10mgtablet. In addition, administration of the 
D/C/F/TAF 10mgtablet resulted in~90% lower stead y-state TFV exposure versus COBI -
boosted DRV plus FTC/TDF. Exposures of COBI -boosted DRV and FTC were comparable 
when administered as a single D/C/F/TAF tablet or as individual components. Study  
GS-US-299-0101 also evaluated the relative bioavailability  of DRV, COBI, FTC, and TFV when 
administered as COBI -boosted DRV plus FTC/TDF relative to the administration of the 
individual components. Results showed that the exposures of all analy tes were similar between 
both treatments. Thus, cumulative results from studies GS-US-120-0104, GS-US-311-0101 and 
GS-US-299-0101 were used in selecting a 10mgTAF dose for subse quent clinical development 
of the D/C/F/TAF FDC tablet.
Toxicity Management
The combination of D/C/F/TAF is not anticipated to exacerbate known toxicities or lead to new 
toxicities. Measures and guidelines for the monitoring and management of specific toxicities 
with DRV, COBI, FTC, or TAF are included in Section 9.8of this protocol. The presented 
toxicity  management guidelines are applicable throughout the entire study  starting from baseline 
through the 48-week main study period and through the extension period (or ESTD and an 
additional follow -up visit, if applicable).
Medical Resource Utilization and Health Economics Data Collection
Treatment of HIV-1 infection with D/C/F/TAF may result in a change in medical resource 
utilization from baseline over the duration of t he study . 
Medical resource utilization data as defined in Section 9.4will be collected throughout the main 
study  period. Additionally , costs will be assigned to type of HRU to calculate a per subject per 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
38
Approved , Date: [ADDRESS_1047593] demonstrated a decrease in overall medical 
resource utilization with the initiation of a boosted -darunavir based regimen.45While there is no 
comparator arm in this study ,the inclusion of these endpoints as part of this study  will help 
describe if similar observations are seen in a prospective cohort starting treatment on 
D/C/F/TAF .The data can also provide input for future economic modeling anal ysis.
Similarly , this study  aims to describe changes in PRO assessed by [CONTACT_941] 10-item HIVTSQ s
throughout the main study period (ie, Weeks4, 24, and 48). Satisfaction with HIV therapy  is 
being evaluated more frequently  in HIV clinical studies. The HIVTSQ was designed specificall y 
to measure satisfaction with medication for people infected with HIV.43,44In FLAMINGO, an 
open -label comparative study  of DRV and DTG incombination with NRTI s, improvements in 
HIVTSQ score from baseline was observed over a 48-week period.6While this study  itself is 
non-comparative, the aim isto describe changes in patient satisfaction as a result of starting 
treatment with D/C/F/T AF. 
4. SUBJECT POPULA TION
Screening for eligible subjects will be performed within 2 weeks following evidence of newl y 
documented HIV-1 infection. The screening and baseline assessments should preferabl y be 
completed the same day (Day 1), but if necessary, can be performed on different days, but must 
be completed within2 business days of signing the ICF. Study drug should not be dispensed 
until all screening procedures have been completed and the investigator has determined that the 
subject meets the inclusion/exclusion criteria .
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following [ADDRESS_1047594] satisfy  all of the following criteria to be enrolled in the study :
1. Sign an informed consent form (ICF) indicating that he or she understands the purpose 
of, and procedures required for, the stud y and is willing to participate in the study .
2. Man or woman at least 18 y ears of age.
3. Newl y diagnosed with HIV-1 evidenced by [CONTACT_764577] 2 weeks of the 
screening/baseline visit:
HIV Rapid Antibody  positive *; OR
HIV Immunoassay  positive; OR
Positive p24 antigen and a HIV -1 RNA viral load ≥5,000 copi[INVESTIGATOR_014]/mL ; OR
Non- reactive HIV-1 antibody /antigen assay s and HIV-1 RNA viral load 
≥5,000 copi[INVESTIGATOR_014]/mL . HIV-[ADDRESS_1047595] be confirmed once within 1 week 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
39
Approved , Date: [ADDRESS_1047596].
* Forthose subjects testing initially  positive on a 4thgeneration HIV Rapid Antibody 
Assay , results should be confirmed on a 3rdgeneration HIV Rapid Antibody  Assay at a 
minimum, or an HIV Immunoassay , unless the investigator suspects acute or recent 
infectio n.
4. Antiretroviral treatment -naïve, except for the use of TRUVADA®for pre-exposure 
prophy laxis (PrEP).
5. Contraceptive use by [CONTACT_764595] g in clinical studies.
Awoman must be either:
Postmenopausal for at least 2 years(medical documentation of cessation of 
menses for at least 2 years and of hormonal ovarian failure [follicle -stimulating 
hormone (FSH) level ≥40mIU/mL ]is required) ; OR
Surgicall y sterile (had total hysterectomy  or bilateral oophorectomy , tubal 
ligation/bilateral tubal clips without reversal operation, or otherwise incapable of 
becoming pregnant); OR
Not heterosexually  active for the duration of the study ;OR
Have a vasec tomized partner; OR
If of childbearing potential and heterosexually  active, practicing a highly effective 
method of birth control (as specified below) before entry , and agree to continue to 
use a highl y effective method of contraception throughout the study, and for at 
least [ADDRESS_1047597] dose of study  drug. Women with tubal 
ligation are required to use one additional contraceptive method.
Estrogen -based hormonal contraception may  not be reliable when taking the study 
drug. Therefore, to be eligible for this study , women of childbearing potential 
should either use:
a double- barrier method (male condom + either diaphragm or cervical cap); OR
non-estrogen hormonal based contraceptives in combination with a barrier 
contraceptive (male condom, diaphragm or cervical cap, or female condom); 
OR
intrauterine device in combination with a barrier contraceptive (male condom, 
diaphragm or cervical cap, or female condom).
Note : A male condom and female condom should not be used together due to risk of 
breakage or damage caused by  [CONTACT_648221] .
6. A woman must agree not to donate eggs (ova, oocy tes) for the purposes of assisted 
reproduction during the study  and for [ADDRESS_1047598] agree to use adequate reliable 
contraceptive methods (see also Inclusion Criterion 5) during the study  until 90 days 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
40
Approved , Date: [ADDRESS_1047599] dose of study drug
Men who have had a vasectom y without reversal operation minimally  2 months 
prior to screening are not required to use birth control methods.
For all male subjects, it is the responsibility  of the subject to ensure that his 
partner(s) do(es) not become pregnant during treatment with the study  drug and for 
up to [ADDRESS_1047600] dose of study  drug (or longer, if dictated b y local regulations).
10. Must be able to swallow whole tablets.
4.2. Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from participating 
in the study :
1. Known active cryptococcal infection, active toxoplasmic encephalitis, Mycobacterium 
tuberculosis infection, or another AIDS -defining condition that in the judgement of the 
investigator would increase the risk of morbi dity or mortality .
2. Known history  of clinically  relevant hepatic disease or hepatitis that in the 
investigator’s judgement is not compatible with D/C/F/TAF FDC .
3. Known h istory  of cirrhosis as diagnosed based on local practices. 
4. Known history  of chronic (≥3 months) renal insufficiency , defined as having aneGFR 
<50mL/min according to the MDRD formula.
5. Pregnant, or breast -feeding, or planning to become pregnant while enrolled in this 
study  or within [ADDRESS_1047601] 5 years or ongoing malignancy  other 
than cutaneous Kaposi’s sarcoma, basal cell carcinoma, or resected, noninvasive 
cutaneous squamous carcinoma.
9. Known active, severe infections (other than HIV-1 infection) requiring parenteral 
antibiotic or antifungal therap y within [ADDRESS_1047602] (eg, compromise the well-
being) or that could prevent, limit, or confound the protocol -specified assessments.
11. Subject unlikely  to comply  with the protocol requirements, based on clinical judgment.
12. Received an invest igational drug (including investigational vaccines) or used an 
invasive investigational medical device within [ADDRESS_1047603] dose of 
study  treatment or is currentl y enrolled in an investigational study  without prior 
approval from the spon sor.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
41
Approved , Date: 16 November 201713. Subjects receiving ongoing therapy  with contraindicated, not recommended, drugs that 
cannot be adequatel y dose -adjusted, or subjects with any known allergies to the 
excipi[INVESTIGATOR_364971] D/C/F/TAF FDC.14,[ADDRESS_1047604] involvement in the proposed 
study  or other studies under the direction of that investigator or study  site, as well as 
family  members of the employ ees or the investigator, or employ ees of Johnson & 
Johnson or [COMPANY_009].
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. Refer to Section 8,Prestudy  and Concomitant Therapy ,for details regarding prohibited 
and restricted therap y during the stud y.
2. Agree to follow all requirements that must be met during the study  as noted in the 
Inclusion and Exclusion Criteria (eg, contraceptive requirements )in Sections 4.1and 
4.2.
3. All HIV-infected subjects should be advised to take the necessary  precau tions to 
reduce the risk of transmitting HIV.
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
As this is single -arm study , randomization is not applicable . All subjects will receive the same 
treatment.
Blinding
As this is an open -label study , blind ing procedures are not applicable.
6. DOSA GEAND ADMINISTRA TION
At the screening/ baseline visit (Day 1), eligible subjects will start treatment with D/C/F/TAF 
FDC in a single -arm open -label fashion. All subjects will receive treatment as follows:
D/C/F/TAF FDC: DRV 800 mg+ COBI 150 mg+ FTC 200mg+ TAF 10 mgFDC
Initiation of study  treatment can only start after all screening/ baseline tests and procedures have 
been completed and must take place within 24 hours after the baseline visit. D/C/F/TAF FDC 
must be taken orally  with food. All subjects will be counseled to swallow D/C/F/TAF whole 
once dail y at approximately  the same time each day , according to their preference. 
Study -site personnel will instruct subjects on how to store study  drug for at-home use as 
indicated for this protocol.
If subjects notice that they  have missed a medication intake and it is still within 12 hours of their 
regular dosing time, they should take the medication immediately  with food. Subjects can then 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
42
Approved , Date: [ADDRESS_1047605] y 
resume the usual dosing schedule. Subjects should not take a double dose to make up for a 
missed dose.
Instructions regarding how to take the study  drug, what to do if a dose is missed and how to store 
the medication will be provided on the wallet (study ) card (refer to Section 12.3. 1).
The last time of study  drug administration will be recorded at each visit.
Prolonged temporary  study treatment interruptions are only deemed acceptable if motivated by 
[CONTACT_45308] y reasons and ifthey do not last longer than 4 consecutive weeks. The sponsor should be 
notified when such temporary  interruption occurs.
In order to maintain continuity  of care, subjects will be given the opportunity  to continue the 
D/C/F/TAF treatment after Week 48 du ring an extension period until the D/C/F/TAF FDC tablet 
becomes commercially  available and is reimbursed, or can be accessed through another source, 
or until the sponsor terminates clinical development.
7. TREA TMENT COMPLIA NCE
Adherence to study  treatment will be assessed by [CONTACT_21173][INVESTIGATOR_764555]-report, using a 
4-day recall period. S ubjects will be requested to bring unused medication and empty  packaging 
to the study  site at each visit, and the amount of study  drug dispensed will be compared with the 
amount returned , and taking into account the period elapsed since the previous visit .
The investigator/designated study -site personnel will maintain a log of all study  drug dispensed 
and returned. Drug supplies for each subject will be inventoried and accounted for throughout 
the study  (see also Section 14.5, Drug Accountability ). If a subject’s medication intake is not 
according to the study  protocol, it will be the investigator’s responsibility  to take the necessary 
measures to ensure future compliance to the protocol.
If non-adherence is identified during drug accountability  the reasons for non-adherence will be 
captured in the electronic case report form (e CRF ).
8. PRESTUDY AND CONCOMI TANT THERAPY
Prestudy  therapi[INVESTIGATOR_43710] 30days before the first dose of study  drug must be 
recorded at screening.
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplement s; non-pharmacologic therapi[INVESTIGATOR_23719], acupuncture, special 
diets, exercise regimens) different from study  drug must be recorded in the eCRF. Recorded 
information will include a description of the type of drug, treatment period, dosing regimen, 
route of administration, and its indication. Modification of an effective pre-existing therap y 
should not be made for the explicit purpose of entering a subject into the study  if such 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
43
Approved , Date: [ADDRESS_1047606] be documented in the 
Adverse Event/HIV -related event section of the eCRF.
Data on concomitant therapi[INVESTIGATOR_764556]. Concomitant therapi[INVESTIGATOR_764557] e vents that meet the criteria outlined in this protocol.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
Contraindicated and Disallowed Concomitant Agents
Darunavir coadministered with COBI is an inhibitor of CYP 3A, CYP2D6, and P-glycoprotein 
(P-gp). Cobicistat also inhibits the transporters breast cancer resistance protein (BCRP ), multi-
antimicrobial extrusion protein (MATE )-1,organic anion- transporting polypeptide ( OATP )1B1 
and OATP1B3. Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or 
CYP2C19. Cobicistat is not expected to induce CYP1A2, CYP3A4, CYP2C9, CYP2C19, 
uridine diphosphate glucuronosy ltransferase 1A1 (UGT1A1), or multidrug resistance protein 1 
(MDR1).
D/C/ F/TAF FDC should not be coadministered with medicinal products that are highl y 
dependent on CYP3A for clearance and for which increased plasma concentrations are 
associated with serious and/or life-threatening events (narrow therapeutic index) . These 
medicinal products include alfuzosin, astemizole, carbamazepi[INVESTIGATOR_050], cisapride, colchicine (in 
subject s with renal and/or hepatic impairment), dronedarone, elbasvir/grazoprevir, ergot 
alkaloids (eg, dihydroergotamine, ergotamine, ergonovine and methy lergonovine), lovastatin, 
lurasidone, oral midazolam, phenobarbital, pheny toin, pi[INVESTIGATOR_3924], ranolazine, rifampin , sildenafil 
(when used for treatment of pulmonary  arterial hypertension), simvastatin, St John's Wort , 
terfenadine, and triazolam.
Emtricitabine is not an inhib itor of human CYP450 enzymes. In vitro and clinical drug 
interaction studies have shown that the potential for CYP -mediated interactions involving FTC 
with other medicinal products is low. FTC is primarily  excreted by [CONTACT_10521] s by a combination 
of glomer ular filtration and active tubular secretion. No drug interactions due to competition for 
renal excretion have been observed; however, coadministration of FTC with drugs that are 
eliminated by [CONTACT_648188]/or the 
coadministered drug. Drugs that decrease renal function may  increase concentrations of FTC.
Tenofovir alafenamide is a substrate of the efflux transporter P-gp. Drugs that induce P-gp 
activity  are expected to decrease the absorption of TAF, resulti ng in decreased plasma 
concentrations of TAF, which may lead to loss of therapeutic effect of D/C/F/TAF FDC and 
development of resistance. These medicinal products include antimy cobacterials (rifabutin, 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
44
Approved , Date: 16 November 2017rifampin, rifapentine) and anticonvulsants (carbamazepi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_050], phenobarbital, 
pheny toin) . Coadministration of D/C/F/TAF FDC with drugs that inhibit P-gp may increase the 
absorption and plasma concentration of TAF. 
Given the possibility  for pharmacokinetic interactions, investigators should refer to the IBfor the 
D/C/F/TAF FDC and individual Prescribing Information for the components of the D/C/F/TAF 
FDC for potential contraindications and management of drug interactions to preserve subject
safet y during the stud y. 
Administration of any of the contraindicated or disallowed concomitant medication must have 
been discontinued at least 30 days before the screening/baseline visit (Day 1)and for the 
duration of the study . If such discontinuation of treatment is not clinically  acceptable, the subject 
should not be allowed to participate in the stud y. 
ARTbeyond study  drug is also prohibited during the study .
Should a subject have a need to initiate treatment with any  excluded concomitant medication, the 
sponsor’s medical monitor must be consulted beforehand. If an excluded medication is initiated 
before discussion with the medical monitor, the investigator must notify  the sponsor as soon as 
becoming aware.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , medical 
resource utilization, health economic, safety , and other measurements applicable to this study .
The protocol procedures are described in detail in Sections 9.2through 9.8.
Additional visits may be required if, in the investigator’s opi[INVESTIGATOR_1649], further clinical or labor atory  
evaluation is needed. Repeat or unscheduled samples may be required for safet y reasons, for 
technical issues with the samples, or for confirmation of protocol -defined virologic failure. 
When an HIV-1 RNA repeat testing is required at an unscheduled visit, an HIV-1 
genot ype/phenot ype plasma sample and a plasma storage sample should also be drawn at the 
same unscheduled visit. Findings during these unscheduled visits or assessments need to be 
reported in the eCRF.
Some flexibility  in the planning of the visits is allowed, however, the total treatment duration at 
the end of the main study period should be 48weeks. A window of ±2 days is allowed for 
Visit 2. All other study visits through Week 48 are to be completed within ±7 days of the 
protocol -specifi ed visit date.
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by [CONTACT_41011], to establish the absence of pregnancy  at any time 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
45
Approved , Date: [ADDRESS_1047607]’s participation in the study .If aserum or urine pregnancy  test is positive, the 
subject will be withdrawn from the study .
The HIVTSQ sassessment should be completed at scheduled visits (see the Time andEvents
Schedule ) before all other study -related procedures planned during these visits to prevent 
influencing subject perceptions. 
9.1.2. Screening Phase
The screening assessments indicated in the TimeandEvents Schedule will occur within [ADDRESS_1047608]’s study  participation. 
Procedures indicated in the TimeandEvents Schedule will only be performed after the subject’s 
written informed consent has been obtained. Relevant historical data obtained from the subject’s 
medical records and/or subject interview will be captured.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will enter the 
open -label treatment phase .
9.1.3. Open -Label Treatment Phase
[IP_ADDRESS]. Main Study Period
All subjects must start dosing within 24 hours of the screening/baseline visit ( Day 1).
Following initiation of treatment, a safet y assessment will be made by [CONTACT_232133] 3 
+1 week (or as soon as the final screening/baseline laboratory  report becomes available) , and the 
ARV screening/baseline resistance data will be reviewed by  [CONTACT_211675]4±7 day s or 
sooner , depending on the availability  of screening/baseline HIV genot ypic drug resistance testing 
results from the central laboratory . The investigator will determine as to whether treatment 
should be discontinued, based on the stoppi[INVESTIGATOR_301142] 3.1.
Subjects will be treated for 48 weeks in the main study  period and will return to the site for visits 
at Weeks 2, 4, 8, 12, 24, 36, and 48(scheduled relative to the date of the baseline visit) and 
complete the procedures indicated in the Time and Events Schedule .Subjects should be
counseled regarding the importance of adherence, and be instructed to bring unused medication 
and empty  packaging to the unit at each visit.
Subjects experiencing protocol -defined virologic failure (as defined in Section 3.1) will undergo 
genot ypic and phenoty pic resistance testing. In case resistance to study  drugs is observed, the 
subject may be discontinued from the study  at the investigator's discretion. Protoc ol-defined 
virologic failure is not considered a stoppi[INVESTIGATOR_1877].
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
46
Approved , Date: [ADDRESS_1047609] completed the Week 48 visit will be given the opportunity  to continue 
D/C/F/TAF treatment during an extension period until the D/C/F/TAF FDC tablet becomes 
commerciall y available and is reimbursed, or can be accessed through another source, or until the 
sponsor terminates clinical development. At Week [ADDRESS_1047610] y of D/C/F/TAF to maintain continuity  of care for the subject, however no more 
than [ADDRESS_1047611] a study  visit at the site once every  6  m onths, if 
applicable, and complete the procedures indicated in the Time and Events Schedule , and 
additionally  at the time of transition to commercial D/C/F/TAF, for final data collection.
Early Study Treatment Discontinuation (ESTD)
Subjects who prematurely  discontinue study  treatment during the open -label treatment period (ie, 
including the extension period) will be required to complete ESTD assessments as soon as 
possible but no later than [ADDRESS_1047612] HIV-1 
RNA ≥400 copi[INVESTIGATOR_014]/mL at the last viral load measurement ,theESTD assessments will also 
include genot ypic and phenoty pic resistance testing. In case of early  discontinuation, an HIV-[ADDRESS_1047613]’s primary  care provider to assist in the selection 
of a new ARV regimen.
30-Day Follow -up
In addition, a follow -up visit is required for anysubject who has an ongoing adverse event or 
serious adverse event at the time of his/her last study  visit.These subjects are required to return 
to the site 30 days (±7 days) after completion of the last study -related visit (unless consent is 
withdrawn) and complete all proce dures indicated in the TimeandEvents Schedule .
End of Study
At the end of the study  (or at ESTD), subjects will resume routine clinical care with their care 
provider who will transition them to an appropriate treatment regimen. 
9.2. Efficacy Evaluations
9.2.1. Antiviral Efficacy  and Immunologic Change
Blood samples for determination of plasma HIV-1 RNA viral load and immunologic parameters 
will be taken at the time points speci fied in the TimeandEvents Schedule . 
Plasma viral load will be measured using a validated assay at a central laboratory . 
Immunologic change will be determined b y changes in CD4+cell count (absolute and %). 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
47
Approved , Date: 16 November 2017Changes in viral load, changes in CD4+cell counts (either decreases or increases), or detected 
resistance will be part of the efficacy  analysis and should not be reported as adverse events or 
serious adverse events. 
9.2.2. Resistance Determinations 
HIV-1 genoty pe/phenot ype resistance testing will be performed at the time points specified in 
the T imeandEvents Schedule . 
Resistance testing at the screening/baseline visit (Day 1) will be performed utilizing the 
GenoSure Prime®assay . Resistance -associated mutations present at baseline will be reported and 
include mutations in the domain of PR, R T,and INI.
To investigate the emergence of resistance, the following subjects will be eligible for 
genot ypic/phenotypic resistance testing (PhenoSense GT®):
Any subject who experiences a protocol -defined virologic failure ;
Any subject who discontinues study  treatment after Week 12 for any reason and has an 
HIV-1 RNA value ≥400 copi[INVESTIGATOR_014]/mL  at the last viral load measurement ;
Any subject who has persistent HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL  past Week 24 but does not 
meet the definition of virologic failure.
Baseline phenot ypi[INVESTIGATOR_764558] y on subjects with confirmed protocol -
defined virologic failure if after virologic failure they showed evidence of reduced phenoty pic 
susceptibility  to any  of the study  drugs. Evaluations may be performed at o ther time points at the 
sponsor’s discretion.
9.3. Pharmacokinetics
Plasma concentrations of DRV and COBI may be determined in subjects experiencing protocol -
defined virologic failure ,or subjects who have persistent HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL past 
Week 24 but do not meet the definition of virologic failure ,using stored blood samp les collected 
throughout the stud y, if deemed necessary .
9.4. Medical Resource Utilization and Health Economics
Medical resource utilization data will be collected in the eCRF by [CONTACT_70449] -site 
personnel. The following will be evaluated through out the study  as noted in the TimeandEvents
Schedule :
Number and duration of hospi[INVESTIGATOR_059] s.
Number of outpatient visits , including ty pe of visit (eg, general practitioner , specialist)
Number of emergency  room visits.
Number and t ype of medi cations used (from the Concomitant Medication page of the eCRF) .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
48
Approved , Date: [ADDRESS_1047614] self-report at the time points 
specified in the TimeandEvents Schedule . 
Subjects should be counseled regarding the importance of adherence, and be instructed to bring 
unused medication and empty  packaging to the unit at each visit.
If non-adherence is identifie d during drug accountability  the reasons for non-adherence will be 
captured in the eCRF.
9.6. Retention in Care
Retention in care will be described as the proportion of subjects who discontinue study  treatment 
prior to Week 48 and remain in care after discontinuation (defined as having a documented 
office visit within 90 days of discontinuing the study  drug). Subjects who withdraw consent will 
not be followed to assess retention in care. 
9.7. Safety  Evaluations
The study  will include the following evaluatio ns of safet y and tolerability  according to the time 
points provided in the Time andEvents Schedule : adverse event reporting, clinical laboratory  
tests (including biochemistry , hematology , urinaly sis, and urine chemistry ), vital signs, and 
physical examinations (complete or symptom -directed). These protocol procedures are described 
below . In addition to these measurements, guidelines for the management of toxicities are 
described in Section 9.8.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF.
Clinical events and clinically  significant laboratory  abnormalities will be graded according to the 
Division of AIDS (DAIDS) Table for Grading the Severity  of Adult and Pediatric Adverse 
Events located in Attachment 2.
Any evaluations show ing abnormal results at any time during the study  will be followed until 
satisfactory  clinical resolution or stabilization. All grade 3 and grade 4 laboratory  abnormalities 
and all laboratory  abnormalities resulting in an increase of 2 DAIDS grades from ba seline will be 
followed until return to baseline or within 1 grade from baseline (ie, ≤ grade 2) (see Section 9.8.1 , 
General Guidance for the Managem ent of Clinical Events and Laboratory  Abnormalities).
Evaluations at the ESTD visit showing abnormal results indicating a possible causal relationship 
with the study  treatment must be followed by [CONTACT_093] (as often as deemed prudent) until 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
49
Approved , Date: 16 November 2017satisfac tory clinical resolution or stabilization. Certain long-term adverse events of ARTcannot 
be followed to resolution within the setting of this protocol; in these cases, follow -up will be the 
responsibility  of the treating physician, which will be agreed upon with the sponsor’s medical 
monitor.
Adverse Events
Adverse events will be reported by  [CONTACT_423] (or, when appropriate, by  a caregiver orsurrogate) 
for the duration of the study . Adverse events will be followed by [CONTACT_244536] 12, Adverse Event Reporting.
Special attention will be paid to those subjects who discontinue the study  for an adverse event, or 
who experie nce severe (grade 3) or potentiall y life-threatening (grade 4) adverse events, or a 
serious adverse events. For reported HIV events, further details will be recorded if these events 
are AIDS-defining illnesses (World Health Organization Clinical Staging ofHIV/AIDS, located 
in Attachment 3). For subjects with specific adverse events, toxicity  management should be done 
as described in Section 9.8, Toxicity  Management.
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  and a urine sample for urinal ysis will be 
collected at predefined time points (see TimeandEvents Schedule ). 
All clinical laboratory  testing will be performed by  [CONTACT_184917]. The investigator must review the laboratory  results, document this review, 
and record an y clinicall y relevant changes occurring during the study  in the adverse event section 
of the eCRF. The laboratory  reports must be filed with the source documents.
The centr al laboratory  will send the investigator and sponsor an alert form whenever a grade 3 or 
grade 4 laboratory  abnormality  (seeAttachment 2) is observed. In case a grade [ADDRESS_1047615] is not mandatory . 
The following laboratory abnormalities do not warrant mandatory  confirmation:
Asymptomatic grade 3 or grade 4 glucose elevations in subjects with pre -existing diabetes.
Asymptomatic grade 3 or grade 4 trigl yceride or cholesterol elevations.
For more details on the management of grade 3 and 4 laboratory  toxicities that occur during the 
open -label treatment phase , see Section 9.8.1 , General Guidance for the Management of Clinical 
Events and Laboratory  Abnormalities, and Attachment 4.Please note that this attachment does 
not apply  to screening/b aseline eGFR, AST, ALT, and lipase , and does also not apply  to the 
allowed retesting of abnormal screening/baseline eGFR, AST, ALT, and lipase values (see 
Section 3.1).
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
50
Approved , Date: 16 November 2017The following tests will be performed b y the central laboratory:
Hematology  Panel *
-hemoglobin -platelet count
-hematocrit -CD4+cell count
-absolute neutrophil count -CD8+cell count
-white blood cell count (WBC) with differential -CD4+CD8+ratio
-red blood cell count (RBC)
* Peripheral blood mononuclear cells (PBMCs) will be isolated from whole blood at the central 
laboratory at predefined time points (see TimeandEvents Schedule ), and stored for future analysis if 
needed.
Serum Chemistry  Panel
-glucose -chloride
-calcium -phosphate
-calcium corrected for albumin -blood urea nitrogen (BUN)
-albumin -serum creatinine , including calculated eGFR
-total protein -alkaline phosphatase (ALP)
-sodium -AST
-potassium -ALT
-bicarbonate (HCO 3) -bilirubin (total, direct, indirect)
Urinaly sis (dipstick)
-specific gravit y -ketones
-pH -bilirubin
-glucose -urobilinogen
-protein -nitrite
-blood -leukocy te esterase
If dipstick results are abnormal, the sediment will be examined microscopi[INVESTIGATOR_897] . 
In the microscopic examination, observations other than the presence of WBCs, RBCs, and casts 
may also be reported b y the laboratory .
Urine chemistry  panel (only  in the setting of a suspected renal adverse event; quantitative)
-creatinine -glucose
-sodium -protein
-phosphate -albumin
Additional clinical laboratory  assessments to be performed are as follows:
Hepatitis C virus (HCV) testing (HCV antibodies [ Ab]and HCV RNA level [only  if HCV 
Ab+]) and hepatitis B virus (HBV) testing (anti-hepatitis B core [HBc], anti-hepatitis B 
surface [HBs], hepatitis B surface antigen [HBsAg ])(at screening only). Whenever clinicall y 
relevant, the investigator can request additional tests at other visits.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
51
Approved , Date: 16 November 2017Aurine pregnancy  test will be performed at screening for all female subjects of childbearing 
potential. A serum human chorionic gonadotropin pregnancy  test will beassessed at a central 
laboratory , but the results arenot required for enrollment. A urine pregnancy  test will be
performed at subsequent study  visits as outlined in the TimeandEvents Schedule . Positive 
urine pregnancy  tests will be confirmed with a serum pregnancy  test. The results of the serum 
and urine pregnancy  tests should be recorded in the eCRF and in the subject’s medical 
records.
Amy lase (pancreatic) (only  at screening and in case of suspected pancreatitis during the study 
period)
Lipase (onl y at screening and reflex if amylase elevated) 
In case of rash, safet y blood samples need to be taken and are to be processed by [CONTACT_11378] . For details on rash management, see Section 9.8.2 , Cutaneous Events/Rash.
Vital Signs (Including Height and Weight)
Blood pressure (systolic and diastolic) and pulse/heart rate measurements (supi[INVESTIGATOR_184819] 
5minutes rest) should be preceded by [CONTACT_2669] [ADDRESS_1047616] in a quiet setting without 
distractions (eg, television, cell phones). Blood pressure and pulse/heart rate measurements will 
be assessed with a completely  automated device. Manual techniques will be used only if an 
automated device is not available.
To obtain the actual bod y weight, subjects should be weighed lightly clothed.
Height should be measured barefooted at the screening visit. 
Any clinicall y relevant findings at screening and changes occurring during the study  must be 
recorded in the Adverse Event section of the eCRF.
Physical Examination
Complete physical examinations, or symptom -directed examinations (physical examinations for 
which symptoms have been reported by [CONTACT_423]) as needed, will take place at the time points 
in the TimeandEvents Schedule . 
Complete physical examinations include skin, eyes, ears, nose, and throat, head, neck, and 
thyroid, heart, lung, chest (incl. breasts), abdomen, genitalia, anorectal, lymph nodes, 
musculoskeletal, and neurological. Urogenital/anorectal examination will be performed at the 
discretion of the investigator if clinicall y relevant. Subjects should be undressed during the 
complete physical examinations, which should be performed by a licensed medical doctor, 
physician’s assistant or nurse practitioner in accordance with local guidelines.
Any clinicall y relevant findings at screening and changes occurring during the study  must be 
recorded in the Adverse Event section of the eCRF .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
52
Approved , Date: [ADDRESS_1047617] starts study  medication through the 48-week m ain study period 
and the e xtension period . 
General guidance for the management of toxicities is provided in Section 9.8.1 . Guidance for 
specific toxicities is provided in Sections 9.8.2 through 9.8.8 . In addition, s ee Section 9.7, Safe ty 
Evaluations, and Section 12, Adverse Event Reporting, for details on procedures concerning the 
measurement and reporting of clinically  relevant abnormalities and toxicities. 
Questions regarding toxicity  management should be directed to the sponsor’s medical monitor.
9.8.1. General Guidance for the Management of Clinical Events and 
Laboratory  Abnormalities
Grade 1 and 2
Continue study  treatment at the discretion of the investigator .
Grade 3 
For a grade 3 clinical event or clinically  relevant laboratory  abnormalit y, study  treatment may 
be continued if the event is considered to be unrelated to study  treatment.
For a grade 3 clinic al event, or clinicall y relevant laboratory  abnormalit y confirmed by [CONTACT_86617] (see Section 9.7), that is considered related to study  treatment, study  treatmen t should 
be withheld until the toxicity  returns to baseline or within 1 grade from baseline, ie, grade 2. 
Mandatory  confirmation is not warranted for asymptomatic grade 3 glucose elevations in 
subjects with pre-existing diabetes, and for asymptomatic grade 3 triglyceride or cholesterol 
elevations.
If a laboratory  abnormality  recurs to grade [ADDRESS_1047618] managed according to local practice. Recurrence of laboratory 
abnormalities considered unrelated may not require permanent discontinuation. 
Grade 4 
For a grade 4 clinical event or clinically  relevant laboratory  abnormalit y confirmed by [CONTACT_86617] (see Section 9.7), that is considered related to study  treatment, study  treatment should 
be permanentl y discontinued and the subject managed according to local practice . The subject 
should be followed as clinically  indicated until the laboratory  abnormalit y returns to baseline 
or is otherwise explained, whichever occurs first. A clinically  relevant grade 4 laboratory  
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
53
Approved , Date: 16 November 2017abnormality  that is not confirmed upon repeat testing should be managed according to the 
algorithm for the new toxicity  grade. 
Mandatory  confirmation is not warranted for asymptomatic grade 4 glucose elevations in 
subjects with pre-existing diabetes, and for asymptomatic grade 4 triglyceride or cholesterol 
elevations.
Study  treatment may be continued without dose interruption for a clinically  nonrelevant 
grade 4 laboratory abnormalities (eg, grade 4 creatine phosphokinase after strenuous exercise, 
or triglyceride elevation that is nonfasting or that can be medically  managed), or a clinical 
event considered unrelated to study  treatment.
A schematic overview of these guidelines is provided in Attachment 4for clinically  relevant 
laboratory  toxicities that occur while on treatment .Please note that this attachment does not 
apply  to screening/baseline eGFR, AST, ALT ,and lipase , and does also not apply  to the allowed 
retesting of abnormal screening/baseline eGFR, AST, AL T, an d lipase values (see Section 3.1).
9.8.2. Cutaneous Events/Rash
Darunavir is a sulfonamide. Subjects who previously  experienced sulfonamide allergy  will be 
allowed to enter the study . To date, no potential for cross -sensitivity  between drugs in the 
sulfonamide class and DRV has been identified.
Cutaneous events/rash should be c aptured in the Adverse Event section of the eCRF.
Management of cutaneous events/rash will be at the discretion of the investigator, taking into 
account the following protocol procedures (see also Table 1), and should follow generally 
accepted medical standards. Cetirizine, levocetirizine, topi[INVESTIGATOR_11930], and antipruritic 
agents will be allowed at the investigator’s discretion for treatment of all grades of ra shes.
Grade 1 and 2 Cutaneous Reaction/Rash
A grade 1 cutaneous reaction/rash is defined as localized rash.
A grade 2 cutaneous reaction/rash is defined as diffuse rash or target lesions.
Subjects experiencing a grade [ADDRESS_1047619] 
their study  treatment interrupted at the investigator’s discretion. Safet y sampling (processed by 
[CONTACT_2237] ) at the time of the rash and clinical follow -up for these adverse events will 
be at the discretion of the investigator; however, close clinical follow -up is recommended to 
monitor for an y progression of the adverse event.
Grade 3 and 4 Cutaneous Reaction/Rash
A grade 3 cutaneous reaction/rash is defined as:
Diffuse rash with vesicles or limited number of bullae or superficial ulceration of mucous 
membrane limited to 1 site.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
54
Approved , Date: 16 November 2017For the purpose of this study , the sponsor considers qualify ing as a grade 3 rash:
Cutaneous reaction/rash with at least 1 of the following:
elevations of ALT/AST >2 ×baseline but ≥5 ×ULN
fever 38°C or 100°F
serum sickness -like reaction
eosinophil count >1,000/mm3
The sy ndromes of DRESS and AGEP
A grade 4 cutaneous reaction/rash is defined as:
Extensive or generalized bullous lesions
Stevens -Johnson sy ndrome (SJS)
Ulceration of mucous membrane involving at least [ADDRESS_1047620] mucosal sites
Toxic epi[INVESTIGATOR_23936] (TEN )
Subjects experiencing a grade [ADDRESS_1047621] and biopsy  are required for these events preferabl y 
within 24 hours after the site becomes aware of the cutaneous event/rash. 
Safety  testing (to be processed by [CONTACT_2237] ) of the following parameters is required 
to determine possible liver or systemic abnormalities: ALT, AST, bilirubin (total, direct and 
indirect), creatinine and a hematology  profile. Close clinical follow -up and appropriate medical 
intervention should be instituted for these events; daily  follow -up is recommended for 5 days 
from the onset of the event to monitor for p rogression of the event and weekly  afterwards as long 
as grade 3 or 4 rash is present. Once grade 3 or 4 rash has resolved to ≤grade 2 rash, follow -up 
should be done according to the instructions for grade 1 or 2 rash.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
55
Approved , Date: 16 November 2017Table 1: Summary of Cutaneous Reaction/Rash Follow -up
DAIDS Toxicity Grade Definitions Investigator Action
Grade [ADDRESS_1047622] may continue study 
treatment 
Grade 3 Diffuse rash with vesicles or limited 
number of bullae
Superficial ulcerations of mucous 
membrane limited to 1 site
For the purpose of this protocol, the 
sponsor considers qualifying as a grade 3 
rash the following:
Cutaneous reaction/rash with at least 1 of 
the follo wing:
-Elevations in ALT and/or AST 
(>2×baseline but ≥5× ULN)
-Fever 38°C or 100 F
-Serum sickness -like reaction
-Eosinophils >1,000/mm3
DRESS and AGEPPerm anently discontinue study 
treatment 
Referral to a dermatologist and 
biopsy, preferably within 24hours 
after the site becomes aware of the 
cutaneous event/rash
Laboratory assessments need to be 
performed 
Grade [ADDRESS_1047623] and 
biopsy, preferably within 24 hours 
after the site becomes aware of the 
cutaneous event/rash
Laboratory assessments need to be 
performed
9.8.3. Acute Systemic A llergic Reaction
Management of acute systemic allergic reactions will be at the discretion of the investigator, 
taking into account the following protocol procedures (see also Table 2), and should follow 
generall y accepted medical standards.
Grade 1
A grade 1 acute systemic allergic reaction is defined as localized urticaria (wheals) with no 
medical intervention indicated.
Subjects may continue study  treatment or have their study  treatment interrupted at the 
investigator’s discretion. The subject should be advised to contact [CONTACT_43054] y if 
there is any worsening of the pruritus, or if any systemic signs or symptoms develop. 
Antihistamines or topi[INVESTIGATOR_184821] (dis)allowed medications as indicated in Section 8, Prestudy  and Concomitant 
Therap y, or in the local Prescribing Information of the ARV agents.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
56
Approved , Date: [ADDRESS_1047624] their study  treatment interrupted at the 
investigator’s discretion. If there is any worsening of the allergic reaction, the subject should be 
advised to contact [CONTACT_764596]. 
Antihistamines or topi[INVESTIGATOR_184822] (dis)allowed medications as indicated in Section 8, 
Prestudy  and Concomitant Therap y, or in the local Prescribing Information of the ARV agents.
Grade [ADDRESS_1047625] management should be undertaken.
Table 2: Summary of Allergic Reaction Follow -up
DAIDS Toxicity Grade Definitions Investigator Action
Grade 1 Localized urticaria (wheals) with no 
medical intervention indicatedSubject may continue study 
treatment 
Grade [ADDRESS_1047626] may continue study 
treatment 
Grade 3 Generalized urticaria, or
angioedema with intervention indicated, or
symptoms of mild bronchospasmPerm anently discontinue study 
treatment
Grade 4 Acute anaphylaxis, or 
life-threatening bronchospasm, or
laryngeal edemaPerm anently discontinue study 
treatment
9.8.4. Potential Renal Toxicity
Estimated glomerular filtration rate for creatinine clearance (eGFR creatinine calculated according to 
the MDRD formula will be followed postbaseline during the treatment phase. 
Any subjects who have an eGFR creatinine of <50 and a decrease of 20% in eGFR creatinine from 
baseline, or who have other clinical and/or laboratory  evidence of acute renal failure will be 
discussed with the sponsor’s medical monitor and may  permanentl y discontinue study  treatment. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
57
Approved , Date: 16 November 2017The eGFR calculation swill be performed and provided to the investigator by [CONTACT_11378] .
Subjects with negative or trace proteinuria at baseline who develop >1+ proteinuria on urinaly sis 
must have urinaly sis repeated, with a concurrent urine chemistry , within 2 weeks of receipt of 
results. Upon confirmation of protei nuria, subjects will be asked to return to the site for a 
scheduled or unscheduled follow -up visit. It is recommended that the investigator contacts the 
sponsor’s medical monitor to discuss if further consultation with a nephrologist is clinically 
warrante d. 
Once an individual subject has developed any of these renal changes and the above management 
guidelines have been applied, it is not necessary  to further unscheduled repeat evaluations if it is 
determined that it is safe for the subject to continue on treatment with standard visits as described 
in the protocol.
9.8.5. Potential Posterior Uveitis Cases
In a 9-month toxicology  study  conducted in dogs, some animals a dministered the highest dose of 
TAF (12 to 18mg/kg) had minimal mononuclear cell infiltration inthe posterior uvea, 
considered secondary  to general debilitation; this finding did not occur in animals given lower 
doses and it has not occurred in other animal studies. This preclinical finding has also not been 
observed in humans where the dose is much lower, nor have there been report s of posterior 
uveitis in human clinical studies. Nonetheless, if subjects develop signs or sympt oms of posterior 
uveitis, which include notable eye pain or redness, reduced visual acuity , or “floaters”, 
investigators in this study  should inform the sponsor’s medical monitor and determine, based on 
their medical judgment, the need for ophthalmologic evaluation including dilated fundoscopy , 
and if required, optical coherence tomograph y.
9.8.6. Hyperglycemia
Grade 3: 13.89 to 27.75 mmol/L (250-500 mg/dL)
Grade 4: >27.75 mmol/L (>500 mg/dL)
Toxicity  management decisions should be based on fasted results. If elevated glucose levels are 
from a nonfasted blood draw, the draw must be repeated after an [ADDRESS_1047627] be started in a timely  fashion if 
applicable. Subjects with persistent grade 3 or 4 glucose elevations despi[INVESTIGATOR_184825]-
hypergly cemic treatment should permanentl y discontinue study  treatment.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
58
Approved , Date: 16 November [ZIP_CODE].8.7. Hypertriglyceridemia and Hypercholesterolemia
Hypertriglyceridemia: Grade 3: 5.7 to 11.4 mmol/L (>500 -1,000 mg/dL)
Grade 4: >11.4 mmol/L (>1,000 mg/dL)
Hypercholesterolemia: Grade 3: ≥7.77 mmol/L (>300 mg/L)
Grade 4: Not applicable
Toxicity  management decisions should be based on fasted results. If elevated lipid levels are 
from a nonfasted blood draw, the draw must be repeated after an [ADDRESS_1047628].
Hypertrigl yceridemia and hypercholesterolemia should be treated according to the specific 
guidelines for treating HIV-positive subjects (see Attachment 5). Current treatment guidelines 
specify  different lipid thresholds for intervention for different degrees of cardiovascular risk. The 
presence or absence of other significant cardiovascular risk factors, which include smoking, age, 
family  history  of premature cardiovascular disease, diabetes, hypertension, low high-densit y 
lipoprotein (HDL ), and prior history  of cardiovascular disease should be taken into account. 
Appropriate clinical management of hyperlipi[INVESTIGATOR_648150] a 
timely  fashion if applicable , and taking into account the disallowed medications (refer to 
Section 8,Prestudy  and Concomitant Therapy ).
9.8.8. Lipody strophy/Fat Redistribution/Body  Changes
Investigators are requested to avoid using the term ‘lipody strophy  acquired’ or ‘fat 
redistribution’ to descr ibe and report body  fat abnormalities, as these terms are not descriptive 
nor fully  accurate. The different symptoms and gradings are listed in the DAIDS grading table 
(Attachment 2) under Endocrine/Metabolic. The following terms are included: lipohy pertrophy , 
lipoatrophy , and gy necomastia.
Although metabolic abnormalities such as hyperlipi[INVESTIGATOR_184827], these events shoul d be recorded separately  at adverse event reporting.
9.9. Sample Collection and Handling
Blood samples drawn will be frozen and stored. These stored samples may be used by [CONTACT_764597]-1 genot ype/phenotype assay s, for retesting the amount 
of HIV-[ADDRESS_1047629] of the sponsor. No human genetic testing will be performed on these samples . See also 
Section 16.2.5 .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
59
Approved , Date: [ADDRESS_1047630] C OMPLETION /DISCONTINUA TION OFSTUDY TREATMENT/ 
WITHDRA WAL FROM THE STUDY
10.1. Completion
In the period up to Week 48, a subject will be considered to have completed the main study 
period if he or she has continued study medication intake up to Week [ADDRESS_1047631] completed the extension period
if he or she continued study  medication intake until D/C/F/TAF becomes commercially  available 
andis reimbursed, or can be accessed through another source, oruntil the sponsor terminates 
clinical development and has completed assessments until that point. Subjects who prematurel y 
discontinue study  treatment for any reason before that point, will notbe considered to have 
completed the extension period.
10.2. Withdrawal From the Study
A subject will be automatically  withdrawn from the study  for any  of the following reasons:
Lost to follow -up
Withdrawal of consent
Discontinuation of study  treatment for any  reason
Subject request to stop study  treatment for any  reason.
A subject's study  treatment must be discontinued if:
The investigator or sponsor believes (eg,that for safety  or tolerability  reasons 
(eg,adverse event) it is in the best interest of the subject to discontinue treatment
The subject becomes pregna nt 
The subject meets any of the safet y stoppi[INVESTIGATOR_004] (see Section 3.1, Overview of Study  
Design)
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
60
Approved , Date: 16 November 2017The subject meets any of the resistance stoppi[INVESTIGATOR_004] (see Section 3.1, Overview of 
Study  Design)
The subject experiences unacceptable toxicity  (as defined in Section 9.8, Toxicity  
Management) 
The subject develops clinical hepatitis
Prolonged temporary  study  treatment discontinuation >4 consecutive weeks
Thestudy  is discontinued at the request of the sponsor, concerned regulatory  agency , or 
Independent Ethics Committee/I nstitutional Review Board ( IEC/IRB )
A subject’s study  treatment may be discontinued if:
A serious adverse event occurs
The subject fails to comply  with the proto col or study  staff requirements
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree
The subject starts disallowed treatment, or requires new onset treatme nt with one of the 
disallowed medications (please refer to Section 8, Prestudy  and Concomitant Therapy)
The subject experiences protocol -defined virologic failure ,shows resistance to study 
drug(s) upon genot ypic and phenoty pic resistance testing , and the investigator makes 
the decision to discontinue study  treatment
The subject experiences persistent HIV-1 RNA ≥400 copi[INVESTIGATOR_014]/mL after Week 24, that 
does not meet the protocol -defined virologic failure criteria , but shows resistance to 
study  drug(s) upon genoty pic and phenot ypic resistance testing, and the investigator 
makes the decision to discontinue study  treatment
Protocol -defined virologic failure is not considered a stoppi[INVESTIGATOR_1877] .
If the investigator considers withdrawing a subject from study  treatment for oneof the above 
reasons, he/she should contact [CONTACT_184920], unless the 
medical condition requires immediate action that cannot wait contact [CONTACT_186054]. 
Subjects who prematurely  discontinue study  treatment during the open -label treatment period
will be required to complete ESTD assessments as soon as possible but no later than [ADDRESS_1047632] who has an ongoing adverse event or 
serious adverse event at the time of his/her last study  visit.These subjects are required to return 
to the site 30 days (±7 days) after completion of the last study -related visit (unless consent is 
withdrawn) . 
Investigators will refer subjects discontinu ing therapy  for any  reason before Week [ADDRESS_1047633] been retained in care,investigators will be 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
61
Approved , Date: [ADDRESS_1047634] ’s engagement with the referral site. Retention in care will be defined as 
having a documented office visit within [ADDRESS_1047635] and determine the reason for discontinuation/withdrawal. The measures 
taken to follow up must be documen ted.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and the source document. Study  drug dispensed to the withdrawn 
subject may not be dispensed to another subject (unless the bottles are unop ened) . Subjects who 
withdraw will not be replaced. 
10.3. Withdrawal From the Use of Research Samples
Withdrawal From the Use of Sample s in Future Research
The subject may  withdraw consent for use of sample sfor research ( refer to Section 16.2.5 , Long -
Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroy ed after they are no longer needed for the clinical study . Details of the sample retention
for research are presented in the main I CF.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods t o be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
The following anal yses will be performed:
The interim analy sis: once all subjects have been assessed for safet y at Day 3,and for 
resistance stoppi[INVESTIGATOR_1877] s at Week 4 .
The primary  analysis: once all subjects have completed the Week 48 assessments and the 
30-day follow -up visit (if applicable), or discontinued earlier.
11.1. Analysis Sets
The following anal ysis sets will be used and are defined:
Intent -to-treat (ITT) population: all subjects who have received at least one dose of study  
drug.
Per-protocol population: ITTpopulation without major protocol deviation that is considered 
to have an impact on the safet y or efficacy asse ssments .
11.2. Subject Information
Subject information will be anal yzed based on the ITTpopulation, unless otherwise specified.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
62
Approved , Date: [ADDRESS_1047636] HIV-1 RNA
<50copi[INVESTIGATOR_014]/mL  at Week 48 as defined by [CONTACT_90706] (ITT). As this is an 
exploratory  study with no formal hypothesis testing on the primary  endpoint, no formal sample 
size calculation was performed. With a sample size of 100 subjects and an expected virologic 
response rate ranging from 60-80%, the exact corresponding 95% confidence intervals (CIs)are: 
60% (49.7%, 69.7%), 70% (60.0%, 78.8%), and 80% (70.8%, 87.3%). The half-width of the 
exact corresponding 2 -sided 95% CI is10.0%, 9.4%, and 8.3%, respectively ,and is therefore 
less than 10% across the range of expected outcomes which is the desired precision. 
Additionally , with a sample size of 100subjects, the probabil ity to observe an adverse event with 
a true incidence of 1% or 4% is 63% and 98% respectivel y.
11.4. Efficacy  Analyses
11.4.1. Antiviral Efficacy  and Immunologic Change
The primary  efficacy  endpoint is the proportion of subjects who have HIV -1 RNA<50 copi[INVESTIGATOR_014]/mL 
at Week 48 as defined b y the FDA snapshot anal ysis (I TT). 
Virologic suppression (HIV -1 RNA<50 copi[INVESTIGATOR_014]/mL) will also be analyzedas secondary  endpoints 
at Week 24 and Week 48 according to the below analy ses:
FDA Snapshot algorithm in the ITT and Per-Protocol populat ion
Time to loss of virological response (TLOVR) algorithm in the I TT population
Virologic decay  will be reported as the mean log 10change in HIV-1 viral load from baseline to 
Weeks 2, 4, 8, 12 ,and 24 as part of the interim analy sis as a secondary  endpoint.
The proportion of subjects experiencing protocol defined virologic failure at Week 24 and 
Week 48 will be tabulated using descriptive statistics along with the 95% CIs. The Wilson 
(Score) met hod for the CI will be used. 
The changes from baseline in CD4+cell count at Weeks 12, 24, and 48 will be summarized using 
descriptive statistics. 
11.4.2. Resistance Determinations 
The number of PR mutations (including IAS-[LOCATION_003] primary  and secondary PI [INVESTIGATOR_764540]), RT 
mutations (including IAS-[LOCATION_003] N[t]RTI  RAMs and IAS-[LOCATION_003] non-nucleoside RT inhibitor 
[NN(t)RTI ] RAMs), and INI mutations (including IAS-[LOCATION_003] primary  and secondary INI-RAMS) 
present will be tabulated based on resistance tests performed at the scre ening/baseline visit . 
The proportion of subjects meeting resistance stoppi[INVESTIGATOR_004], requiring discontinuation of study 
drug, based on the findings of screening/ baseline resistance testing will be tabulated as part of 
the interim anal ysis. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
63
Approved , Date: 16 November 2017HIV-1 genot ype/phenot ype will be analy zed from samples of subjects with protocol -defined 
virologic failure and with HIV -1 RNA ≥400 copi[INVESTIGATOR_014]/mL . 
The number of treatment -emergent PRmutations (including IAS-[LOCATION_003] primary  and secondary  PI 
[INVESTIGATOR_764540]) andRT mutations (including IAS-[LOCATION_003] N(t)RTI RAMs andIAS-[LOCATION_003] NNRTI RAMs), 
as well as specific mutations associated with resistance to DRV, FTC, and TAF will be tabulated 
based on the observed virologic failures through the study  period . 
Fold change (FC) in 50% effective concentration (EC 50)of ARVs will betabulated .Loss of 
phenoty pic susceptibility may be analy zed dependent on the number of virologic failures and 
phenoty pes available through the study  period.
11.5. Medical Resource Utilization and Health Economics A nalyses 
All-cause and HIV-specific HRU during the study  period will be summarized overall and by 
[CONTACT_764598] (PPPM) . Monthly  average counts per subject will 
also be calculated to show the temporal trend for each category . 
Costs of care will be calculated by [CONTACT_764580] & Medicaid 
Services (CMS )fee schedule to assessed HRU on a per subject per month basis. Descriptive 
statistics will be calculated to compare the costs of care from baseline to Weeks 12, 24, and 48.
11.6. Adherence Analyses
Treatment adherence based on pi[INVESTIGATOR_764541] -report will be summarized by  [CONTACT_764599].
Adherence rates will be reported according to the proportion of subject s taking >95%, 80-95% 
and <80% of study  drug as assessed by [CONTACT_21173][INVESTIGATOR_764559] 4, 8, 12, 24, 36, and 
48.
11.7. Retention in Care Analyses
Number of subject with retention of care by [CONTACT_654], gender, race, sexual orientation, time from 
diagnosis to baseline visit, baseline CD4+ cell count, baseline HIV-1 RNA, patient satisfaction 
as assessed b y HIVTSQs, and socioeconomic factors will be tabulated . 
11.8. Safety  Analyses
For all safet y endpoints listed in Section 2.1.2 ,descriptive statistics will be used to summarize 
the endpoints. 
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_764600] y Activities (MedDRA). Treatment -emergent adverse 
events are adverse events with onset during the treatment phase orthat are a consequence of a 
pre-existing condition that hasworsened since baseline .All reported adverse events will be 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
64
Approved , Date: [ADDRESS_1047637] narratives may be provided, as appropriate, for those 
subjects who die, who di scontinue treatment due to an adverse event, or who experience a severe 
or life -threatening (grade 3 or 4) or a serious adverse event.
Additionally , a summary and listing of those subjects meeting predefined stoppi[INVESTIGATOR_764560] y or resistance findings will be tabulated.
Clinical Laboratory Tests
Abnormalities will be analy zed according to the DAIDS grading table (see Attachment 2) and in 
accordance with the normal ranges of the clinical laboratory . Maximum toxicity  grades after 
baseline will be tabulated, and special attention will be given to subjects who develop grade [ADDRESS_1047638]. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and for observed values and changes from baseline at each scheduled time point. Changes from 
baseline results will be presented in pre-versus posttreatment cross -tabulations (with classes for 
below, within, and above normal ranges).
Vital Signs
Descriptive statistics of blood pressure (systolic and diastolic) , pulse/heart rate, and body  weight
and changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinicall y important limits will be summarized. See Attachment [ADDRESS_1047639] been assessed for safet y at Day 3,and for 
resistance stoppi[INVESTIGATOR_764532] 4 .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
65
Approved , Date: [ADDRESS_1047640] Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_764601] p rocedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event d oes not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_1047641] adverse event recording).
An adverse event does not include the following:
Medical or surgical procedur es if the condition that leads to the procedure is an adverse event.
Pre-existing diseases or conditions or laboratory  abnormalities present or detected before the 
screening visit that do not worsen; any medical condition or clinically  significant laborator y 
abnormality  with an onset date before the ICF is signed, is not an adverse event. It is 
considered to be pre -existing and should be documented in the medical history  eCRF.
Situations where no untoward medical occurrence has occurred (eg, hospi[INVESTIGATOR_764561] , social and/or convenience admissions).
Overdose without clinical sequelae.
Uncomplicated pregnancy.
See also Section 12.2, Special Re porting Situations and Section 12.3.3 , Pregnancy .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
66
Approved , Date: [ADDRESS_1047642] medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it wer e more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicin al product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious. Examples of such events are:
Intensive treatment in an emergency  room or at home for allergic bronchospasm.
Blood d yscrasias or convulsions that do not result in hospi[INVESTIGATOR_059].
Development of drug dependency  or drug abuse.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mortalit y). 
Additio nal clarification on adverse events/serious adverse events:
Complications occurring during hospi[INVESTIGATOR_764562]. If a complication 
prolongs the hospi[INVESTIGATOR_059], it is a serious adverse event.
In-patient hospi[INVESTIGATOR_764563] a hospi[INVESTIGATOR_99325], for any length of time; this may or may not be overnight. It does not include 
presentation or care within an emergency  department.
The investigator should attempt to establish the diagnosis of an event on the basis of signs, 
symptoms, and/or other clinical information; in such cases, the diagnosis must be documented 
as the adverse event and/or serious adverse event and not the individual signs or sy mptoms.
A distinction should be made between seriousness and severit y of adverse events. An adverse 
event that is assessed as grade 4 (potentially  life-threatening) should not be confused with a 
serious adverse event. Severit y is a category  utilized for rating the intensity  of an event, and 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
67
Approved , Date: 16 November 2017both advers e events and serious adverse events can be assessed as grade 4. An adverse event 
is defined as ‘severe’ when it meets the predefined criteria as described the DAIDS toxicity  
grading table in Attachment 2(see also Section 12.1.3 , Severity  Criteria).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information at the time the adverse event is reported . For
D/C/F/TAF FDC tablet , the expectedness of an adverse event will be determined by [CONTACT_764602].
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel y by [CONTACT_23826] 12.1.2 , Attribution Definitions .
12.1.2. Attribution Def initions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant dis ease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria 
An assessment of severity  grade will be made using the general categorical descriptors outlined 
in the DAIDS toxicity  grading table in Attachment 2.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
68
Approved , Date: [ADDRESS_1047643] (eg, laboratory  abnormalities).
A distinction should be made between seriousness and severit y of adverse events. An adverse 
event assessed as grade 4 (potentially  life-threatening) should not be confused with a serious 
adverse event. Severity  is a category  utilized for rating the intensi ty of an event, and both adverse 
events and serious adverse events can be assessed as grade 4. An event is defined as ‘serious’ 
when it meets one of the predefined outcomes listed in Section 12.1.[ADDRESS_1047644] be 
recorded as an adv erse event as well as a serious adverse event, if applicable. Laboratory  or other 
abnormal assessments (eg, vital signs) that are associated with signs and/or symptoms must be 
recorded as an adverse event or serious adverse event if they meet the definitio ns as described in 
Section 12.1.1 , Adverse Event Definitions and Classifications. If the laboratory  abnormalit y is 
part of a syndrome, the sy ndrome /diagnosis (ie, anemia) must be recorded and not the laboratory  
result (ie, decreased hemoglobin).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting or safet y 
evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Accidental or occupational exposure to a sponsor study  drug
Any failure of expected pharmacologic action (ie, lack of effect) of a sponsor study  drug
Unexpected therapeutic or clinical benefit from use of a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
Exposure to a sponsor study  drug from breastfe eding
Lack of effect reports
Pregnancy  reports, whether or not maternal exposure to the product occurred (see also 
Section 12.3.3 , Pregnancy)
Reports of adverse reactions in infants following exposure from breastfeeding .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
69
Approved , Date: [ADDRESS_1047645]’s last 
study -related procedur e, which may include contact [CONTACT_20687] -up of safet y. Serious adverse 
events, including those spontaneously  reported to the investigator within 30days after the last 
dose of study  drug, must be reported using the Serious Adverse Event Form. The sponsor will 
evaluate an y safet y information that is spontaneously  reported b y an investigator bey ond the time 
frame specified in the protocol.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. Anticipated events will be 
recorded and reported as described in Attachment 8. 
All adverse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due toa common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the eCRF their opi[INVESTIGATOR_154890] y. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). For 
anticipated events reported as individual serious adverse events the sponsor will make a 
determination of relatedness in addition to and independent of the investigator’s assessment. The 
sponsor will periodicall y evaluate the accumulating data and, when there is sufficient evidence 
and the sponsor has determined there is a reasonable possibility  that the drug caused a serious 
anticipated event, they  will submit a safety  report in narrative format to the investigators (and the 
head of the investigational institute where required). The investigator (or sponsor where 
required) must report S[LOCATION_003]Rs to the appropriate IEC/IRB that approved the protocol unless 
otherwise required and documented by [CONTACT_6179]/IRB. A S[LOCATION_003]R will be reported to regulatory 
authorities unblinded. Participating investigators and IEC/I RB will receive a blinded S[LOCATION_003]R 
summary , unless otherwise specified. 
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the followin g:
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
70
Approved , Date: 16 November 2017Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_1047646] telephone number (for medical staff only )
Site num ber
Subject number
12.3.2. Serious A dverse Events
All serious adverse events occurring during the study  must be reported to the appropriate sponsor 
contact [CONTACT_9702] b y stud y-site personnel within [ADDRESS_1047647] be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax).
All serious adverse events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the follow ing occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that anyadditional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medici nal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event, except hosp italizations for the following:
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF). Note: Hospi[INVESTIGATOR_23743], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744] , will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
71
Approved , Date: 16 November 2017Disease progression should not be recorded as an adverse event or serious adverse event term; 
instead, signs and symptoms of clinical sequelae resulting from disease progression/lack of 
efficacy  will be reported if they fulfill the serious adverse event definition (refer to 
Section 12.1.1 , Adverse Event Definitions and Classifications).
12.3.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy ) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form. Any subject who 
becomes pregnant during the study  must be promptly  withdrawn from the study .
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male 
subjects included in the study  will be reported as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required. 
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMPLA INT HA NDLING
A product quality  complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, including its labeling or package integrit y. A PQC may 
have an impact on the safet y and efficacy  of the product. Timely , accurate, and complete 
reporting and analysis of PQC information from studies are crucial for the protection of subjects, 
investigators, and the sponsor, and are mandated by [CONTACT_23824]. The sponsor 
has established procedures in conformit y with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_1047648] report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by [CONTACT_456].
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
72
Approved , Date: [ADDRESS_1047649] Quality
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
D/C/F/TAF FDC tablets will be manufactured and provided under the responsibility  of the 
sponsor . 
The D/C/F/TAF FDC tablets supplied for this study  are y ellow capsule -shaped, plain- faced, film -
coated tablets containing 800mgof DRV (as 867mgof DRV ethanolate), 150mgof COBI 
(288 mgtotal weight of COBI on silicon dioxide carrier), 200 mgofFTC, and 10mgof TAF (as 
11.2 mgTAF fumarate). The D/C/F/TAF tablet cores contain silicon dioxide, croscarmellose 
sodium, microcry stalline cellulose, magnesium stearate polyvinyl alcohol, iron oxide yellow,
polyethylene gly col, talc, and titanium dioxide. 
14.2. Packaging
D/C/F/TAF FDC tablets will be packaged under responsibility  of the sponsor
The D/C/F/TAF FDC tablets are packaged in white, high-density  polyethylene (HDPE) bottles 
with a silica gel desiccant andpolyester coil fiber in each bottle. Each bottle is capped with a 
white, continuous thread, child- resistant pol ypropylene screw cap fitted with an induction -sealed, 
aluminum -faced liner.
No study  drug can be repacked without prior approval from the sponsor.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
No study  drug can be relabeled without prior approval from the sponsor.
14.4. Preparation, Handling, and Storage
All study  drug must be stored according to the storage conditions printed on the label.
To ensure the stability  of D /C/F/TAF FDC tablets, the study  drug should not be dispensed into a 
container other than the container in which it is supplied.
Refer to the pharmacy  manual/ study  site investigational product and procedures manual for 
additional guidance on study  drug preparation, handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The dispensing of study  drug to the subject, and the 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
73
Approved , Date: [ADDRESS_1047650] (if applicable), must be documented on the drug 
accountability  form. Subjects must be instructed to return all original containers, whether empty 
or containing stud y drug. All study  drug will be stored and disposed of according to the sponsor's 
instructions. Study -site personnel must not combine contents of the study  drug containers.
Study  drug must be hand led in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug, and study  drug returned by [CONTACT_423], must be 
available for verification by  [CONTACT_456]'s study  site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study  drug for destruction, will be 
documented on the drug return form. When the study site is an authorized destruction unit and 
study  drug supplies are destroy ed on -site, this must also be documented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospit al/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject , unless the bottles are unopened . Whenever a subject brings his or her study 
drug to the study  site for pi[INVESTIGATOR_692], this is not seen as a return of supplies. Study  drug may  not be
relabeled or reassigned for use by [CONTACT_23837]. The investigator agrees neither to dispense the 
study  drug from, nor store it at, any  site other than the study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator 'sBrochure and Addendum14,15
Pharmacy  manual/ study  site investigational product and procedures manual
Labor atory  manual
HIVTSQs questionnaire 
electronic Data Capture ( eDC)Manual
Sample I CF
Interactive Web Response System manual
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study is voluntary  and may 
be withdrawn at any time with no reason g iven and without penalt y or loss of benefits to which 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
74
Approved , Date: 16 November 2017they would otherwise be entitled. Only subjects who are fully  able to understand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntarily  will be 
enrolled.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
count ry-specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provide s public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional R eview  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]):
Final protocol and, if applicable, amendments
Sponsor -approved ICF (and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_8152], institutional affili ations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely  administrative, with no 
consequences for subjects, data or study  conduct, unless required locally), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearly identify the IEC/IRB and the 
documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/ IRB for their review and approval, where appropriate:
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
75
Approved , Date: 16 November 2017Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to I CF and any  other written materials to be provided to sub jects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the IBand amendments/adden da
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICF revisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s). 
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/IRB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution). 
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/are used must be approved by [CONTACT_764603]/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulator y requirements, and sponsor policy.
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
76
Approved , Date: [ADDRESS_1047651], to the extent permitted by [CONTACT_6983](s) or 
regulations. By  [CONTACT_4876] I CF the subject is authorizing such access, which includes permission 
to obtain information about his or her survival status. It also denotes that the subject agrees to 
allow his or her study  physician to recontact [CONTACT_66882] y evaluations, and subsequent disease -related treatments, if needed. The 
physician may also recontact [CONTACT_764604].
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel yrecorded 
by [CONTACT_19720]'s personally  dated signature. After having obtained the consent, a copy 
of the I CF must be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information) and 
should personally  date and sign the ICF after the oral consent of the subject is obtained.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subject s enrolled in this study  will be 
limited to those data that are necessary  to fulfill the objectives of the stud y.
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
77
Approved , Date: [ADDRESS_1047652], the 
conditions of the study , and the applicable laws and regulations.
16.2.5. Long -Term Retention of Samples for A dditional Future Research 
Blood samples collected in this study  (including PBMC s isolated from whole blood) may be 
stored for up to 15 years (or according to local regulations) for additional research. Samples will 
only be used to understand D/C/F/TAF FDC tablet, to understand HIV-[ADDRESS_1047653] -study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.3, Withdrawal From the Use of Samples in Future 
Research.
17. ADMINISTRA TIVE RE QUIREMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by [CONTACT_456]. All protocol amendments must be issued by  [CONTACT_456], and signed and dated by 
[CONTACT_093]. Protocol amendment s must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_307510](s), which will be provided as a separate 
document. Except in emergency  situations, this contact [CONTACT_23848]. In all cases, contact [CONTACT_233869]. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requir ing it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulat ory 
requirements are met.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
78
Approved , Date: [ADDRESS_1047654] be provided to the sponsor before shipment of study  drug to the 
study  site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specifi c 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) b y the chairman or authorized designee.
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
membe r of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748].
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and date d clinical trial agreement, which includes the financial agreement
Any other documentation required by  [CONTACT_43782]:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentialit y, no copy  will be made. All 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
79
Approved , Date: [ADDRESS_1047655] be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility , and study identification; study  
discussion and date of signed informed consent; dates of visits; results of safety  and efficacy  
parameters as required by [CONTACT_760]; record of all AEs and follow -up of AEs; concomitant 
medication; drug receipt/dispensing/return records; study  drug administration information; and 
date of study  completion and reason for early discontinuation of study  drug or withdrawal from 
the study , if applicable. 
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consiste nt with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
Data that will be recorded directl y into the eCRF are specified in the Source Document 
Identification Form.
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_476009] w or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are prepared and provided b y the sponsor for each subject in electronic format.
Electronic Data Capture will be used for this study . The study  data will be transcribed by [CONTACT_3449]-
site personnel from the source documents onto an electronic eCRF, if applicable. Study -specific 
data will be transmitted in a secure manner to the sponsor within the timeframe agreed upon 
between the sponsor and the study  site. The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to the 
study  must be recorded in eCRFs prepared b y the sponsor. Data must be entered into the eCRF in 
English. The eCRF must be completed as soon as possible after a subject visit and the forms 
should be available for review at the next scheduled monitoring visit. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
80
Approved , Date: 16 November 2017All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by [CONTACT_23856].
All eCRF entries, corrections, and alterations must be made by [CONTACT_170191] -site personnel. The investigator must verify  that all data entries in the eCRF are accurate 
and correct.
If necessary , queries will be generated in the eDC tool. The investigator or study -site personnel 
must adjust the eCRF (if applicable) and complete the query . 
If corrections to a eCRF are needed after the initial entry  into the eCRF, this can be done in 
either of the following way s:
Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]).
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -site personnel before 
the start of the study . The sponsor will review eCRF sfor accuracy  and completeness during on-
site monitoring visits and after transmission to the sponsor; any discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study  database 
they will be verified for accuracy  and consistency  with the data sources. 
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_764605] 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
81
Approved , Date: 16 November 2017agreement with the sponsor. It is the responsibility  of the sponsor to inf orm the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written app roval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
postinitiation visit will be made as soon as possible after enrollment has begun. Atthese visits, 
the monitor will compare the data entered into the eCRF swith the source documents 
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the sponsor and study -site personnel and are accessible for verification by 
[CONTACT_43786] -site contact. If electronic records are maintained at the study  site, the method 
of verification must be dis cussed with the study -site personnel. 
Direct access to source documents (medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel. The sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source documents will 
be accessible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study  to 
provide feedback on the study  conduct.
17.9. Study Completion/Termination
17.9.1. Study Completion/End of Study
The study  is considered completed with the last visit for the last subject participating in the 
study . The final data from the study  site will be sent to the sponsor (or designee) after completion 
of the final subject visit at that study  site, in the time frame specified in the Clinical Trial 
Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study  completion. A 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
82
Approved , Date: [ADDRESS_1047656] been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study  site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP g uidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be 
respec ted. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_170192]. 
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or she has 
been contact[INVESTIGATOR_530] b y aregulatory  agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding D/C/F/TAF FDC tablet or the 
sponsor's operations (eg,patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by [CONTACT_66894], and any data generated as a result of this study , are considered 
confidential and remain the sole prope rty of the sponsor. The investigator agrees to maintain this 
information in confidence and use this information only to accomplish this study , and will not 
use it for other purposes without the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_764606] D/C/F/TAF FDC tablet , and thus may 
be disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
inform ation derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
83
Approved , Date: [ADDRESS_1047657] identifiers will not be used in 
publication of results. Any work created inconnection with performance of the study  and 
contained in the data that can benefit from copyright protection (except any publication by [CONTACT_23868]) shall be the propert y of the sponsor as author and owner of 
copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study , a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days toallow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recog nize the integrity  of a multicenter study  by [CONTACT_269327], within 12 months of the availability  of the fin al data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requireme nts for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
84
Approved , Date: 16 November 2017REFERENCES
1. ACTG Guidelines for the evaluation and management of dyslipi[INVESTIGATOR_184835] 
(HIV) -Infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association 
of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin I nfect Dis. 
2003;37 (5):613 -662.
2. Baugh B, Van Landuyt E, Vanveggel S et al. Development of a protease inhibitor -based single- tablet 
complete HIV -1 regimen of Darunavir/Cobicstat/Emtricitabine/Tenofovir Alafenamide (DCFTAF) HIV 
DART & Emerging Viruses. Los Cabos, Abstract O_04, 2016.
3. Bradley H, Hall I, Wolitski RJ et al. Vital signs: HIV diagnosis, care, and treatment among persons living 
with HIV —[LOCATION_002], 2011. MMWR Morb Mortal Wkly Rep 2014;63:1113 -1117.
4. Cahn P, Fourie J, Grinsztejn B et al. Week 48 analysis of once -daily vs. twice -daily darunavir/ritonavir in 
treatment -experienced HIV -1-infected patients. AIDS. 2011; 25 :929– 939.
5. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171 -
S6.
6. Clotet B, Feinberg J, van Lunzen J, et al. Once -daily dolutegravir versus darunavir plus ritonavir in 
antiretroviral -naive adults with HIV- 1 infection (FLAMINGO): 48 w eek results from the randomised open -
label Phase 3b study. Lancet. 2014;383(9936):2222 -2231.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV -1 infection with early antiretroviral therapy. N 
Engl J Med. 2011;365(6):493 -505. 
8. DESCOVY®[package insert]. Foster City, CA: [COMPANY_009] Sciences, Inc; March 2016.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents 
in adults and adolescents living with HIV . Department of Health and Human Services. Available at 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed Octobe r 19, 2017. 
10. EMTRIVA®[package insert]. Foster City, CA: [COMPANY_009] Sciences, Inc; November 2012.
11. GENVOYA®[package insert]. Foster City, CA: [COMPANY_009] Sciences, Inc; December 2016.
12. HIV-Treatment Satisfaction Questionnaire. Available at 
http://www.healthpsychologyresearch.com/sites/default/files/guidelines/HIVTSQ%20Summary_rev.11.8.15.
pdf . Accessed 3 March 2017.
13. INSIGHT START Study Group. Initiation of antiretroviral therapy in earl y asymptomatic HIV infection. 
NEngl J Med. 2015;373(9):795 -807.
14. Investigator's Brochure: D/C/F/TAF. Addendum 1 to Edition 3. Janssen Research & Development (March 
2015)
15. Investigator's Brochure: D/C/F/TAF. Edition 3. [COMPANY_009] Sciences, Inc. (Sep 2014).
16. Jayaweera D, Dejesus E, Nguyen KL, et al. Virologic suppression, treatment adherence, and improved 
quality of life on a once -daily efavirenz -based regimen in treatment naïve HIV -1 infected patients over 
96weeks. HIV Clin. Trials 2009;10(6):[ADDRESS_1047658] WEAE0202, 2 016.
18. Lathouwers E, Gupta S, Haddad M et al. Trends in darunavir resistance -associated mutations and phenotypic 
resistance in commercially tested [LOCATION_002] clinical samples betw een 2006 and 2012. AIDS Res Hum 
Retroviruses. 2015;31(6):[ADDRESS_1047659] study equation for estimating GFR with IDMS 
traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005; 276:69A. Abstract.
20. Maggiolo F, Migliorino M, Maserati R, Rizzi L, Pan A, Rizzi A, et al. Once -a-day treatment for HIV 
infection: Final 48 -week results. 8thConference on Retroviruses and Opportunistic Infections; 2001 February 
4-8; Chicago, IL. Abstract 320.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
85
Approved , Date: 16 November 201721. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality 
across Europe in patients infected with HIV -1. Lancet. 1998;352(9142):1725 -1730.
22. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a 
report from the Laboratory Working Group of the Nati onal Kidney Disease Education Program. Clin Chem 
2006;52:5 -18.
23. ODEFSEY®[package insert]. Foster City, CA: [COMPANY_009] Sciences, Inc; March 2016
24. Orkin C, DeJesus E, Khanlou H, et al. Final 192 -week efficacy and safety of once -daily darunavir/ritonavir 
compared with lopi[INVESTIGATOR_054]/ritonavir in HIV -1-infected treatment -naïve patients in the ARTEMIS trial. HIV 
Med. 2013;14:49 -59.
25. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity 
and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 
1998;338 (13):[ADDRESS_1047660]. 2017;74(1):44 -51.
27. PREZCOBIX®[package insert]. Titusville, NJ: Janssen Therapeutics; September 2016
28. PREZISTA®[package insert]. T itusville, NJ: Janssen Therapeutics; September [ADDRESS_1047661] Study Group. N Engl J Med. 2000;342(13):921 -929
30. Rapid initiation of antiretroviral therapy to promote early HIV/AIDS treatment in South Africa (RapIT 
Study) (RapIT). Available at: https://www.clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=RapIT&rank=1. 
Accessed December 14, 2016.
31. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among 
adolescents and adults. MMWR. 1992;41(RR -17):1 -19.
32. Revised classification system HIV infection in children less than 13 years of age. MMWR 1994;43[RR -12].
33. Stevens LA, Coresh J, Greene T, Lev ey AS. Assessing kidney function —measured and estimated glomerular 
filtration rate. N Engl J Med 2006;354:2473 -2483.
34. Stone VE, Jordan J, Tolson J, Miller R, Pi[INVESTIGATOR_44768] T. Perspectives on adherence and simplicity for HIV -infected 
patients on antiretroviral ther apy: Self -report of the relative importance of multiple attributes of highly active 
antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr Hum 
Retrovirol. 2004;36(3):[ADDRESS_1047662] 486, 2002.
36. Tashima K, Crofoot G, Tomaka FL et al. Cobicistat -boosted darunavir in HIV-1- infected adults: Week48 
results of a Phase IIIb, open -label single -arm trial. AIDS Res Ther. 2014;11:39. 
37. TEMPRANO ANRS Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. 
N Engl J Med. 2015;373(9):808 -822. 
38. TRIUMEQ®[package insert]. Research Triangle Park, NC: ViiV Healthcare; April 2016.
39. TYBOST®[package insert]. Foster City, CA: [COMPANY_009] Sciences, Inc; June 2016.
40. UNAIDS 2016. AIDS by [CONTACT_184939]. Available at: 
http://www.unaids.org/sites/default/files/media_asset/ AIDS -by-the-numbers-2016_en.pdf. Accessed 
3March 2017.
41. Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Pérez- Molina JA; Investigadores del 
Estudio CUVA. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once -daily 
versus twice -daily antiretroviral therapy in a Spanish cohort of HIV- infected patients (CUVA study). Enferm 
Infecc Microbiol Clin 2008;26(3):127 -134.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
86
Approved , Date: 16 November 201742. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification 
of HIV- related disease in adults and children, 2007. Available at 
http://www. who.int/hiv/pub/guidelines/HIVstaging150307.pdf?ua=1. Accessed 13 October 2016.
43. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HI VTSQ). Qual Life 
Res. 2001;10(6):517 -531.
44. Woodcock A, Bradley C. Validation of the revised 10 -item HIV Treatment Satisfaction Questionnaire status 
version and new change version. Value Health. 2006;9(5):320 -333.
45. Woodruff, K, Mao J, Brown K et al. Evaluation of healthcare resource use among HIV patients in a large 
insured U.S. population. Poster presented at IDWeekTM 2016; October 26 -30, 2016; New  Orleans, LA.
46. World Health Organization. WHO HIV Drug Resistance Report 2012. Geneva, Switzerland. Avai lable at 
http://www. who.int/hiv/pub/drugresistance/report2012. Accessed December 14, 2016.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
87
Approved , Date: 16 November 2017ATTACHMENTS
Attachment 1: Schema for Follow -up of Subjects who Meet the Criteria for Protocol -Defined 
Virologic Failure ........................................................................................................................ 88
Attachment 2: DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events ............. 90
Attachment 3: WHO Clinical Staging of HIV/AIDS .............................................................................. 111
Attachment 4: Management of Clinically Significant Laborator y Toxicities* ....................................... 113
Attachment 5: Management of Dyslipi[INVESTIGATOR_035] ...................................................................................... 114
Attachment 6: Cardiovascular Safety: Definitions of Abnormalities .................................................... 117
Attachment 7: HIV-Treatment Satisfaction Questionnaire (HIVTSQs) ............................................... 118
Attachment 8: Antici pated Events ....................................................................................................... 119
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
88
Approved , Date: 16 November 2017Attachment 1: Schema for Follow -up of Subjects who Meet the Criteria for Protocol -Defined 
Virologic Failure 
Virologic Nonresponse Schema
Screening/
BaselineTreat ment Phase ESTD
Week 12Unscheduled visit, 
within 2 to 4 weeks after 
Week 12HIV -1 RNA result
HIV-RNA 
1 log10reduction 
from baseline 
AND
400 copi[INVESTIGATOR_014]/mL 
Blood drawn for repeat of HIV- 1 
RNA testing
and potential genotype/phenotype
Contact [CONTACT_764607], 
assess potential causes and provide adherence 
counsellation as appropriate or take any other 
action as deemed appropriate.
Unconfirmed virologic 
nonresponse: remain on 
study drugaConfirmed virologic 
nonresponseb
HIV-1 
genotype/phenotypec,d
If no resistance to study 
drug is detected, continue 
on study drug at the 
investigator’s discretionIf resistance to study drug 
is detected, study drug may 
be discontinued at the 
investigator’s discretione
aIf virologic nonresponse is not confirmed, the subject will continue study drug and the subject’s viral load will 
be further monitored.
bUpon confirmation of virologic nonresponse potential causes should be documented. Assessment should 
include lack of adherence, concom itant medication, and comorbidities (eg, active substance abuse, depression, 
or other intercurrent illnesses).
cIf virologic nonresponse is confirmed, the HIV -1 genotype/phenotype ( PhenoSense GT®)will be analyzed.
dIn case of early discontinuation, an HIV-[ADDRESS_1047663] inform the sponsor’s medical monitor before study drug discontinuation. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
89
Approved , Date: 16 November 2017Virologic Rebound Sche ma 
Screening/
BaselineTreat ment Phase ESTD
At any visit, after achieving confirmed consecutive HIV- 1 RNA 
<50 copi[INVESTIGATOR_014]/mL, a rebound in HIV-1 RNA to ≥50copi[INVESTIGATOR_014]/mL, 
OR
At any visit, a >[ADDRESS_1047664] as soon as results are 
known, assess potential causes and provide 
adherence counsellation as appropriate or take 
any other action as deemed appropriate.
Within 2 to 4 weeks of HIV -1 RNA result, return for 
scheduled/unscheduled visit for repeat of HIV -1 RNA testing
and potential genotype/phenotype
Unconfirmed virologic rebound : 
remain on study druga Confirmed virologic reboundb
HIV-1 genotype/phenotypec,d
If no resistance to study drug is 
detected, continue on study drug at 
the investigator’s discretionIf resistance to study drug is detected, 
study drug may be discontinued at the 
investigator’s discretione
aIf virologic rebound is not confirmed, the subject will continue study drug and the subject’s viral load will be 
further monitored.
bUpon confirmation of virologic rebound , potential causes should be documented. Assessment should include 
lack of adherence, concomitant medication, and comorbidities (eg, active substance abuse, depression, or other 
intercurrent illnesses).
cIf virologic rebound is confirmed, the HIV -1 genotype/phenotype ( PhenoSense GT®) will be analyzed.
dIn case of early discontinuation, an HIV-[ADDRESS_1047665] inform the sponsor’s medical monitor before study drug discontinuation. 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
90
Approved , Date: 16 November 2017Attachment 2: DAIDS Table for Grading the Severity of A dult and Pediatric A dverse Events
The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v 2.0, 
November 2014), or ‘DAIDS grading table’, is a descriptive terminology to be utilized for adverse event 
reporting in this study. A grading (severity) scale is provided for each adverse event term.
General Instructions
Estimating Severity Grade for Parameters Not Identified in the Grading Table
If the need arises to grade a clinical adverse event that is not identified in the DAIDS grading table, use 
the category ‘Estimating Severity Grade’ located at the top of the tab le on the following page. In addition, 
all deaths related to an adverse event are to be classified as grade 5.
Grading Adult and Pediatric Adverse Events
The DAIDS grading table includes parameters for grading both adult and pediatric adverse events. When 
a single set of parameters is not appropriate for grading specific types of adverse events for both adult and 
pediatric populations, separate sets of parameters for adult and/or pediatric populations (with specified 
respective age ranges) are provided. If there is no distinction in the table between adult and pediatric 
values for a type of adverse event, then the single set of parameters listed is to be used for grading the 
severity of both adult and pediatric events of that type.
Determining Severity Grade
If the severity of an adverse event could fall under either 1 of 2 grades (eg, the severity of an adverse 
event could be either grade 2 or grade 3), select the higher of the 2 grades for the adverse event.
Laboratory normal ranges should be taken into con sideration to assign gradings to a laboratory value.
Definitions
Basic Self -care Functions AdultActivities such as bathing, dressing, toileting, transfer or movement, 
continence, and feeding.
Young Children Activities that are age and culturally appropriate, such as feeding 
one’s self with culturally appropriate eating implements.
Usual Social & Functional 
ActivitiesActivities which adults and children perform on a routine basis and those which are 
part of regular activities of daily living, for example:
AdultsAdaptive tasks and desirable activities, such as going to w ork, shoppi[INVESTIGATOR_007], 
cooking, use of transportation, or pursuing a hobby.
Young Children Activities that are age and culturally appropriate, s uch as social 
interactions, play activities, or learning tasks.
Intervention Medical, surgical, or other procedures recommended or provided by a healthcare 
professional for the treatment of an adverse event.
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Clinical adverse 
event NOT 
identified 
elsewhere in the 
grading table Mild symptoms 
causing no or minimal 
interference with 
usual social & 
functional activities 
with intervention not 
indicated Moderate symptoms 
causing greater than 
minimal interference 
with usual social & 
functional activities 
with intervention 
indicated Severe symptoms 
causing inability to 
perform usual social & 
functional activities 
with intervention or 
hospi[INVESTIGATOR_764564] -
threatening symptoms 
causing inability to 
perform basic self -care 
functions with 
intervention indicated to 
prevent permanent 
impairment, persistent 
disability, or death 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
91
Approved , Date: 16 November 2017MAJOR CLINICAL CONDITIONS
CARDIOVASCULAR
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Arrhythmia 
(by [CONTACT_223081]) 
Specify type, if 
applicableNo symptoms AND 
No intervention 
indicated No symptoms AND 
Non-urgent 
intervention indicated Non-life-threatening 
symptoms AND Non-
urgent intervention 
indicated Life-threatening 
arrhythmia OR Urgent 
intervention indicated 
Blood Pressure 
Abnormalities1
Hypertension (with 
the lowest reading 
taken after repeat 
testing during a visit) 
≥18 years of age 140 to <160 mmHg 
systolic OR 90 to 
<100 mmH g diastolic ≥160 to <180 mmHg 
systolic OR ≥100 to 
<110 mmHg diastolic ≥180 mmHg systolic 
OR ≥110 mmHg 
diastolic Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (eg, 
malignant 
hypertension) OR 
Hospi[INVESTIGATOR_373] 
<18 years of age >120/80 mmHg ≥95th to <99th 
percentile + 5 mmHg 
adjusted for age, 
height, and gender 
(systolic and/or 
diastolic) ≥99th percentile + 
5mmHg adjusted for 
age, height, and gender 
(systolic and/or 
diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (eg, 
malignant 
hypertension) OR 
Hospi[INVESTIGATOR_764565] (stable 
angina) OR New 
testing consistent with 
ischemia Unstable angina OR 
Acute myocardial 
infarction 
Heart Failure No symptoms AND 
Laboratory or cardiac 
imaging abnormalities Symptoms with mild to 
moderate activity or 
exertion Symptoms at rest or 
with minimal activity 
or exertion (eg, 
hypoxemia) OR 
Intervention indicated 
(eg, oxygen) Life-threatening 
consequences OR 
Urgent intervention 
indicated (eg, 
vasoactive 
medications, 
ventricular assist 
device, heart 
transplant) 
Hemorrhage (with 
significant acute blood 
loss) NA Symptoms AND No 
transfusion indicated Symptoms AND 
Transfusion of ≤2 units 
packed RBCs indicated Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs (for 
children, packed RBCs 
>10 cc/kg) indicated 
1Blood pressure norms for children <18 years of age can be found in: Expert Panel on Integrated Guidelines for Cardiovascular 
Health and Risk Reduction in Children and Adolescents. Pediatrics 2011;128;S213; originally published online November 14, 
2011; DOI: 10.1542/peds.2009-2107C.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
92
Approved , Date: 16 November 2017CARDIOVASCULAR
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Prolonged PR 
Interval or AV Block 
Report only one 
>16 years of age PR interval 0.21 to 
<0.25 seconds PR interval 
≥0.25 seconds OR 
Type I 2nd degree AV 
block Type II 2nd degree AV 
block OR Ventricular 
pause ≥3.0 seconds Complete AV block 
≤[ADDRESS_1047666] degree AV block 
(PR interval >normal 
for age and rate) Type I 2nd degree AV 
block Type II 2nd degree AV 
block OR Ventricular 
pause ≥3.0 seconds Complete AV block 
Prolonged QTc 
Interval20.45 to 0.47 seconds >0.47 to 0.50 seconds >0.50 seconds OR 
≥0.06 seconds above 
baseline Life-threatening 
consequences (eg, 
Torsade de pointes, 
other associated 
serious ventricular 
dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention indicated Symptoms AND 
intervention indicated Life-threatening 
embolic event (eg, 
pulmonary embolism, 
thrombus) 
2Per Bazett’s formula.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
93
Approved , Date: 16 November 2017DERMATOLOGIC
PARAMETER GRADE 1 
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Alopecia (scalp only) Detectable by [CONTACT_8712], caregiver, 
or physician AND 
Causing no or minimal 
interference with usual 
social & functional 
activities Obvious on visual 
inspection AND 
Causing greater than 
minimal interference 
with usual social & 
functional activities NA NA 
Bruising Localized to one area Localized to more than 
one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment indicated (eg, 
oral antibiotics, 
antifungals, antivirals) IV treatment indicated 
(eg, IV antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (eg, 
sepsis, tissue necrosis) 
Hyperpi[INVESTIGATOR_184839] & functional 
activities Marked or generalized 
causing greater than 
minimal interference 
with usual social & 
functional activities NA NA 
Hypopi[INVESTIGATOR_184839] & functional 
activities Marked or generalized 
causing greater than 
minimal interference 
with usual social & 
functional activities NA NA 
Petechiae Localized to one area Localized to more than 
one area Generalized NA 
Pruritus3(without skin 
lesions) Itching causing no or 
minimal interference 
with usual social & 
functional activities Itching causing greater 
than minimal 
interference with usual 
social & functional 
activities Itching causing 
inability to perform 
usual social & 
functional activities NA
Rash 
Specify type, if 
applicable 
For the rash management 
applicable in this study, 
see Section 9.8.[ADDRESS_1047667] mucosal sites 
OR Stevens-Johnson 
syndrome OR Toxic 
epi[INVESTIGATOR_194] 
3For pruritus associated with injections or infusions, see the Site Reactions to Injections and I nfusions section.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
94
Approved , Date: 16 November 2017ENDOCRINE AND METABOLIC
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Diabetes Mellitus Controlled without 
medication Controlled with 
medication OR 
Modification of current 
medication regimen Uncontrolled despi[INVESTIGATOR_184840]-threatening 
consequences (eg, 
ketoacidosis, 
hyperosmolar non -
ketotic coma , end 
organ failure) 
Gynecomastia Detectable by [CONTACT_8712], caregiver, 
or physician AND 
Causing no or minimal 
interference with usual 
social & functional 
activities Obvious on visual 
inspection AND 
Causing pain with 
greater than minimal 
interference with usual 
social & functional 
activities Disfiguring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social & 
functional activities NA
Hyperthyroidism No symptoms AND 
Abnormal laboratory 
value Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Thyroid 
suppression therapy 
indicated Symptoms causing 
inability to perform 
usual social &
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (eg, 
thyroid storm) 
Hypothyroidism No symptoms AND 
Abnormal laboratory 
value Symptoms causing 
greater than minimal 
interference with usual 
social & fun ctional 
activities OR Thyroid 
replacement therapy 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (eg, 
myxedema coma) 
Lipoatrophy4Detectable by [CONTACT_8712], caregiver, 
or physician AND 
Causing no or minimal 
interference with usual 
social & functional 
activities Obvious on visual 
inspection AND 
Causing greater than 
minimal interference 
with usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy5Detectable by [CONTACT_8712], caregiver, 
or physician AND 
Causing no or minimal 
interference with usual 
social & functional 
activities Obvious on visual 
inspection AND 
Causing greater than 
minimal interference 
with usual social & 
functional activities Disfiguring changes NA 
4Definition: A disorder characterized by [CONTACT_184941], extremities, and buttocks. 
5Definition: A disorder characterized by [CONTACT_184942], breasts, and abdomen.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
95
Approved , Date: 16 November 2017GASTROINTESTINAL
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Anorexia Loss of appetite 
without decreased oral 
intake Loss of appetite 
associated with 
decreased oral intake 
without significant 
weight loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive 
intervention indic ated 
(eg, tube feeding, total 
parenteral nutrition) 
Ascites No symptoms Symptoms AND 
Intervention indicated 
(eg, diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despi[INVESTIGATOR_144482]-threatening 
consequences 
Bloating or 
Distension 
Report only one Symptoms causing no 
or minimal interference 
with usual social & 
functional activities Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms causing 
inability to perf orm 
usual social & 
functional activities NA 
Cholecystitis NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (eg, 
sepsis, perforation) 
Constipation NA Persistent constipation 
requiring regular use 
of dietary 
modifications, 
laxatives, or enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (eg, 
obstruction) 
Diarrhea 
≥1 year of age Transient or 
intermittent epi[INVESTIGATOR_184841] ≤3 stools 
over baseline per 24 -
hour period Persistent epi[INVESTIGATOR_114747] 
4 to 6 stools over 
baseline per 24 -hour 
period Increase of ≥7 stools 
per 24 -hour period OR 
IV fluid replacement 
indicated Life-threatening 
consequences (eg, 
hypotensive shock) 
<1 year of age Liquid stools (more 
unformed than usual) 
but usual number of 
stools Liquid stools with 
increased number of 
stools OR Mild 
dehydration Liquid stools with 
moderate dehydration Life-threatening 
consequences (eg, 
liquid stools resulting 
in severe dehydration, 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one and 
specify location Symptoms but able to 
eat usual diet Symptoms causing 
altered dietary intake 
with no intervention 
indicated Symptoms causing 
severely altered dietary 
intake with 
intervention indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other than 
iron supplement Endoscopic 
intervention indicated Transfusion indicated Life-threatening 
consequences (eg, 
hypotensive shock) 
Mucositis or 
Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes or 
ulcerations Confluent 
pseudomembranes or 
ulcerations OR 
Mucosal bleeding with 
minor trauma Life-threatening 
consequences (eg, 
aspi[INVESTIGATOR_1516], choking) 
OR Tissue necrosis 
OR Diffuse 
spontaneous mucosal 
bleeding 
Nausea Transient (< 24 hours) 
or intermittent AND 
No or minimal 
interference with oral 
intake Persistent nausea 
resulting in decreased 
oral intake for 24 to 
48hours Persistent nausea 
resulting in minimal 
oral intake for 
>48hours OR 
Rehydration indicated 
(eg, IV fluids) Life-threatening 
consequences (eg, 
hypotensive shock) 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
96
Approved , Date: 16 November 2017GASTROINTESTINAL
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Pancreatitis NA Symptoms with 
hospi[INVESTIGATOR_184842]-threatening 
consequences (eg, 
circulatory failure, 
hemorrhage, sepsis) 
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort with 
no intervention 
indicated Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Medical 
intervention indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (eg, 
perforation) 
Rectal Discharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND No 
or minimal interference 
with oral intake Frequent epi[INVESTIGATOR_184843] (eg, IV 
fluids) Life-threatening 
consequences (eg, 
hypotensive shock) 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
97
Approved , Date: 16 November 2017MUSCULOSKELETAL
PARAMETER GRADE 1 
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Arthralgia Joint pain causing no or 
minimal interference 
with usual social & 
functional activities Joint pain causing 
greater than minimal 
interference with usual 
social & functional 
activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self -care 
functions 
Arthritis Stiffness or joint 
swelling causing no or 
minimal interference 
with usual social & 
functional activities Stiffness or joint 
swelling causing 
greater than minimal 
interference with usual 
social & functional 
activities Stiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activities Disabling joint 
stiffness or swelling 
causing inability to 
perform basic self -care 
functions 
Myalgia (generalized) Muscle pain causing no 
or minimal interference 
with usual social &
functional activities Muscle pain causing 
greater than minimal 
interference with usual 
social & functional 
activities Muscle pain causing 
inability to perform 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self-care 
functions 
Osteonecrosis NA No symptoms but with 
radiographic findings 
AND No operative 
intervention indicated Bone pain with 
radiographic findings 
OR Operative 
intervention indicated Disabling bone pain 
with radiographic 
findings causing 
inability to perform 
basic self -care 
functions 
Osteopenia6
≥30 years of age BMD t -score -2.5 to -1 NA NA NA 
<30 years of age BMD z -score -2 to -1 NA NA NA 
Osteoporosis6
≥30 years of age NA BMD t -score <-2.5 Pathologic fracture 
(eg, compression 
fracture causing loss of 
vertebral height) Pathologic fracture 
causing life -
threatening 
consequences 
<30 years of age NA BMD z -score <-2 Pathologic fracture 
(eg, compression 
fracture causing loss of 
vertebral height) Pathologic fracture 
causing life -
threatening 
consequences 
6Bone mineral density ( BMD ) t and z scores can be found in: Kanis JA on behalf of the World Health Organization Scientific 
Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization 
Collaborating Centre for Metabolic Bone D iseases, University of Sheffield, [LOCATION_008]. 2007: Printed by [CONTACT_308286].
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
98
Approved , Date: 16 November 2017NEUROLOGIC
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Acute CNS Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accident (eg, stroke 
with neurological 
deficit) 
Altered Mental Status 
(for Dementia, see 
Cognitive, Behavioral, 
or Attentional 
Disturbance below) Changes causing no or 
minimal interference 
with usual social &
functional activities Mild lethargy or 
somnolence causing 
greater than minimal 
interference with usual 
social & functional 
activities Confusion, memory 
impairment, lethargy, 
or somnolence causing 
inability to perform 
usual social & 
functional activitiesDelirium OR 
Obtundation OR Coma 
Ataxia Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities OR No 
symptoms with ataxia 
detected on 
examination Symptoms causing 
greater than minimal 
interference with usual 
social & fun ctional 
activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self -care 
functions 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance (includes 
dementia and attention 
deficit disorder) 
Specify type, if 
applicable Disability causing no 
or minimal 
interference with usual 
social & functional 
activities OR 
Specialized resources 
not indicated Disability causing 
greater than minimal 
interfe rence with usual 
social & functional 
activities OR 
Specialized resources 
on part -time basis 
indicated Disability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full -
time basis indicated Disability causing 
inability to perform 
basic self -care 
functions OR 
Institutionalization 
indicated 
Developmental Delay
<18 years of age 
Specify type, if 
applicable Mild developmental 
delay, either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental delay, 
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Severe developmental 
delay, either motor or 
cognitive, as 
determin ed by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either 
motor or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting 
Headache Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms causing 
inability to perform 
usual social & 
functional activities Symptoms causing 
inability to perform 
basic self -care 
functions OR 
Hospi[INVESTIGATOR_184844] (includes 
myopathy and 
neuropathy) 
Specify type, if 
applicable Minimal muscle 
weakness causing no 
or minimal 
interference with usual 
social & functional 
activities OR No 
symptoms with 
decreased strength on 
examination Muscle weakness 
causing greater than 
minimal interference 
with usual social & 
functional a ctivities Muscle weakness 
causing inability to 
perform usual social & 
functional activities Disabling muscle 
weakness causing 
inability to perform 
basic self -care 
functions OR 
Respi[INVESTIGATOR_184845] 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
99
Approved , Date: 16 November 2017NEUROLOGIC
PARAMETER GRADE 1 
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Neurosensory 
Alteration (includes 
paresthesia and painful 
neuropathy) 
Specify type, if 
applicable Minimal paresthesia 
causing no or minimal 
interference with usual 
socia l & functional 
activities OR No 
symptoms with 
sensory alteration on 
examination Sensory alteration or 
paresthesia causing 
greater than minimal 
interference with usual 
social & functional 
activities Sensory alteration or 
paresthesia causing 
inability to p erform 
usual social & 
functional activities Disabling sensory 
alteration or 
paresthesia causing 
inability to perform 
basic self -care 
functions 
Seizures 
New Onset Seizure 
≥18 years of age NA NA 1 to 3 seizures Prolonged and 
repetitive seizures (eg, 
status epi[INVESTIGATOR_7397]) OR 
Difficult to control (eg, 
refractory epi[INVESTIGATOR_002]) 
<18 years of age 
(includes new or pre -
existing febrile 
seizures) Seizure lasting 
<5minutes with 
<24hours postictal 
state Seizure lasting 5 to 
<20 minutes with 
<24hours postictal 
state Seizure lasting 
≥20minutes OR 
>24hours postictal 
state Prolonged and 
repetitive seizures (eg, 
status epi[INVESTIGATOR_7397]) OR 
Difficult to control (eg, 
refractory epi[INVESTIGATOR_002]) 
Pre-existing Seizure NA Increased frequency 
from previous level of 
control without change 
in seizure character Change in seizure 
character either in 
duration or quality (eg, 
severity or focality) Prolonged and 
repetitive seizures (eg, 
status epi[INVESTIGATOR_7397]) OR 
Difficult to con trol (eg, 
refractory epi[INVESTIGATOR_002]) 
Syncope Near syncope without 
loss of consciousness 
(eg, pre -syncope) Loss of consciousness 
with no intervention 
indicated Loss of consciousness 
AND Hospi[INVESTIGATOR_184846], PUERPERIUM, AND PERINATAL
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Fetal Death or 
Stillbirth (report using 
mother’s participant 
ID) 
Report only one NA NA Fetal loss occurring at 
≥20 weeks gestation NA 
Preterm Delivery7
(report using mother’s 
participant ID) Delivery at 34 to 
<37weeks gestational 
age Delivery at 28 to 
<34weeks gestational 
age Delivery at 24 to 
<28weeks gestational 
age Delivery at <24 weeks 
gestational age 
Spontaneous 
Abortion or
Miscarriage8(report 
using mother’s 
participant ID) 
Report only one Chemical pregnancy Uncomplicated 
spontaneous abortion 
or miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
7Definition: A delivery of a live -born neonate occurring at ≥20 to <37 weeks gestational age. 
8Definition: A clinically recognized pregnancy occurring at <20 weeks gestational age.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
100
Approved , Date: 16 November 2017PSYCHIATRIC
PARAMETER GRADE 1 
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Insomnia Mild difficulty falling 
asleep, staying asleep, 
or waking up early Moderate difficulty 
falling asleep, staying 
asleep, or waking up 
early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric Disorders 
(includes anxiety, 
depression, mania, and 
psychosis) 
Specify disorder Symptoms with 
intervention not 
indicated OR Behavior 
causing no or minimal 
interference with usual 
social & functional 
activities Symptoms with 
intervention indicated 
OR Behavior causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms with 
hospi[INVESTIGATOR_184847] & 
functional activities Threatens harm to self 
or others OR Acute 
psychosis OR 
Behavior causing 
inability to perform 
basic self -care 
functions 
Suicida l Ideation or 
Attempt 
Report only one Preoccupi[INVESTIGATOR_184848] 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Acute Bronchospasm Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow reduced to 
≥70 to <80% OR Mild 
symptoms with 
intervention not 
indicated Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow 50 to <70% 
OR Symptoms with 
intervention indicated 
OR Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow 25 to <50% 
OR Symptoms 
causing inability to 
perform usual social 
& functional activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow < 25% OR 
Life-threatening 
respi[INVESTIGATOR_764566] &
functional activities 
OR Wheezing OR 
Minimal increase in 
respi[INVESTIGATOR_184851] & 
functional activities OR 
Nasal flaring OR 
Intercostal retractions 
OR Pulse oximetry 90 
to <95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional activities 
OR Pulse oximetry 
<90% Respi[INVESTIGATOR_184852] (eg, CPAP, 
BPAP, intubation) 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
101
Approved , Date: 16 November 2017SENSORY
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Hearing Loss 
≥12 years of age NA Hearing aid or 
intervention not 
indicated Hearing aid or 
intervention indicated Profound bilateral 
hearing loss (>80 dB at 
2 kHz and above) OR 
Non-serviceable 
hearing (ie, >50 dB 
audiogram and <50% 
speech discrimination) 
<12 years of age 
(based on a 1, 2, 3, 
4, 6 and 8 kHz 
audiogram) >20 dB hearing loss at 
≤4 kHz >20 dB hearing loss at 
>4 kHz >20 dB hearing loss at 
≥3 kHz in one ear with 
additional speech 
language relat ed 
services indicated 
(where available) OR 
Hearing loss sufficient 
to indicate therapeutic 
intervention, including 
hearing aids Audiologic indication 
for cochlear implant 
and additional speech -
language related 
services indicated 
(where available) 
Tinnitus Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities with 
intervention not 
indicated Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities with 
intervention indicated Sympt oms causing 
inability to perform 
usual social & 
functional activities NA 
Uveitis No symptoms AND 
Detectable on 
examination Anterior uveitis with 
symptoms OR 
Medicamylasal 
intervention indicated Posterior or pan -uveitis 
OR Operative 
intervention indicated Disabling visual loss in 
affected eye(s) 
Vertigo Vertigo causing no or 
minimal interference 
with usual social & 
functional activities Vertigo causing greater 
than minimal 
interference with usual 
social & functional 
activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self -care 
functions 
Visual Change s 
(assessed from 
baseline) Visual changes causing 
no or minimal 
interference with usual 
social & functional 
activities Visual changes causing 
greater than minimal 
interference with usual 
social & functional 
activities Visual changes causing 
inability to perform 
usual social & 
functional activities Disabling visual loss in 
affected eye(s) 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
102
Approved , Date: 16 November 2017SYSTEMIC
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Acute Allergic 
Reaction Localized urticaria 
(wheals) with no 
medical intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with no 
intervention indicated Generalized urticaria 
OR Angioedema with 
intervention indicated 
OR Symptoms of mild 
bronchospasm Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9Mild signs and 
symptoms AND 
Therapy (ie, antibody 
infusion) interruption 
not indicated Therapy (ie, antibody 
infusion) interruption 
indicated AND 
Responds promptly to 
symptomatic treatment 
OR Prophylactic 
medications indicated 
for ≤24 hours Prolonged severe signs 
and symptoms OR 
Recurrence of 
symptoms following 
initial improvement Life-threatening 
consequences (eg, 
requirin g pressor or 
ventilator support) 
Fatigue or Malaise 
Report only one Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating 
symptoms of fatigue or 
malaise causing 
inability to perform 
basic self -care 
functions 
Fever (non-axillary 
temperatures only) 38.0 to <38.6°C or 
100.4 to <101.5°F ≥38.6 to <39.3°C or 
≥101.5 to <102.7°F ≥39.3 to <40.0°C or 
≥102.7 to <104.0°F ≥40.0°C or ≥104.0°F 
Pain10(not associated 
with study agent 
injections and not 
specified elsewhere) 
Specify location Pain causing no or 
minimal interference 
with usual social & 
functional activities Pain causing greater 
than minimal 
interference with usual 
social & functional 
activities Pain causing inability 
to perform usual social 
& functional activities Disabling p ain causing 
inability to perform 
basic self -care 
functions OR 
Hospi[INVESTIGATOR_184853]11Mild signs and 
symptoms Moderate signs and 
symptoms AND 
Intervention indicated 
(eg, antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(eg, steroids or IV 
fluids) Life-threatening 
consequences (eg, 
requiring pressor or 
ventilator support) 
Underw eight12
>5 to 19 years of 
age NA WHO BMI z -score <-2 
to ≤-3 WHO BMI z -scor e <-3 WHO BMI z -score <-3 
with life -threatening 
consequences 
2 to 5 years of age NA WHO Weight -for-
height z -score 
<-2 to ≤-3 WHO Weight -for-
height z -score <-3 WHO Weight -for-
height z -score <-3 with 
life-threatening 
consequences 
<2 years of age NA WHO Weight -for-
length z -score 
<-2 to ≤-3 WHO Weight -for-
length z -score <-3 WHO Weight -for-
length z -score <-3 with 
life-threatening 
consequences 
9Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of breath. 
10For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section. 
11Definition: A disorder characterized by [CONTACT_411], arthralgia, myalgia, skin eruptions, lymphadenopathy, marked discomfort, and/o r 
dyspnea.
12WHO reference tables may be accessed by [CONTACT_184944]: 
http://w ww.who.int/growthref/who2007_bmi_for_age/en/ for participants >5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤5 years of age. BMI: Body mass index.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
103
Approved , Date: 16 November 2017SYSTEMIC
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Weight Loss (excludes 
postpartum weight 
loss) NA 5 to <9% loss in body 
weight from baseline ≥9 to <20% loss in 
body weight from 
baseline ≥20% loss in body 
weight from baseline 
OR Aggressive 
intervention indicated 
(eg, tube feeding, total 
parenteral nutrition) 
URINARY
PARAMETER GRADE [ADDRESS_1047668] 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing 
life-threatening 
consequences 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
104
Approved , Date: 16 November 2017SITE REACTIONS TO INJECTIONS AND INFUSIONS
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Injection Site Pain or 
Tenderness 
Report only one Pain or tenderness 
causing no or minimal 
limitation of use of 
limb Pain or tenderness 
causing greater than 
minimal limitation of 
use of limb Pain or tenderness 
causing inability to 
perform usual social & 
functional activities Pain or tenderness 
causing inability to 
perform basic self -care 
function OR 
Hospi[INVESTIGATOR_184854]13
Report only one 
>15 years of age 2.5 to <5 cm in 
diameter OR 6.25 to 
<25 cm2surface area 
AND Symptoms 
causing no or minimal 
interference with 
usual social & 
functional activities ≥5 to <10 cm in 
diameter O R ≥25 to 
<100 cm2surface area 
OR Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities ≥10 cm in diameter OR 
≥100 cm2surface area 
OR Ulceration OR 
Secondary infection 
OR Phlebitis OR 
Sterile abscess OR 
Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities Potentially life -
threatening 
consequences (eg, 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
≤15 years of age ≤2.5 cm in diameter >2.5 cm in diameter 
with <50% surface area 
of the extremity 
segment involved (eg, 
upper arm or thigh) ≥50% surface area of 
the extremity segment 
involved (eg, upper 
arm or thigh) OR 
Ulceration OR 
Secondary infection 
OR Phlebitis OR 
Sterile abscess OR 
Drain age Potentially life -
threatening 
consequences (eg, 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or 
Swelling 
Report only one 
>15 years of age Same as for Injection 
Site Erythema or 
Redness, >15 years 
of age Same as for Injection 
Site Erythema or 
Redness, >15 years of 
age Same as for Injection 
Site Erythema or 
Redness, >15 years of 
age Same as for Injection 
Site Erythema or 
Redness, >15 years of 
age 
≤15 years of age Same as for Injection 
Site Erythema or 
Redness, ≤15 years of 
age Same as for Injection 
Site Erythema or 
Redness, ≤15 years of 
age Same as for Injection 
Site Erythema or 
Redness, ≤15 years of 
age Same as for Injection 
Site Erythema or 
Redness, ≤15 years of 
age 
Injection Site Pruritus Itching localized to 
the injection site that 
is relieved 
spontaneously or in 
<48 hours of 
treatment Itching beyond the 
injection site that is not 
generalized OR Itching 
localized to the 
injection site requiring 
≥48 hours treatmentGeneralized itching 
causing inability to 
perform usual social & 
functional activities NA 
13Injection Site Erythema or Redness should be evaluated and graded using the greatest single diameter or measured surface 
area.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
105
Approved , Date: 16 November 2017LABORATORY VALUES
CHEMISTRIES
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Acidosis NA pH ≥7.3 to <LLN14pH <7.3 without life -
threatening 
consequences pH <7.3 with life-
threatening 
consequences 
Albumin, Low (g/dL; 
g/L) 3.0 to < LLN 
30 to <LLN ≥2.0 to <3.0 
≥20 to <30 <2.0 
<20 NA 
Alkaline 
Phosphatase, High 1.25 to <2.5 ×ULN 2.5 to <5.0 ×ULN 5.0 to <10.0 ×ULN ≥10.0 ×ULN 
Alkalosis NA pH > ULN to ≤7.5 pH >7.5 without life -
threatening 
consequences pH > 7.5 with life -
threatening 
consequences 
ALT or SGPT, High 
Report only one 1.25 to <2.5 ×ULN 2.5 to <5.0 ×ULN 5.0 to <10.0 ×ULN ≥10.0 ×ULN 
Amylase (Pancreatic) 
or Amylase (Total), 
High 
Report only one 1.1 to <1.5 ×ULN 1.5 to < 3.0×ULN 3.0 to <5.0 ×ULN ≥5.0×ULN 
AST or SGOT, High 
Report only one 1.25 to <2.5 ×ULN 2.5 to <5.0 ×ULN 5.0 to <10.0 ×ULN ≥10.0 ×ULN 
Bicarbonate, Low 
(mEq/L; mmol/L ) 16.0 to <LLN 
16.0 to <LLN 11.0 to <16.0
11.0 to <16.0 8.0 to <11.0 
8.0 to <11.0 <8.0 
<8.[ADDRESS_1047669] Bilirubin15, 
High 
>28 days of age NA NA >ULN >ULN with life -
threatening 
consequences (eg, 
signs and symptoms of 
liver failure) 
≤[ADDRESS_1047670] to ≤1mg/dL >1 to ≤1.5 mg/dL >1.5 to ≤2mg/dL >2mg/dL 
Total Bilirubin, 
High 
>28 days of age 1.1 to <1.6 ×ULN 1.6 to <2.6 ×ULN 2.6 to <5.0 ×ULN ≥5.0×ULN 
≤28 days of age See Appendix A. Total 
Bilirubin for Term and 
Preterm Neonates See Appendix A. Total 
Bilirubin for Term and 
Preterm Neonates See Appendix A. Total 
Bilirubin for Term and 
Preterm Neonates See Appendix A. Total 
Bilirubin for Term and 
Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L ) 
≥7 days of age 10.6 to <11.5 
2.65 to <2.88 11.5 to <12.5 
2.88 to <3.13 12.5 to <13.5 
3.13 to <3.38 ≥13.5 
≥3.38 
<7 days of age 11.5 to <12.4 
2.88 to <3.10 12.4 to <12.9 
3.10 to <3.23 12.9 to <13.5 
3.23 to <3.38 ≥13.5 
≥3.38 
Calcium (Ionized), 
High (mg/dL; 
mmol/L ) >ULN to <6.0 
>ULN to <1.5 6.0 to <6.4 
1.5 to <1.6 6.4 to < 7.2 
1.6 to <1.8 ≥7.2 
≥1.8 
Calcium, Low 
(mg/dL; mmol/L ) 
≥7 days of age 7.8 to <8.4 
1.95 to <2.10 7.0 to <7.8 
1.75 to <1.95 6.1 to <7.0 
1.53 to <1.75 <6.1 
<1.53 
<7 days of age 6.5 to <7.5 
1.63 to <1.88 6.0 to <6.5 
1.50 to <1.63 5.50 to < 6.0 
1.38 to <1.50 <5.50 
<1.38 
Calcium (Ionized), 
Low (mg/dL; mmol/L ) <LLN to 4.0 
<LLN to 1.0 3.6 to <4.0 
0.9 to <1.0 3.2 to <3.6 
0.8 to <0.9 <3.2 
<0.[ADDRESS_1047671] bilirubin >1.5 mg/dL in a participant <28 days of age should be graded as grade 2, if <10% of the total bilirubin.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
106
Approved , Date: 16 November 2017CHEMISTRIES
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Creatine Kinase, 
High 3 to <6 ×ULN 6 to <10 ×ULN 10 to <20 ×ULN ≥20×ULN 
Creatinine, High 1.1 to 1.3 ×ULN >1.3 to 1.8 ×ULN OR 
Increase of >0.3 mg/dL 
above baseline >1.8 to <3.5 ×ULN OR 
Increase of 1.5 to 
<2.0×above baseline ≥3.5×ULN OR 
Increase of 
≥2.0×above baseline 
Creatinine 
Clearance16or 
eGFR, Low 
Report only one NA <90 to 60 ml/min or 
ml/min/1.73 m2OR 10 
to <30% decrease from 
baseline <60 to 30ml/min or 
ml/min/1.73 m2OR 
≥30 to <50% decrease 
from baseline <30 ml/min or 
ml/min/1.73 m2OR 
≥50% decrease from 
baseline or dialysis 
needed 
Glucose 
(mg/dL; mmol/L ) 
Fasting, High 110 to 125 
6.11 to <6.95 >125 to 250 
6.95 to <13.89 >250 to 500 
13.89 to <27.75 >500 
≥27.75 
Nonfasting, High 116 to 160 
6.44 to <8.89 >160 to 250 
8.89 to <13.89 >250 to 500 
13.89 to <27.75 >500 
≥27.75 
Glucose, Low 
(mg/dL; mmol/L ) 
≥1 month of age 55 to 64 
3.05 to 3.55 40 to <55 
2.22 to <3.05 30 to <40 
1.67 to <2.22 <30 
<1.67 
<1 month of age 50 to 54 
2.78 to 3.00 40 to <50 
2.22 to <2.78 30 to <40 
1.67 to <2.22 <30 
<1.[ADDRESS_1047672] to <2.0 ×ULN 
without acidosis ≥2.0×ULN without 
acidosis Increased lactate with 
pH <7.3 without life -
threatening 
consequences Increased lactate with 
pH <7.3 with life-
threatening 
consequences 
Lipase, High 1.1 to <1.5 ×ULN 1.5 to <3.0 ×ULN 3.0 to <5.0 ×ULN ≥5.0×ULN 
Lipid Disorders 
(mg/dL; mmol/L ) 
Cholesterol, 
Fasting, High 
≥18 years of age 200 to <240 
5.18 to <6.19 240 to <300 
6.19 to <7.77 ≥300 
≥7.77 NA 
<18 years of age 170 to <200 
4.40 to <5.15 200 to <300 
5.15 to <7.77 ≥300 
≥7.77 NA 
LDL17, Fasting, 
High 
≥18 years of age 130 to <160 
3.37 to <4.12 160 to <190 
4.12 to <4.90 ≥190 
≥4.90 NA 
>2 to <18 years of 
age 110 to <130 
2.85 to <3.34 130 to <190 
3.34 to <4.90 ≥190 
≥4.90 NA 
Triglycerides, 
Fasting, High 150 to 300 
1.71 to 3.42 >300 to 500 
>3.42 to 5.7 >500 to <1,000 
>5.7 to 11.4 >1,000 
>11.4 
Magnesium18, Low 
(mEq/L; mmol/L ) 1.2 to <1.4 
0.60 to <0.70 0.9 to <1.2 
0.45 to <0.60 0.6 to <0.9 
0.30 to <0.45 <0.6 
<0.30 
Phosphate, Low 
(mg/dL; mmol/L ) 
>14 years of age 2.0 to < LLN 
0.81 to < LLN 1.4 to < 2.0 
0.65 to < 0.81 1.0 to <1.4 
0.32 to <0.65 <1.0 
<0.32 
1 to 14 years of age 3.0 to <3.5 
0.97 to <1.13 2.5 to <3.0 
0.81 to <0.97 1.5 to <2.5 
0.48 to <0.81 <1.5 
<0.48 
<1 year of age 3.5 to <4.5 
1.13 to <1.45 2.5 to <3.5 
0.81 to <1.13 1.5 to <2.5 
0.48 to <0.81 <1.5 
<0.48 
Potassium, High 
(mEq/L; mmol/L ) 5.6 to <6.0 
5.6 to <6.0 6.0 to <6.5 
6.0 to <6.5 6.5 to <7.0 
6.5 to <7.0 ≥7.0 
≥7.0 
Potassium, Low 
(mEq/L; mmol/L ) 3.0 to <3.4 
3.0 to <3.4 2.5 to <3.0 
2.5 to <3.0 2.0 to <2.5 
2.0 to <2.5 <2.0 
<2.0 
16Use the applicable formula ( Modific ation of Diet in Renal Disease [ MDRD ]).
17Low-density lipoprotein
18To convert a magnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
107
Approved , Date: 16 November 2017CHEMISTRIES
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Sodium, High 
(mEq/L; mmol/L ) 146 to <150 
146 to <150 150 to <154 
150 to <154 154 to <160 
154 to < 160 ≥160 
≥160 
Sodium, Low 
(mEq/L; mmol/L ) 130 to <135 
130 to <135 125 to <130 
125 to <135 121 to <125 
121 to <125 ≤120 
≤120 
Uric Acid, High 
(mg/dL; mmol/L ) 7.5 to <10.0 
0.45 to <0.59 10.0 to <12.0 
0.59 to <0.71 12.0 to <15.0 
0.71 to < 0.89 ≥15.0
≥0.89 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
108
Approved , Date: 16 November 2017HEMATOLOGY
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Absolute CD4+
Count, Low 
(cell/mm3; cells/L ) 
>5 years of age 
(not HIV infected) 300 to <400 
300 to <400 200 to <300 
200 to <300 100 to <200 
100 to <200 <100 
<100 
Absolute Lymphocyte 
Count, Low 
(cell/mm3; cells/L ) 
>5 years of age 
(not HIV infected) 600 to <650 
0.600 ×109to 
<0.650 ×109500 to <600 
0.500 ×109to 
<0.600 ×109350 to <500 
0.350 x109to 
<0.500 ×109<350 
<0.350 ×109 
Absolute Neutrophil 
Count (ANC), Low 
(cells/mm3; cells/L ) 
>7 days of age 800 to 1,000 
0.800 ×109to 
1.000 ×109600 to 799 
0.600 ×109to 
0.799 ×109400 to 599 
0.400 ×109to 
0.599 ×109<400 
<0.400 ×109
2 to 7 days of age 1,250 to 1,500 
1.250 ×109to 
1.500 ×1091,000 to 1,249 
1.000 ×109to 
1.249 ×109750 to 999 
0.750 ×109to 
0.999 ×109<750 
<0.750 ×109
≤1 day of age 4,000 to 5,000 
4.000 ×109to 
5.000 ×1093,000 to 3,999 
3.000 ×109to 
3.999 ×1091,500 to 2,999 
1.500 ×109to 
2.999 ×109<1,500 
<1.500 ×109
Fibrinogen, 
Decreased (mg/dL; 
g/L) 100 to <200 
1.00 to <2.00 
OR 
0.75 to <1.00 ×LLN 75 to <100 
0.75 to <1.00 
OR 
≥0.50 to <0.75 ×LLN 50 to <75 
0.50 to <0.75 
OR 
0.25 to <0.50 ×LLN <50 
<0.50 
OR 
<0.25 ×LLN 
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L )18
≥13 years of age 
(male only) 10.0 to 10.9 
6.19 to 6.76 9.0 to <10.0 
5.57 to <6.19 7.0 to <9.0 
4.34 to <5.57 <7.0 
<4.34 
≥13 years of age 
(female only) 9.5 to 10.4 
5.88 to 6.48 8.5 to <9.5 
5.25 to <5.88 6.5 to <8.5 
4.03 to <5.25 <6.5 
<4.03 
57 days of age to 
<13 years of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to <9.5 
5.25 to <5.88 6.5 to <8.5 
4.03 to <5.25 <6.5 
<4.03 
36 to 56 days of 
age (male and 
female) 8.5 to 9.6 
5.26 to 5.99 7.0 to <8.5 
4.32 to <5.26 6.0 to <7.0 
3.72 to <4.32 <6.0 
<3.72 
22 to 35 days of 
age (male and 
female) 9.5 to 11.0 
5.88 to 6.86 8.0 to <9.5 
4.94 to < 5.88 6.7 to <8.0 
4.15 to <4.94 <6.7 
<4.15 
8 to ≤21 days of 
age (male and 
female) 11.0 to 13.0 
6.81 to 8.10 9.0 to <11.0 
5.57 to <6.81 8.0 to <9.0 
4.96 to <5.57 <8.0 
<4.96 
≤7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to <13.0 
6.19 to <8.05 9.0 to <10.0 
5.59 to <6.19 <9.0 
<5.59 
INR19, High 
(not on anticoagulation 
therapy) 1.1 to <1.5 ×ULN 1.5 to <2.0 ×ULN 2.0 to <3.0 ×ULN ≥3.0×ULN 
Methemoglobin (% 
hemoglobin) 5.0 to <10.0% 10.0 to <15.0% 15.0 to < 20.0% ≥20.0% 
17Male and female sex are defined as sex at birth. 
18The conversion factor used to convert g/dL to mmol/L is 0.[ADDRESS_1047673] be converted to
g/dL using the appropriate conversion factor for the particular laboratory.
19International normalized ratio.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
109
Approved , Date: 16 November 2017HEMATOLOGY
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
PTT20, High 
(not on anticoagulation 
therapy) 1.1 to <1.66 ×ULN 1.66 to <2.33 ×ULN 2.33 to <3.00 ×ULN ≥3.00 ×ULN 
Platelets, Decreased 
(cells/mm3; cells/L ) 100,000 to <124,999
100.000 ×109to 
<124.999 ×[ZIP_CODE],000 to <100,000 
50.000 ×109to 
<100.000 ×[ZIP_CODE],000 to < 50,000 
25.000 ×109to 
<50.000 ×109<25,000 
<25.000 ×109
PT21, High 
(not on anticoagulation 
therapy 1.1 to <1.25 ×ULN 1.25 to <1.50 ×ULN 1.50 to <3.00 ×ULN ≥3.00 ×ULN 
WBC, Decreased 
(cells/mm3; cells/L ) 
>7 days of age 2,000 to 2,499 
2.000 ×109to 
2.499 ×1091,500 to 1,999 
1.500 ×109to 
1.999 ×1091,000 to 1,499 
1.000 ×109to 
1.499 ×109<1,000 
<1.000 ×109
≤7 days of age 5,500 to 6,999 
5.500 ×109to 
6.999 ×1094,000 to 5,499 
4.000 ×109to 
5.499 ×1092,500 to 3,999 
2.500 ×109to 
3.999 ×109<2,500 
<2.500 ×109
20Partial thromboplastin time .
21Prothromb in time
URINALYSIS
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Glycosuria ( random 
collection tested by 
[CONTACT_5230]) Trace to 1+ or 
≤250 mg2+ or ˃250 to ≤500 mg >2+ or >500 mg NA 
Hematuria (not to be 
reported based on 
dipstick findings or on 
blood believed to be of 
menstrual origin) 6 to <10 RBCs per 
high power field ≥10 RBCs per high 
power field Gross, with or without 
clots OR With RBC 
casts OR Intervention 
indicated Life-threatening 
consequences 
Proteinuria (random 
collection tested by 
[CONTACT_5230]) 1+ 2+ 3+ or higher NA 
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
110
Approved , Date: 16 November 2017APPENDIX A: TOTAL BILIRUBIN TABLE FOR TERM AND PRETERM NEONATES
PARAMETER GRADE 1
MILDGRADE 2 
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE-
THREATENING
Total Bilirubin19,
High (mg/dL; 
μmol/L )20
Term Neonate21
<24 hours of age 4 to <7 
68.4 to <119.7 7 to <10 
119.7 to <171 10 to <17 
171 to <290.7 ≥17 
≥290.7 
24 to <48 hours of 
age 5 to <8 
85.5 to <136.8 8 to <12 
136.8 to <205.2 12 to <19 
205.2 to <324.9 ≥19 
≥324.9 
48 to <72 hours of 
age 8.5 to <13 
145.35 to <222.3 13 to <15 
222.3 to <256.5 15 to <22 
256.5 to <376.2 ≥22 
≥376.2 
72 hours to 
<7days of age 11 to <16 
188.1 to <273.6 16 to <18 
273.6 to <307.8 18 to <24 
307.8 to <410.4 ≥24 
≥410.4 
7 to 28 days of age 
(breast feeding) 5 to <10 
85.5 to <171 10 to <20 
171 to <342 20 to <25 
342 to <427.5 ≥25 
≥427.5 
7 to 28 days of age 
(not breast 
feeding) 1.1 to <1.6 ×ULN 1.6 to <2.6 ×ULN 2.6 to <5.0 ×ULN ≥5.0×ULN 
Preterm Neonate21
35 to <37 weeks 
gestational age Same as for Total 
Bilirubin, High, Term 
Neonate (based on 
days of age). Same as for Total 
Bilirubin, High, Term 
Neonate (based on 
days of age). Same as for Total 
Bilirubin, High, Term 
Neonate (based on 
days of age). Same as for Total 
Bilirubin, High, Term 
Neonate (based on 
days of age). 
32 to <35 weeks 
gestational age 
and < 7 days of age NA NA 10 to <14 
171 to <239.4 ≥14 
≥239.4 
28 to <32 weeks 
gestational age 
and <7 days of age NA NA 6 to <10 
102.6 to <171 ≥10 
≥171 
<28 weeks 
gestational age 
and <7 days of age NA NA 5 to <8 
85.5 to <136.8 ≥8 
≥136.8 
7 to 28 days of age 
(breast feeding) 5 to <10 
85.5 to <171 10 to <20 
171 to <342 20 to <25 
342 to <427.5 ≥25 
≥427.5 
7 to 28 days of age 
(not breast 
feeding) 1.1 to <1.6 ×ULN 1.6 to <2.6 ×ULN 2.6 to <5.0 ×ULN ≥5.0×ULN 
19Severity grading for total bilirubin in neonates is complex, because of rapi[INVESTIGATOR_764567]. Severity grading in th is 
appendix corresponds approximately to cut-offs for indications for phototherapy at grade 3 and for exchange transfusion at 
grade 4. 
20A laboratory value of 1 mg/dL is equivalent to 17.1 μmol/L. 
21Definitions: Term is defined as ≥37 weeks gestational age; near -term, as ≥35 weeks gestational age; preterm, as <35 weeks 
gestational age; and neonate, as 0 to 28 days of age.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
111
Approved , Date: 16 November 2017Attachment 3: WHO Clinical Staging of HIV/A IDS
The clinical stages of HIV infection for adults andadolescents are defined as follows. (Adapted from: 
1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS 
among adolescents and adults. MMWR 1992;41(RR -17):1 -19; and WHO 2007 Case definitions of HIV 
for surveillance and revised clinical staging and immunological classification of HIV-related disease in 
adults and children [ Table 3]).31,42
Clinical Stage 1
Clinical Stage 1 consists of one or more of the conditions listed below in adolescents or adults ( 13years) 
with documented HIV infection. Conditions listed in Clinical Stages 2, [ADDRESS_1047674] occurred.
-Asymptomatic HIV infection
-Persistent generalized lymphadenopathy
Clinical Stage 2
Clinical Stage 2 consis ts of symptomatic conditions in an HIV-infected adolescents or adults that are not 
included among conditions listed in Clinical Stage 3, and that meet one or more of the following criteria: 
a) the conditions are attributed to HIV infection or are indicativ e of a defect in cell -mediated immunity; or 
b) the conditions are considered by [CONTACT_124793] a clinical course or to require management that is 
complicated by [CONTACT_124794]. Examples of conditions in Clinical Stage 2 include, but are not limited to 
the following.
-Moderate unexplained weight loss (<10% of presumed or measured body weight)
-Recurrent respi[INVESTIGATOR_648163], tonsillitis, otitis media and pharyngitis)
-Herpes zoster
-Angular cheilitis
-Recurrent oral ulceration
-Papular pruritic eruptions
-Seborrhoeic dermatitis
-Fungal nail infections
Clinical Stage 3
Clinical Stage 3 includes the clinical conditions listed in the AIDS surveillance case definition. For 
classification purposes, once a Clinical Stage 3 condition has occurred , the person will remain in Clinical 
Stage 3. Conditions in Clinical Stage 3 include the following.
- Unexplained (not explained by [CONTACT_22714]) severe weight loss (>10% of presumed or measured 
body weight)
- Unexplained chronic diarrhea for longer than 1 mon th
- Unexplained persistent fever (above 37.6°C intermittent or constant, for longer than 1 month)
- Persistent oral candidiasis
- Oral hairy leukoplakia
- Pulmonary tuberculosis (current)
- Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, 
meningitis or bacteremia)
- Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
- Unexplained anemia (<8 g/dL), neutropenia (<0.5x109/L) or chronic thrombocytopenia (<50x109/L)
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
112
Approved , Date: 16 November 2017Clinical Stage 4
HIV wasting syndrome:
- Pneumocystis pneumonia
- Recurrent severe bacterial pneumonia
- Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month’s duration 
or visceral at any site)
- Esophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
- Extrapulmonary tuberculosis
- Kaposi’s sarcoma
- Cytomegalovirus infection (retinitis or infection of other organs)
- Central nervous system toxoplasmosis
- HIV encephalopathy
- Extrapulmonary cryptococcosis including meningitis
- Disseminated non- tuberculous mycobacterial infection
- Progressive multifocal leukoencephalopathy
- Chronic cryptosporidiosis (with diarrhea)
- Chronic isosporiasis
- Disseminated mycosis (coccidiomycosis or histoplasmosis)
- Recurrent non- typhoidal Salmonella bacteremia
- Lymphoma (cerebral or B -cell non -Hodgkin) or other solid HIV -associated tumors
- Invasive cervical carcinoma
- Atypi[INVESTIGATOR_184856]
- Symptomatic HIV -associated nephropathy or symptomatic HIV -associated cardiomyopathy
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
113
Approved , Date: 16 November 2017Attachment 4: Management of Clinically Significant Laboratory Toxicities *
a Mandatory confirmation is not w arranted for asymptomatic grade 3 or grade 4 glucose elevations in subjects w ith pre -existing diabetes, and asymptomatic 
grade 3or grade 4 triglyceride or cholesterol elevations.
* Please n ote that this Attachment does no t apply to s creening /baseline eGFR , AST, ALT, and lipase , and does also not apply to the allowed retesting of 
abnorm al screening/baseline eGFR, AST, ALT, and lipase values (see Section 3.1).Grade [ADDRESS_1047675] possibly related to study medication:
-Withhold to study medication until Grade [ADDRESS_1047676] possibly 
related to study medication, discontinue all study medication dosing 
perma nentlyIf Grade 3 or 4 recurrence that is considered unrelated to study 
medication, continue study medication at the same dose at the 
discretion of the investigator
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
114
Approved , Date: 16 November 2017Attachment 5:Management of Dyslipi[INVESTIGATOR_764568] 
(Adapted from: Guidelines for the evaluation and management of dyslipi[INVESTIGATOR_764569] [HIV] -Infected adults receiving antiretroviral therapy: Recommendations of the 
HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical 
Trials Group. Clin Infect Dis. 2003;37(5):613 -627.)1
Clinicians should monitor patients receiving ARV therapy for dyslipi[INVESTIGATOR_184859] a fasting lipid 
profile before and after starting ARV therapy. Frequent monitoring may be indicated by [CONTACT_764608], cardiovascular risk factors, or cardiovascular symptoms.
Clinicians should recommend lifestyle modifications, such as increased exercise, weight loss, nutrition 
therapy, smo king cessation, and drug addiction treatment.
Pharmacologic treatment of dyslipi[INVESTIGATOR_764570].
Lipid abnormalities in HIV-infected patients, specifically hypocholesterolemia and hypertriglyceridemia, 
were described before the advent of ARV therapy; however, the number of patients with lipid 
abnormalities appears to be increasing in the highly active antiretroviral therapy (HAART) era. Patients 
often develop lipid abnormalities within 3 months of initiation of ARV therapy. The full clinical 
significance of these laboratory abnormalities is not yet clear, although the abnormalities may be 
associated with premature coronary artery disease (CAD) in some patients, especially those with other 
risk factors for coronary heart disease (CHD) or the metabolic syndrome previously referred to as 
syndrome X.
Major risk factors (LDL cholesterol excluded) that modify LDL goals*are:
 cigarette smoking;
 hypertension (blood pressure ≥140/90 mmHg or on antihypertensive medication);
 low HDL cholesterol (<40 mg/dL)†;
 family history of premature CHD
(CHD in male first -degree relative <55 years; CHD in female first -degree relative <65 years)
 age (men ≥45 years; women ≥55 years)
*All these risk factors are captured in the eCRF.
†HDL cholesterol ≥60 mg/dL counts as a ‘negative’ risk factor; its presence removes one risk 
factor from the total count
Hypertriglyceridemia, low HDL cholesterol levels, and elevated LDL cholesterol levels have been 
described in patients receiving ARV therapy, especially PIs. Non- nucleoside reverse transcriptase 
inhibitor (NNRTI )use has been associated with hypercholesterolemia. The mechanism by [CONTACT_764609][INVESTIGATOR_764571]. Hypertriglyceridemia seems to be most significant in patients with 
regimens that include low-dose rtv. Significant hypertriglyceridemia (>500 mg/dL) is associated with an 
increased risk of pancreatitis, particularly in patients with other risk factors for pancreatitis eg,alcohol or 
didanosine use).
Lipid abnormalitie s in HIV-infected patients receiving ARV therapy may occur in conjunction with body 
fat changes. Secondary causes of dyslipi[INVESTIGATOR_035], including diabetes, hypothyroidism, liver disease, chronic 
renal failure, and other medications, such as progestins, anabolic steroids, and corticosteroids, should be 
considered in patients with new onset dyslipi[INVESTIGATOR_035].
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
115
Approved , Date: 16 November 2017A fasting lipid profile (total, LDL and HDL cholesterol, triglycerides) should be obtained before starting 
ARV treatment (ideally at baseline visit). A fasting lipid profile should be obtained 3 to 6 months after 
starting or changing ARV therapy (ideally at each visit of the study protocol).
Alternatively, if collection of a fasting sample is not feasible, a nonfasted total cholesterol and HDL 
cholesterol may be obtained. The clinician should proceed with a fasting lipoprotein profile when the 
nonfasted total cholesterol is >200 mg/dL or HDL cholesterol is <40 mg/dL.
The management of lipid disorders in HIV-infected patients parallels management in non-HIV-infected 
patients (see Table 3and Table 4). Individual risk assessments for an acute coronary event and 
management of lipid disorders can be accomplished by [CONTACT_764610], such as those published by [CONTACT_569137] (NCEP) andthe 
AIDS Clinical Trial Group (ACTG) Cardiovascular Disease Focus Group (see Table 3and Table 4). 
Treatment of dyslipi[INVESTIGATOR_764572].
For patients without known CAD, therapeutic lifestyle changes should be the first intervention for the 
treatment of lipid disorders. These changes include increased physical exercise, weight reduction when 
indicated, smoking cessation and dietary changes. Consultation with a registered dietitian may be helpful 
in achieving dietary goals [restriction of total fat to 25%- 30% of total caloric intake, and dietary 
cholesterol to <200 mg/day; use of plant sterols (2 g/d) found in commercial margarines (eg, Benecol or 
Basikol), and increased soluble fiber (10 -25 g/d)].
Lipid -lowering agents should be considered for hyperlipi[INVESTIGATOR_764573], or for patients in whom such modifications are not appropriate. 
The first-line pharmacological treatment for patients with isolated elevation of LDL cholesterol is statin 
therapy (see Table 4). Pravastatin is the safest drug for treating hyperlipi[INVESTIGATOR_764574]. Atorvastatin can be used cautiously at lower doses (5-10mg) with 
careful titration. Rosuvastatin will not likely interact with PIs and NNRTIs. Use of other statins, 
particularly lovastatin and simvastatin, is contraindicated.
Fibric acid derivatives, such as gemfibrozil and fenofibrate, are the first-line treatment for isolated 
elevation of fasting triglyceride levels. The threshold suggested for intervention is 500 mg/dL.
Gemfibrozil and fenofibrate are not metabolized via the CYP system and are generally safe to use in 
patients receiving ARV therapy. For patients with high triglycerides in whom LDL cholesterol cannot be 
measured, the non-HDL cholesterol level may be calculated to guide initiation of therapy (total –HDL 
cholesterol). 
Patients with persistent high-grade hypertriglyceridemia (>1,000 mg/dL) may benefit from a very low-fat 
diet, even if they are not overweight.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
116
Approved , Date: 16 November 2017Table 3: LDL and non -HDL Cholesterol Goals and Thresholds for Therapeutic Lifestyle Chan ges and 
Drug Therapy in Different Risk Categories
Risk CategoryLDL Goal 
(mg/dL)LDL Level at 
Which to Initiate 
Lifestyle Changes 
(mg/dL)LDL Level at 
Which to 
Consider Drug 
Therapy (m g/dL)Non-HDL Goal 
(mg/dL)*
CHD or CHD risk equivalents: 
diabetes mellitus, atherosclerotic 
disease (CAD or stroke), or multiple 
risk factors (10 -year risk >20%)<100 ≥100 <130 (100 -129: 
drug optional)†≥130
2+ risk factors: HDL <40, strong
family history, age >45 years, and
smoking (10 -year risk >20%)<130 ≥130 10-year risk
10%-20%: ≥130
10-year risk 
<10%: ≥160<160
0-1 risk factor‡<160 ≥160 ≥190 (160 -189: 
LDL -lowering 
drug optional)<190
*Non-HDL cholesterol = (total –HDL cholesterol). When LDL cholesterol cannot be measured because the triglyceride level 
is >200 mg/dL, non-HDL cholesterol may be used as a secondary goal. The non-HDL cholesterol goal is 30mg/dL higher 
than the LDL cholesterol goal.
†Some authorities recommend use of LDL -lowering drugs in this category if an LDL cholesterol level of <100 mg/dL cannot 
be achieved by [CONTACT_184949] (dietary and exercise intervention). Others prefer use of drugs that primarily 
modify triglycerides and HDL cholesterol (eg, nicotine acid or fibrate). Clinical judgment also may suggest deferring drug 
therapy in this subcategory.
‡Almost all people with [ADDRESS_1047677] a 10-year risk <10%; thus, 10-year risk assessment in people with 0 or 1 risk 
factors is not necessary.
For those with both elevated serum LDL cholesterol and triglyceride levels, combination therapy with a 
statin and fibrate may be needed but should be used with extreme caution because of overlappi[INVESTIGATOR_5171]  
(rhabdomyolysis) profiles. Therapy should begin first with a statin, followed by [CONTACT_764611] 3to 4 months of treatment. 
Routine monitoring for hepatic and muscle toxicity should be performed in these situations.
The use of additional drugs, such as nicotinic acid or bile sequestrants, may be necessary to manage 
dyslipi[INVESTIGATOR_035]. Nicotinic acid may cause hepatotoxicity and elevated serum glucose levels. Therefore, low -
dose therapy with incremental dose increases is advisable for those patients who require this drug. Bile 
acid sequestrants (eg, colesevelam 3 tablets twice daily or ezetimibe 10mgonce daily) may also be used 
but may interfere with absorption of oral medications; therefore, proper timing of the dosing of this drug 
is important when used in conjunction with ARV medications (ie, 1 h our before or 4 hours after).
Table 4: C hoice of Drug Therapy for Dyslipi[INVESTIGATOR_184864]-i nfected Individuals Receiving HAART
Lipid Abnormality First ChoiceSecond Choice (or if Additional 
Treat ment is Needed) Comments
Isolated high LDL 
cholesterolStatin*Fibrate Start with low doses of statins and 
titrate upward.
Patients receiving PIs may be at 
increased risk of statin -induced 
myopathy.
Combined 
hyperlipi[INVESTIGATOR_035] (high 
cholesterol and high 
triglycerides)Fibrate or statin*If starting with fibrate, add statin*
If starting with statin*, add fibrateCombining statin and a fibrate may 
increase risk for myopathy
Isolated 
hypertriglyceridemiaFibrate Statin* Combining statin and a fibrate may 
increase risk for myopathy.
* Statins should be dosed at bedtime. Simvastatin and lovastatin are not allowed in patients receiving DRV.
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
117
Approved , Date: 16 November 2017Attachment 6: Cardiovascular Safety: Definitions of A bnormalities
Vital Signs
Abnormality CodePulse 
(bpm)DBPa
(mm Hg)SBPa
(mm Hg)
Abnorm ally low 50 50 90 
Grade 1 or mild - >90 -<100 >140 -<160 
Grade 2 or moderate - 100 -<110 160 -<180 
Grade 3 or severe - 110 180 
Abnorm ally high 120 - -
aClassification of adverse events related to hypotension/hypertension should be done according to the DAIDS 
grading table ( Attachment 2).
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
118
Approved , Date: 16 November 2017Attachment 7: HIV- Treatment Satisfaction Questionnaire (HIVTSQ s)
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
119
Approved , Date: 16 November 2017Attachment 8:Anticipated Events
Anticipated Event
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the following events will be considered anticipated events: 
 AIDS dementia (PT AIDS dementia complex)
 Bacterial infections, multiple or recurrent* 
 Candidiasis of bronchi, trachea, or lungs 
 Candidiasis of esophagus†
 Cervical cancer, invasive§
 Chronic hepatitis secondary to hepatitis B infection
 Chronic hepatitis secondary to hepatitis C infection
 Coccid ioidomycosis, disseminated or extrapulmonary 
 Cryptococcosis, extrapulmonary 
 Cryptosporidiosis, chronic intestinal (>1 month's duration) 
 Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month 
 Cytomegalovirus retinitis (with loss of vision)†
 Encephalopathy, HIV related 
 Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or esophagitis 
(onset at age >1 month) 
 Herpes zoster infections
 Histoplasmosis, disseminated or extrapulmonary 
 Isosporiasis, c hronic intestinal (>1 month's duration) 
 Kaposi sarcoma†
 Leishmaniasis
 Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex*†
 Lymphoma, Burkitt (or equivalent term) 
 Lymphoma, immunoblastic (or equivalent term) 
 Lymphoma, primary, of brain 
 Mycobacterium avium complex or Mycobacterium kansasii, disseminated or extrapulmonary†
 Mycobacterium tuberculosis of any site, pulmonary,†§disseminated,†or extrapulmonary†
 Mycobacterium , other species or unidentified specie s, disseminated†or extrapulmonary†
 Oral candidiasis 
 Peripheral neuropathy
 Pneumocystis jirovecii pneumonia†
 Pneumonia, recurrent†§
 Progressive multifocal leukoencephalopathy 
 Salmonella septicemia, recurrent 
 Toxoplasmosis of brain, onset at age >1 m onth†
 Tuberculosis
 Wasting syndrome attributed to HIV
* Only among children aged <13 years32
† Condition that might be diagnosed presumptively
§ Only among adults and adolescents aged >13 years31
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
120
Approved , Date: 16 November 2017Reporting of Anticipated Events
All adverse events will be recorded in the CRF regardless of whether considered to be anticipated events 
and will be reported to the sponsor asdescribed in Section 12.3.1 , All Adverse Events . Any anticipated 
event that meets serious adverse event criteria will be reported to the sponsor as described in 
Section 12.3.2 , Serious Adverse Events. These anticipated events are exempt from expedited reporting as 
individual single cases to Health Authorities. However if based on an aggregate review, it is determined 
that an anticipated event is possibly related to study drug, the sponsor will report these events in an 
expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within t he sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP ).
[STUDY_ID_REMOVED]
D/C/F/TAF (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
Clinical Protocol TMC114FD2HTX3002 Amendment 1
121
Approved , Date: [ADDRESS_1047678] of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: [CONTACT_1782]:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: [CONTACT_1782]:
(Day Month Year)
Sponsor's Responsible Medical Officer:
Nam e (typed or printed): R. Nettles
Institution: Janssen Scientific Affairs, LLC .
Signature: [electronic signature [CONTACT_111203]] Date:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by [CONTACT_68477], and a protocol amendment will not be required.
[STUDY_ID_REMOVED]
  
SIGNATURES 
    
Signed by  [CONTACT_764612]
29Nov2017, 14:17:02 PM, UTC
Document Approval
[STUDY_ID_REMOVED]